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I. Executive Summary
My case for a Higher Doctoral Degree, DOCTOR OF SCIENCE, by academic
publications in Neuroscience and Metabolism is based upon the originality, significant
contribution to scientific knowledge, and international recognition of my research
publications.
Goal: My research goal is to find the means to prevent and treat schizophrenia, obesity
and their related metabolic disorders. My research has largely focused on the regulation
of body metabolism in normal and diseased situations. I have employed modern
molecular biology techniques to study the pathologies of the diseases using human
tissue, animal models and cell culture. I have carried out some translational research
aiming to translate new findings from basic research into novel pharmacological and
clinical interventions for the benefit of human diseases.
Career: I have a Doctor degree in Medicine and PhD degree in Neuroscience. I have
gained broad experience in medical research through working at the Medical College in
China (1983-1988), the Schools of Medicine and Psychology of University of New
South Wales (1989-1995), the School of Health Sciences at the University of
Wollongong (1995-present), and Illawarra Health and Medical Research Institute (2010present).
Publications: I have produced 273 publications including 3 books, 8 book chapters, 103
international peer-reviewed journal articles, 21 letters to the editor and 138 conference
proceedings since 1993. My research articles have been cited 1,505 times and my books
have been cited 857 times. My research ‘h-Index’ is 22.
Grants: I have been awarded numerous research grants for my research, totalling $3.8
million dollars including 9 NHMRC, 1 ARC Linkage, 1 AINSE and 1 NISDA
fellowship since 2002, consisting of 35 research proposals.
Leadership: Since 1996, I have mentored 7 post-doctoral fellows and 6 research
assistants. I have been the principal or co-supervisor of 14 successful PhD/Master
degree research students. I have coordinated and taught a number of subjects for
undergraduate students including anatomy, motor control and dysfunction, neuroscience
and pathophysiology. I have been awarded Highly Commended for the Vice
Chancellor’s Excellence in Research Supervision Award in 2009, and received the Vice
Chancellor’s Excellence in Research Supervision Award in 2010 at the University of
Wollongong.
Peer review: Panel member: NHMRC-GRP-5e, 2010; ARC-ERA panels, 2010; ANSTO
Life Science External Panel, 2009; AstraZeneca External Advisory Board 2001 to 2004;
Grant reviewer: NHMRC (2003-2010); NHMRC Principal Research Fellowship and
Promotions (2005); CRC (09), NHF (2001); Diabetes Australia (2009, 2010); AustraliaIndia Collaborative Research (2007); Welcome Trust, UK (2001); Editorial Board
Member: International Journal of Obesity; Journal reviewer: American Journal of
Physiology; International Journal of Obesity; Neuropsychopharmacology; American
Journal of Physiology; Brain Research; Journal of Endocrinology; Journal of Obesity,
Journal of Neuroscience Research; Brain Research Bulletin; Progress in NeuroPsychopharmacology and Biological Psychiatry.
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Contributions to discipline: Scientific Director for the Illawarra Health and Medical
Research Institute Metabolic Theme from 2009 to present; Director of the Centre for
Translational Neuroscience at the University of Wollongong, 1999 to present; Council
Member of the Schizophrenia Research Institute and a Panel Member of the
Developmental Neurobiology of the Neuroscience Institute of Schizophrenia, 2000 to
present; Director of the Schizophrenia Research Institute-Wollongong Centre for
Collaborative Human Brain Research from 1999 to present. Member of the University
Academic Senate from 1997 to 1999; Member of the Faculty Research Committee from
2009-present; and Member of the BioSafety Committee. I hold memberships with
several national and international professional bodies including the American
Association for the Advancement of Science; Australian Neuroscience Society;
Australian Obesity Society; Society for Neuroscience (USA); North American
Association for the study of Obesity and Australian Neuroscience Society.
Invited talks: I have been invited to give numerous talks including: Title: Understanding
the progressive central dysregulation caused by the chronic consumption of a highenergy diet, AstraZeneca Company Advisory Board meeting, Nice, France, March
2001; Title: Target identification of chemical coded neural networks for treating chronic
diet-induced obesity, Garvan Medical Research Institute, Sydney, Australia, September
2002; Title: Glutamate and serotonin receptor ligand-binding in the human cortex,
AstraZeneca Company, Wilmington, USA, October 2002; Title: Integrative approaches
to identify the key targets for treating the late stages of obesity, AstraZeneca Company,
Sweden, November 2003; Title: Neurotransmitter bases of pathology and therapy of
schizophrenia, POWMRI, October 2009; Title: Neuropathology of schizophrenia and
obesity, Intelligent polymer research institute (IPRI), March 2010; Title: Nanomaterial
in cancer therapy, Institute for superconducting and electronic materials (ISEM), August
2010; Title: Brain to the mind and shape: Schizophrenia and obesity, University
Research Showcase Series, September 2010; Title: The role of Histamine in Obesity,
Australian and New Zealand Obesity Society Annual scientific Meeting, Sydney,
October 2010.

II. Studies on Schizophrenia
Schizophrenia is a major mental health disorder affecting 1% of the population
worldwide, with more than 26,000 children born with schizophrenia in Australia in the
last decade alone. Schizophrenia is a research priority both nationally and
internationally. I have published more than 40 international peer-reviewed research
papers and over 50 conference presentations in this difficult research area.
1. Neuropathology of Schizophrenia: Over the last 15 years, I have spent substantial
amount of time investigating the brain pathology of schizophrenia. This type of
work is exclusively based on examination of post mortem brain tissue of
schizophrenia. I have studied numerous neurotransmitter systems covering both
excitatory and inhibitory systems of the brain. I have also studied those brain areas
most relevant to schizophrenia, including the prefrontal cortex, anterior and
posterior cingulate cortices, superior temporal gyrus and hippocampal formation.
My studies have formed a unique body of literature, supporting the evidence that the
brain of schizophrenia patients has imbalanced neurotransmission between the
excitatory and inhibitory systems. In particular, the neurotransmitter systems that I
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have studied are the glutamatergic, cannabinoid, muscarinic, serotoninergic and
GABAergic systems.
a. Glutamate Receptors: The glutamatergic system is the most important
excitatory neurotransmitter system in the brain. The literature in this area is
controversial in terms of the role of this system in the pathology of
schizophrenia. My group has made significant contributions to understanding
the role of the glutamatergic system within specific brain areas involved in
the pathology of schizophrenia. We reported that there are increased binding
sites for glutamatergic NMDA receptors in the anterior and posterior
cingulate cortices of schizophrenia (Neuropsychopharmacology, 2002, 82633, cited 33 times; NeuroReport, 2005, 1363-67, cited 9 times). On the other
hand, we found no changes in other glutamatergic metabotropic receptors
such as the binding sites for AMPA and Kainate receptors in these brain
regions. The cingulate cortex is an important area of the limbic system in the
brain and is involved in information processing relevant to the mood,
learning and memory, which are altered in schizophrenia. Therefore,
correcting altered NMDAR expression could be an important strategy for
treating schizophrenia.
b. Cannabinoid System: CB1 is the most important receptor of the cannabinoid
system in the brain and has a number of important functions. Its relevance to
schizophrenia largely lies in its modulation of dopaminergic neuronal
activity, which is one of the main central components of the neuropathology
of schizophrenia. My group’s studies have confirmed the importance of the
CB1 receptor in schizophrenia. We found a significant 64% increase in CB1
receptor binding sites in the anterior cingulate cortex (Progress in NeuroPsychopharmacology and Biological Psychiatry, 2004, 355-60, cited 80
times) and a 25% increase in the posterior cingulate cortex (Experimental
Research, 2006, 556-560, cited 34 times) of schizophrenia compared to
controls. An altered expression of CB1 receptors in the cingulate cortex
could be related to the neuropathology of schizophrenia, since CB1 receptors
regulate motivation and attention.
c. Muscarinic Receptors: Muscarinic receptors play an important role in the
regulation of cognitive function. It is thought that deficits in muscarinic
receptor function contribute to an altered cognitive function in schizophrenia.
We identified that muscarinic receptors are significantly decreased in the
superior temporal gyrus of schizophrenia. We further reported that it is M1/4
receptors rather than M2 receptors that are altered in schizophrenia. These
results provided strong evidence to suggest that M1 receptors may
potentially be a good target for the development of drugs for treating
schizophrenia (Journal of Neuroscience Research, 2005; 883-890, cited 29
times).
d. GABA(A) Receptors: GABA is a major inhibitory neurotransmitter in the
brain. Our study showed increased GABA(A) receptors in the superior
temporal cortex and posterior cingulate cortex of schizophrenia patients
(Experimental Brain Research, 2006, 587-590, cited 19 times; Progress in
Neuro-Psychopharmacology and Biological Psychiatry, 2007, 225-233, cited
18 times). I believe there is a deficiency in GABA transmission in the
superior temporal cortex and posterior cingulate cortex in schizophrenia.
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2. Antipsychotic drug induced obesity: The second generation of antipsychotic drugs
(also known as ‘atypical’ antipsychotics) are widely used in treating a variety of
mental illnesses including schizophrenia. Atypical antipsychotics are more effective
than the first generation drugs in terms of their efficacy in improving cognitive
function for schizophrenia. However, these effective antipsychotics can lead to
significant weight gain and an increased risk for obesity-related metabolic disorders
including dyslipidaemia, diabetes and cardiovascular disease. These problems
contribute to a serious lack of compliance in taking medication, which leads to
symptom relapse plus a worsened long-term outcome, and results in a huge cost for
society and the families of patients. My contribution to this area of research is aimed
at: 1) establishing an animal model mimicking the metabolic disorder of patients
following atypical antipsychotic drug treatment; 2) identifying the key brain areas
and neurotransmitter/receptors causing the metabolic side effects; and 3) developing
new compounds for a better treatment of schizophrenia.
a. Development of an animal model for the study of antipsychotic-induced
obesity and metabolic disorders: Not all species of rodents will develop
obesity following antipsychotic treatment. In order to establish a suitable
model similar to the patient situations, I have carried out a number of studies
using different species of animal models. I tested their responses to
antipsychotic treatments and examined the side effects. After many trials, we
have successfully established a rat model suitable for the study of
antipsychotic-induced obesity. We have systematically investigated the
response of central neurotransmitter systems after antipsychotic drug
treatment, including the 5-HT system (Behavioural Brain Research, 2006,
355-62, cited 21 times), neuropeptide Y system (Neuropeptides, 2006, 213219, cited 14 times) and histaminergic system (Psychoneuroendocrinology,
2008, 619-625, cited 12 times). The animal model is now well accepted in
the literature and has made some significant advances to our understanding
of the mechanism of the therapeutic effects as well as the side effects of
antipsychotics.
b. Identification of the key brain areas and neurotransmitter and receptors
causing metabolic side effects following antipsychotic treatment:
Approximately 38% of patients on atypical antipsychotic treatment develop
metabolic disorders. After carefully studying brain neurotransmitter systems,
we have found that the histamine H1 receptor in the ventromedial
hypothalamic nucleus plays a critical role in causing obesity. After extensive
analyses, we found the histamine H1 receptor to be an excellent target to
work on for the prevention and treatment of antipsychotic drug-induced
obesity and metabolic disorders.
c. Development of new compounds for treating schizophrenia: In collaboration
with experts from medicinal chemistry at the University of Wollongong, we
have used computer modelling techniques to search for and design a better
compound for treating schizophrenia based on the chemical structure of
olanzapine. We have focused on the histamine H1 receptor and its function
in the ventromedial hypothalamic nucleus. With a structure modification, we
have now removed the H1 receptor antagonist site from the olanzapine
molecule (Australian provisional patent, No AU2010901520). Hopefully, the
new compound developed in our laboratory will be able to remove the
obesity side effect while at the same time retain the therapeutic efficacy of
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olanzapine. This compound is in the development of validation and further in
vivo phase studies.
3. NMDA receptor and animal model of schizophrenia. My study in this area is largely
focused on the hypotheses of ‘developmental neurobiology’ and ‘phencyclidine
(PCP) blockade of NMDA receptor’ of schizophrenia. Disruption of brain
development is known to play a critical role in schizophrenia. This is because
abnormal brain development can lead the brain becoming fragile to late aversive
impact. PCP is the best known pharmacological agent that can induce schizophrenialike symptoms in humans and animals. We have published four peer reviewed
papers in this area. We showed that early interruption of the NMDA receptor can
alter brain development in the dopaminergic, muscarinic, glutamatergic and
GABAergic systems. More importantly, we have found that PCP administration can
alter NMDAR-neuregulin 1 signalling (via NMDAR-PSD95-ErbB4-NRG1
pathway). This has advanced our understanding of the mechanisms of brain
development and is relevant to schizophrenia as neuregulin 1 and its receptor erbB4
are candidate genes for schizophrenia risk.

III. Studies on Obesity
Obesity is a major health problem today. My research largely focuses on
neuroendocrine regulation of body weight and metabolism. I have been studying the
basic physiology and pathological condition of metabolic disorders of obesity. I am
extremely interested in using functional food and herb molecules to prevent and treat
obesity and its related metabolic disorders. Using modern molecular and biological
techniques I have investigated and answered a number of key issues.
1. Identifying the localisation of leptin receptor expression in the brain: Leptin
signalling plays a key role in body weight regulation for both energy intake and
expenditure. I, together with my group members, have made a significant
contribution to this area. We were the first to report the location of leptin
receptor mRNA expression in the neurons of the hypothalamic arcuate nucleus
in mice (NeuroReport, 1996, 15-17; cited 92 times). We showed that leptin
receptor in the hypothalamic arcuate nucleus can be down regulated in the late
stages of diet-induced obesity in mice, which is accompanied by glucose
intolerance peripherally. We also showed that the downstream regulatory
molecules of the leptin receptor are neuropeptide Y and proopiomelanocortin,
which respond to high-fat diet and contribute to the development of diet-induced
obesity (Brain Research, 2000, 89-95; Cited 86 times).
2. Central leptin resistance theory in the late stage of diet-induced obesity: Leptin,
produced from adipocytes, can act on the neurons in the hypothalamic arcuate
nucleus and promote negative energy balance against weight gain.
Paradoxically, obesity has increased blood leptin concentration, indicating the
existence of leptin resistance. Our group was the first to report central leptin
resistance in the late stages of diet-induced obesity using a diet-induced obese
mouse model (International Journal of Obesity, 2000, 639-46, cited 121 times).
We showed, in a systematic fashion, how central leptin resistance progressively
develops: being initiated peripherally and then becoming central with a loss of
food intake inhibition and dramatic failure of energy balance regulation. My
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group was the first to show how leptin signals central neurotransmitter systems
regulating energy balance including leptin-leptin receptor-neuropeptide Y-proopiomelanocortin in diet-induced obesity (Brain Research, 2000, 89-95, cited 86
times). These findings distinguished the differences between physiological and
pathophysiological conditions of obesity at the early and late stages. The central
leptin resistance theory has contributed to obesity research significantly because
it opened up a new avenue for considering and designing treatment regimes for
human obesity.
3. Individual susceptibility to obesity development. It is known that some develop
obesity but others do not while on a high-energy diet in both humans and
rodents. My group was the first to establish mouse models of diet-induced obese
and diet-resistant mice under an isocaloric diet (Brain Research Bulletin, 2000,
235-242; Brain Research, 2003, 9-19; cited 63 times). As mice are on the same
diet, comparing the differences in the regulatory system for energy balance
between diet-induced obese and diet-resistant mice has allowed us to identify a
number of neuromodulators that play significant roles in the prevention of dietinduced obesity. We reported the existence of differential regulations of
neuropeptide Y and its Y2 receptors, 5-HT2a, and its transporter enzyme in the
diet-induced obese mice.
4. Some, but not all, fats are obesogenic: We know that saturated fats are
obesogenic while n-3 polyunsaturated fats are not. My group tested gene
responses in the central nervous system to different types of dietary fats. We
reported that saturated fats differentially affect the mRNA expression of the
hypothalamic leptin receptor, neuropeptide Y and agouti-related peptide and
proopiomelanocortin compared to n-3 and n-6 polyunsaturated fatty acid diet in
mice. A high saturated fat diet reduces neuropeptide Y and agouti-related
peptide mRNA expression while n-3 and n-6 polyunsaturated fat diets do not.
Down regulated neuropeptide Y and agouti-related peptide are unable to
effectively counteract the obesogenic drive derived from a high saturated fat
diet. On the other hand, high fat diets emphasizing polyunsaturated fatty acids
can protect against obesity (American Journal of Physiology-Endocrinology and
Metabolism, 2002, 1352-1359; cited 77 times).
5. Dietary fiber and obesity: I am very interested in dietary fiber studies as dietary
fiber has been reported to have numerous beneficial effects to obesity and
diabetes. I am particularly interested in the structure and function of beta
glucans, which are a soluble dietary fiber. Our studies have shown that oat betaglucans (soluble dietary fiber) increase postprandial cholecystokinin levels,
decrease insulin response and extend subjective satiety in overweight subjects
(Molecular Nutrition and Food Research, 2009, 1343-1351). Furthermore, we
showed that a high beta-glucan diet increases PYY production, which can downregulate positive energy balance in overweight and obese subjects (Nutrition
Research, 2009, 705-9).

IV. Mapping the Human and Monkey Brains
The Institute of Medicine (US Academy of Science) reported that, ‘Mapping the Brain
and its Functions’ urges the construction of ‘standard’ atlases of the human, monkey,
and rodent brain. In 1905, Brodmann constructed a map of the monkey cortex. The
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rhesus monkey has been the principal non-human primate used to test theories of
human brain organisation and function. However, no comprehensive map of the
cortex, let alone the entire brain, of this species has been attempted by anyone in the
last century. In this project, I undertook a trip to UCLA where the brain of a rhesus
monkey was imaged using MRI. The entire monkey brain was then sectioned at 800
μm intervals. Prof. Paxinos and I examined the sectioned monkey brain stained for 11
different neurochemicals. After 6 years of work, our book ‘The Rhesus Monkey Brain
in Stereotaxic Coordinates’ was published. This book is the ‘most comprehensive,
detailed atlas of the monkey brain ever constructed’ (comment by Academic Press).
Prof. Paxinos and I also published in 1996 (Academic Press, San Diego), the ‘Atlas of
the Human Brainstem’ the first book of its kind on the human brain, since the work of
Olszewski and Baxter (1954). In this work, we identified for the first time 47 human
homologues to nuclei identified in other animals and it is the most authoritative work
in its field. The identification of regions and homologues permitted us to propose
organisational schemes, which are in harmony with functional data. Some new
concepts have now been adopted in research publications as well as in text books
based on our studies. ‘The Atlas of the Human Brainstem’ is a major accomplishment
and a unique resource’ (Prof. C. Saper, of Harvard Medical School and Beth Israel
Hospital). These two books are recognised as standard reference books in
Neuroscience.

V. Curriculum Vitae
1. Personal Details
Last Name: Xu-Feng, First Name: Huang; Title: Doctor; Current Position:
Professor; Academic Unit: School of Health Sciences; Faculty: Health and
Behavioural Sciences
2. Academic Qualifications
Post-doc
Pathology
1994–1995
Post-doc
Psychology
1993–1994
PhD
Neuroanatomy
1989–1993
MBBS
Medicine
1977–1982
*UNSW: University of New South Wales, Australia

UNSW*
UNSW
UNSW
XuZhou Medical College

3. Awards, Fellowships & Scholarships
1994–1995
NHMRC#
Postdoctoral Award, RO2 & RO3
1993–1994
NHMRC
Postdoctoral Award, RO1
1989–1993
NHMRC
Postgraduate Scholarship
2009
Vice chancellor
Excellence in Research Supervision
UoW*
(Highly commended)
2010
Vice chancellor
Excellence in Research Supervision
#NHMRC: National Health and Medical Research Council of Australia
*UoW: University of Wollongong, Australia
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4. Panel and Board Member
• Member of NHMRC Grant Review Panel, GRP-5E, 2010, Psychology, Psychiatry
and Cognitive Sciences, 2010
• Member of the Research Evaluation Committee for ERA Cluster 7 (BCH),
Excellence in Research in Australia, Australia Research Council, 2010
• Member of External Advisory Board, Australia Nuclear Science and Technology
Organisation (ANSTO), 2010
• Council Member of Schizophrenia Research Institute, Australia, 2007–present
• Member of Developmental Neurobiology Panel, SRI, Australia, 1999–present
• Scientific Director of IHMRI Metabolic Theme, 2009–present
• AstraZeneca Pharmaceutical Company of Sweden, External Advisor for obesity
research (2001–2003)
5. Memberships of Professional Societies
1999–present
North American Association for the Study of Obesity
1998–present
Australian Society for the Study of Obesity
1996–present
American Association for the Advancement of Science
1991–present
Neuroscience, USA
1989–present
Australian Neuroscience Society
6. Positions Previously Held
2006–present Professor, School of Health Sciences, UoW
2002–2005
Associate Professor, Department of Biomedical Science, UoW
1997–2001
Senior Lecturer, Department of Biomedical Science, UoW
1995–1997
Lecturer, Department of Biomedical Science, UoW
1994–1995
Research Officer (RO2 & 3), NHMRC, Sch of Pathology, UNSW
1993–1994
Research Officer (RO1), NHMRC, School of Psychology, UNSW
1989–1991
Tutor (Part time), School of Anatomy, UNSW
1989–1991
Research Assistant (Part time), School of Anatomy, UNSW
1983–1987
Associate/Lecturer, XuZhou Medical College, China
7. Industrial/Commercial/Professional Activities and Other Relevant Experience
University, Faculty and Department Committees/Responsibilities
• University Bio-safety committee, member (2005-2008)
• University of Wollongong – Anatomy License (2005)
• University Academic Senate, Faculty Representative (1997–1999)
• Faculty Research Committee, member (1997–1999)
• Department Acting Head, Department of Biomedical Science in July 1998,
December 1998, and July 2001
• Course Coordinator for Medical Science (2001–2004)
• Academic Advisor for the first year undergraduate students in the
Department of Biomedical Science/School of Health Sciences (1997–2000)
• Radioactive Safety Officer of the Department of Biomedical Science/School
of Health Sciences (2005–2008)
External to UoW
• Uncle Toby’s Company of Australia, R & D Research Collaborator for the
study of whole grain in prevention of obesity and health benefit (2005–
2008)
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•
•
•
•
•

Director of NISAD-Wollongong Centre for Collaborative Human Brain
Research (1999–present)
Invited Reviewer of NHMRC Project Grants (1999, 2000, 2003, 2004,
2005)
Invited Reviewer of NHMRC Principal Research Fellowship and Promotion
(2005)
Invited Reviewer of National Heart Foundation (2000, 2001), and The
Welcome Trust, UK (2000)
Chair and Convenor, NISAD Satellite Meeting held in the University of
Wollongong, 2005

8. Journal Reviewer and Editorial Board Member
• Reviewer for journal articles: American Journal of Physiology; Brain
Research; Molecular Brain Research; Neurochemistry;
Neuropsychopharmacology; American Journal of Physiology; Journal of
Neuroscience Research;Molecular Carcinogenesis;Cancer Research
• Editorial board member: Members of Translational Neuroscience
Editorial Board, 2010; International Journal of Obesity
9. Visiting Scientist/Professor
• Sabbatical, 2000, Obesity and Metabolism, AstraZeneca R&D Sweden
• Established industry collaborative research project ‘Differential expressed
genes in the late stage of obesity’; published two peer reviewed articles.
• Sabbatical, 2005, Obesity and Metabolism, AstraZeneca R&D, Sweden
• Established industry collaborative research project ‘Cause and consequence
genes of obesity’
• Sabbatical, 2005, Medicine, Xuzhou Medical College, PR China.
• Sabbatical, 2007, Beijing University, PR China

VI. Publications
1. Contributions including individual and joint collaborative work: Standard practice
with respect to authorship in the discipline of neuroscience research and in my
laboratory is to list the research fellow and doctoral student as the first authors,
while the senior author is normally listed last on the author list. The senior author
develops the original ideas, assists in analysis and interpretation of the results of
the study, and provides funding and infrastructure for the study. As a senior author,
my percentage of intellectual input (PI) ranges from 60 to 80% and my percentage
of labour work (PL, e.g.: tissue sectioning, histology, feeding mice, statistics, etc.)
approximates 20%. I am either the 1st or senior author for 80% (20 papers as the 1st
Author, 56 papers as the last Author) of total 103 journal papers that I, together
with my colleagues, have published. Among all 273 publications (including
conference presentations), the works are about 82% derived from my laboratory in
the School of Health Science, at the University of Wollongong. Those publications
from my PhD work are not included in this application.
2. My journal article citations: Based on the collection of the ‘ISI’ Web of
Knowledge” in March 2011, my journals articles have been cited 1,505 times in

13

international research articles. The figure below shows a sustained contribution to
the knowledge as evidenced by yearly increased citations.
3. My book citations (857 citations): I, together with my colleagues, have published
three brain atlases with Academic Press, San Diego, USA. They are now used as
standard reference books by neuroscientists worldwide. ‘The Rhesus Monkey
Brain in Stereotaxic Coordinates’ has been cited 698 times (Google scholar,
12/12/2010). ‘The Atlas of the Human Brainstem’ has been cited 159 times
(Google scholar, 12/12/2010). The second edition of ‘The Rhesus Monkey Brain in
Stereotaxic Coordinates’ has recently been published.

Journal Article Citation Report of Xu‐Feng Huang, UoW

Summary:
ISI Web of Knowledge
Key words: Huang Xu-Feng
Day: March, 10th, 2011

Results found: 121
Sum of the Times Cited: 1505
Average Citations per Item: 11
h-index: 22

4. List of Publications
Books
1. Paxinos G, Huang XF, Petrides M and Toga A (2009). The Rhesus Monkey
Brain in Stereotaxic Coordinates, 2nd Ed, Elsevier, Academic Press, San
Diego. ISBN 978-0123736192.
2. Paxinos G, Huang XF and Toga A (2000). The Rhesus Monkey Brain in
Stereotaxic Coordinates. Academic Press, San Diego. ISBN 012-358255-5.
3. Paxinos G and Huang XF (1995). Atlas of the Human Brainstem. Academic
Press, San Diego. ISBN 0-12-547615-9.
Book Chapters
4. Paxinos G, Kayalioglu G, Huang XF and Watson (in press). The human
brainstem nuclei.
5. Paxinos, G. Kayalioglu, Huang & Watson (2009). The Human Nervous
System. Academic Press, San Diego; G Paxinos & JK Mai. ISBN
9780080495316.
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6.

du Bois TM and Huang XF (2009). Neurodevelopment, neurotransmitter
imbalance and cognitive dysfunction in schizophrenia. In ‘New Frontiers in
Neurological Research’ Research Signpost. ISBN: 978-81-308-0284-8.
1:187-206
7. Koutcherov Y, Huang XF, Halliday G and Paxinos G (2004). Organization of
Human Stem Nuclei. The Human Nervous System. Academic Press, 2nd
edition; G Paxinos & JK Mai 10: 267–276.
8. Storlien L, Huang XF, Lin S, Xin X, Wang HQ and Else P (2001). Dietary Fat
Subtypes and Obesity, in Fatty Acids and Lipids. Karger: Besel. Hamazaki
& H Okuyama. 1: 148–154.
9. Paxinos G, Huang XF and Toga A (2000). Photographic and diagrammatic
atlas of the monkey brain. The Rhesus Monkey Brain in Stereotaxic
Coordinates, Academic Press, San Diego; G Paxinos, XF Huang & AW
Toga. 1–151.
10. Petrides M, Paxinos G, Huang XF, Morris R and Pandya DN (2000). The
delineation of the rhesus monkey cortex on the basis of a neurofilament
protein (SMI-32). The Rhesus Monkey Brain in Stereotaxic Coordinates.
Academic Press, G Paxinos, XF Huang & A Toga. 152–230.
11. Paxinos G, XF Huang, Carrive P, Wang HQ, and Toga AW (1995).
Neurotransmitters as a tool for mapping the human brain.
Neurotransmitters in the Human Nervous System. Raven Press, NY, D
Tracy, J Stone & G Paxinos. 1–24.
Articles in International Refereed Journals
12. Dawson AE, Newell KA and Huang XF (2011). Reciprocal signalling
between NR2 subunits of the NMDA receptor and Neuregulin1 and their
role in schizophrenia. Progress in Neuro-Psychopharmacology and
Biological Psychiatry, accepted for publication (ERA Journal Ranking: B;
FoR1=17)
13. Yang F, Wang X, Liu X, Zhao K, Fu W, Hao X, Zhang X, Huang G, Qu S,
Bai J, Huang XF, Kosten T and Zhang X (2011). Sex difference in QTc
prolongation in chronic institutionalized patients with schizophrenia on
long-term treatment with typical and atypical antipsychotics.
Psychopharmacology, accepted for publication (ERA Journal Ranking: A;
FoR1=1701; Impact Factor=4.263)
14. Frank E, Newell K and Huang XF (2011). Density of metabotropic glutamate
receptors 2 and 3 (mGluR2/3) in the dorsolateral prefrontal cortex does not
differ with schizophrenia diagnosis but decreases with age. Schizophrenia
Research, accepted for publication (ERA Journal Ranking: A; FoR1=1109;
Impact Factor=4.945)
15. Weston-Green K, Huang XF and Deng C (2011). Dosage response of
metabolic dysfunction to olanzapine treatment in female Sprague Dawley
rats. Behavioural Brain research 217:337-346. (ERA Journal Ranking: B;
FoR1=1109; Impact Factor=3.206)
16. Beck E, Tapsell L, Batterham M and Huang XF (2010). Oat β-glucan
supplementation does not enhance the effectiveness of an energy-restricted
diet in overweight women. British Journal of Nutrition 103:1212-22. (ERA
Journal Ranking: A; FoR1=1111; Impact Factor=3.569)
17. Boucher AA, Hunt GE, Micheau J, Huang XF, McGregor IS, Karl T, Arnold
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18.

19.

20.

21.

22.
23.

JC (2010). The schizophrenia susceptibility gene neuregulin 1 modulates
tolerance to the effects of cannabinoids. International Journal of
Neuropsychopharmacology 12:1-13. (ERA Journal Ranking: A; FoR1=17;
Impact Factor=4.640)
Deng C, Weston-Green K and Huang XF (2010). The role of histaminergic H1
and H3 receptors in food intake: A mechanism for antipsychotic-induced
weight gain? Progress in Neuro-Psychopharmacology & Biological
Psychiatry 34:1-4. (ERA Journal Ranking: B; FoR1=17; Impact
Factor=2.891)
Hu CH, Deng C, Mackovski N, Long L, Yang Y, Zhu C, Wang Y, Chen J,
Huang XF and Wang Q (2010). Effects of simvastatin and 6hydroxydopamine on histaminergic H1 receptor binding density in rat
brains. Progress in Neuro-Psychopharmacology and Biological Psychiatry
34:1419-25. (ERA Journal Ranking: B; FoR1=17; Impact Factor=2.891)
Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC and Karl T
(2010). A behavioural comparison of acute and chronic delta9tetrahydrocannabinol and cannabidiol in C57Bl/6Arc mice. International
Journal of Neuropsychopharmacology 13:861-876. (ERA Journal Ranking:
A; FoR1=17; Impact Factor=4.640)
Li Y, Huang XF, Deng C, Meyer B and Wang Q (2010). Alterations in 5-HT2A
receptor binding in various brain regions among 6-hydroxydopamineinduced Parkinsonian rats. Synapse 63:224-230. (ERA Journal Ranking: B;
FoR1=1109; Impact Factor=2.584)
Magee CA, Huang XF, Iverson DC and Caputi P (2010). Examining the
pathways linking chronic sleep restriction to obesity. Journal of Obesity
2010:1-8.
Tapsell L, Batterham M, Huang XF, Tan SY, Teuss G, Charlton K, O’Shea J
and Warensjo E (2010). Short term effects of energy restriction and dietary
fat sub-type on weight loss and disease risk factors. Nutrition Metabolism
and Cardiovascular Diseases 20:317-325. (ERA Journal Ranking: A;
FoR1=1111; Impact Factor=3.296)

24. Beck E, Batterham M, Tapsell L, Tosh S and Huang XF (2009). Oat ßglucan increases postprandial cholecystokinin levels, decreases insulin
response and extends subjective satiety in overweight subjects. Molecular
Nutrition & Food Research 53:1343–1351. (ERA Journal Ranking: A*;
FoR1=0908; Impact Factor=4.247)
25. Beck E, Tapsell LC, Batterham MJ, Tosh SM and Huang XF (2009).
Increase in PYY levels following oat beta-glucan ingestion is dose
dependant in overweight adults. Nutrition Research 29:705–709. (ERA
Journal Ranking: C; FoR1=1111; Impact Factor=1.177)
26. Chen J and Huang XF (2009). The effects of diets enriched in beta-glucans
on blood lipoprotein concentrations. Journal of Clinical Lipidology 3:154–
158.
27. Chen J and Huang XF (2009). The signal pathways in azoxymethaneinduced colon cancer and preventive implications. Cancer Biology &
Therapy 8:1313–1317. (ERA Journal Ranking: B; FoR1=1112; Impact
Factor=3.049)
28. du Bois T, Deng C and Huang XF (2009). Excitatory and inhibitory
neurotransmission is chronically altered following perinatal NMDA
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29.

30.

31.

32.
33.

34.

35.

36.

37.

38.
39.

receptor blockade. European Neuropsychopharmacology 19:256–265.
(ERA Journal Ranking: A; FoR1=1701; Impact Factor=3.793)
du Bois T, Deng C, Newell K, Han M and Huang XF (2009). Perinatal PCP
treatment alters the developmental expression of prefrontal and
hippocampal
muscarinic
receptors.
Progress
in
NeuroPsychopharmacology and Biological Psychiatry 33:37–40. (ERA Journal
Ranking: B; FoR1=17; Impact Factor=2.891)
Han M, Huang XF and Deng C (2009). Aripiprazole differentially affects
mesolimbic and nigrostriatal dopaminergic transmission: implications for
long-term drug efficacy and low extrapyramidal side-effects. The
International Journal of Neuropsychopharmacology 12:941–952. (ERA
Journal Ranking: A; FoR1=17; Impact Factor=4.640)
Han M, Huang XF, T du Bois and Deng C (2009). The effects of
antipsychotic drugs administration on 5-HT1A receptor expression in the
limbic system of the rat brain. Neuroscience 164:1754–1763. (ERA Journal
Ranking: A; FoR1=1109; Impact Factor=3.520)
Huang XF and Chen J (2009). Obesity, the PI3K/Akt signal pathway and
colon cancer. Obesity Reviews 10:610–616. (ERA Journal Ranking: A*;
FoR1=1111; Impact Factor=5.086)
Kang K and Huang XF (2009). Decreased density of serotonin 2A receptors
in the superior temporal gyrus in schizophrenia—a post-mortem study.
Progress in Neuro-Psychopharmacology & Biological Psychiatry 33:867–
871. (ERA Journal Ranking: B; FoR1=17 Impact Factor=2.891)
Li Y, South T, Han M, Chen JZ, Wang R and Huang XF (2009). High-fat
diet decreases tyrosine hydroxylase mRNA expression irrespective of
obesity susceptibility in mice. Brain Research 1268:181–189. (ERA
Journal Ranking: B; FoR1=1109; Impact Factor=2.551)
Magee C, Caputi P, Iverson D and Huang XF (2009). Acute sleep restriction
alters neuroendocrine hormones and appetite in healthy male adults. Sleep
and Biological Rhythms 7:125–127. (ERA Journal Ranking: B;
FoR1=1109; Impact Factor=0.812)
Wang Q, Zengin A, Deng C, Li Y, Newell K, Yang GY, Lu Y, Wilder-Smith
E, Zhao H and Huang XF (2009). High dose of simvastatin induces
hyperlocomotive and anxiolytic-like activities: the association with the upregulation of NMDA receptor binding in the rat brain. Experimental
Neurology 216:132–138. (ERA Journal Ranking: B; FoR1=1103; Impact
Factor=4.144)
Yu YH, Deng C and Huang XF (2009). Obese reversal by a chronic energy
restricted diet leaves an increased Arc NPY/AgRP, but no alteration in
POMC/CART, mRNA expression in diet-induced obese mice. Behavioural
Brain Research 205:50–56. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=3.206)
Yu YH, South T and Huang XF (2009). Inter-meal interval is increased in
mice fed a high whey, as opposed to soy and gluten, protein diets. Appetite
52:372–379. (ERA Journal Ranking: B; FoR1=1701; Impact Factor=2.966)
Yu YH, Wang Q and Huang XF (2009). Energy restricted pair-feeding
normalizes low levels of BDNF/TrkB mRNA expression in the
hippocampus, but not VMH in diet-induced obese mice. Neuroscience
160:295–306. (ERA Journal Ranking: A; FoR1=1109; Impact
Factor=3.520)
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40. du Bois T, Huang XF and Deng C (2008). Perinatal administration of PCP
alters adult behaviour in female Sprague-Dawley rats. Behavioural Brain
Research 188:416–419. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=3.206)
41. du Bois T, Hsu CW, Li YL, Han M, Tan YY, Deng C and Huang XF (2008).
Altered dopamine receptor and dopamine transporter binding and tyrosine
hydroxylase mRNA expression following perinatal NMDA receptor
blockade. Neurochemical Research 33:1224–1231. (ERA Journal Ranking:
C; FoR1=1109; Impact Factor=2.392)
42. Han M, Deng C, Burne T, Newell K and Huang XF (2008). Short and longterm effects of antipsychotic drug treatment on weight gain and H1
receptor expression. Psychoneuroendocrinology 33:569–580. (ERA Journal
Ranking: B; FoR1=1103; Impact Factor=4.959)
43. Han M, Newell K, Zavitsanou K, Deng C and Huang XF (2008). Effects of
Antipsychotic Medication on Muscarinic M1 Receptor mRNA Expression
in the Rat Brain. Journal of Neuroscience Research 86:457–464. (ERA
Journal Ranking: B; FoR1=1109; Impact Factor=3.190)
44. Huang XF, Yu Y, Li Y, Deng C and Wang Q (2008). Ventromedial
hypothalamic NPYY2 receptor in the maintenance of body weight in dietinduced obesity in mice. Neurochemical Research 33:1881–1888. (ERA
Journal Ranking: C; FoR1=1109; Impact Factor=2.392)
45. Huang XF, Liu Y, Rahardjo G, McLennan P, Tapsell L and Buttemer WA
(2008). Effects of diets high in whey, soy, red meat and milk protein on
body weight maintenance in diet-induced obesity in mice. Nutrition and
Dietetics 65:53–59. (ERA Journal Ranking: C; FoR1=1111)
46. Magee CA, Caputi P, Iverson D and Huang XF (2008). An investigation of
the dimensionality of the pittsburgh sleep quality index in australian adults.
Sleep and Biological Rhythms 6:222–227. (ERA Journal Ranking: B;
FoR1=1109; Impact Factor=0.812)
47. Magee CA, Iverson D, Huang XF and Caputi P (2008). A Link between
Chronic Sleep Restriction and Obesity: Methodological Considerations.
Public Health 122:1373–1381. (ERA Journal Ranking: C; FoR1=1117;
Impact Factor=1.423)
48. South T and Huang XF (2008). Temporal and site-specific brain alterations
in CB1 receptor binding in high-fat diet-induced obesity in C57Bl/6 Mice.
Journal of Neuroendocrinology 20:1288–1294. (ERA Journal Ranking: B;
FoR1=1103; Impact Factor=3.281)
49. South T and Huang XF (2008). High-fat diet exposure increases dopamine
D2 receptor and decreases dopamine transporter binding density in the
nucleus accumbens and caudate putamen of mice. Neurochemical Research
33:598–605. (ERA Journal Ranking: C; FoR1=1109; Impact Factor=2.392)
50. Wang Q, Zengin A, Ying W, Newell K, Wang P, Yeo W, Wong P, Yenari M
and Huang XF (2008). Chronic treatment with simvastatin upregulates
muscarinic M1/4 receptor binding in the rat brain. Neuroscience 154:1100–
1106. (ERA Journal Ranking: A; FoR1=1109; Impact Factor=3.520)
51. Wang Q and Huang XF (2008). Effects of chronic treatment of olanzapine
and haloperidol on peptide YY binding densities in the rat brain.
Experimental Neurology 209:261–267. (ERA Journal Ranking: B;
FoR1=1103; Impact Factor=4.144)
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52. Weston-Green K, Huang XF, Han M and Deng C (2008). The effects of
antipsychotics on the density of cannabinoid receptors in the dorsal vagal
complex of rats: Implications for olanzapine-induced weight gain. The
International Journal of Neuropsychopharmacology 11:827–835. (ERA
Journal Ranking: A; FoR1=17; Impact Factor=4.640)
53. Yu YH, South T, Wang Q and Huang XF (2008). Differential expression of
hypothalamic CART mRNA in response to body weight change following
different dietary interventions. Neurochemistry International 52:1422–
1430. (ERA Journal Ranking: B; FoR1=1101; Impact Factor=3.541)
54. Zavitsanou K, Nguyen V, Newell K and Huang XF (2008). Rapid corticolimbic alterations in AMPA receptor densities after administration of PCP:
implications for schizophrenia. Journal of Chemical Neuroanatomy 36:71–
76. (Era Journal Ranking: B; FoR1=1109; Impact Factor=1.930)
55. Brown M, Wickham M, McAndrew DJ and Huang XF (2007). Muscles
within muscles: coordination of 19 muscle segments within three shoulder
muscles during isometric motor tasks. Journal of Electromyography and
Kinesiology 17:57–73. (ERA Journal Ranking: B; FoR1=1106; Impact
Factor=2.373)
56. Deng C and Huang XF (2007). No changes in densities of cannabinoid
receptors in the superior temporal gyrus in schizophrenia. Neuroscience
Bulletin 23:341–347. (ERA Journal Ranking: C; FoR1=1109)
57. Deng C, Weston-Green KL, Han M and Huang XF (2007). Olanzapine
treatment decreases the density of muscarinic M2 receptors in the dorsal
vagal complex of rats. Progress in Neuro-Psychopharmacology and
Biological Psychiatry 31:915–920. (ERA Journal Ranking: B; FoR1=17;
Impact Factor=2.891)
58. du Bois T and Huang XF (2007). Early brain development disruption from
NMDA receptor hypofunction: Relevance to Schizophrenia. Brain
Research Reviews 53:260–270. (ERA Journal Ranking: A; FoR1=1109;
Impact Factor=7.330)
59. Huang XF, Tan YY, Huang X and Wang Q (2007). Effect of chronic
treatment with clozapine and haloperidol on 5-HT2A and 2C receptor
mRNA expression in the rat brain. Neuroscience Research 59:314–321.
(ERA Journal Ranking: C; FoR1=1109; Impact Factor=2.372)
60. Newell K, Zavitsanou K and Huang XF (2007). Short and Long term
changes in NMDA receptor binding in mouse brain following chronic
phencyclidine treatment. Journal of Neural Transmission 114:995–1001.
(ERA Journal Ranking: B; FoR1=1109; Impact Factor=2.744)
61. Newell K, Zavitsanou K and Huang XF (2007). Opposing short-and long-term
effects on muscarinic M1/M4 receptor binding following chronic
phencyclidine treatment. Journal of Neuroscience Research 85:1358–1363.
(ERA Journal Ranking: B; FoR1=1109; Impact Factor=3.190)
62. Newell K, Zavitsanou K, Jew SK and Huang XF (2007). Alterations of
muscarinic and GABA receptor binding in the posterior cingulate cortex in
schizophrenia. Progress in Neuro-Psychopharmacology & Biological
Psychiatry 31:225–233. (ERA Journal Ranking: B; FoR1=17; Impact
Factor=2.891)
63. Rahardjo GL, Huang XF, Tan YY and Deng C (2007). Decreased plasma
PYY accompanied by an elevated PYY and Y2 receptor binding sites in the
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medulla oblongata of diet-induced obese mice. Endocrinology 148:4704–
4710. (ERA Journal Ranking: A*; FoR1=1103; Impact Factor=5.103)
64. South T, Deng C and Huang XF (2007). AM 251 and beta-Funaltrexamine
reduce fat intake in a fat-preferring strain of mouse. Behavioural Brain
Research 181:153–157. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=3.206)
65. Wang Q, Kannan KT, Erle C, Lim Y, Chan H, Deng C, Huang XF and Einar
P (2007). A static handgrip method for distal quantitative sweat
measurements. Neuroscience Letters 421:229–233. (ERA Journal Ranking:
C; FoR1=1109; Impact Factor=2.114)
66. Zavitsanou K, Nguyen V, Han M and Huang XF (2007). Effects of typical
and atypical antipsychotic drugs on rat brain muscarinic receptors.
Neurochemical Research 32:525–532. (ERA Journal Ranking: C;
FoR1=1109; Impact Factor=2.392)
67. Bjursell MA, Gerdin AK, Jonsson M, Surve VV, Svensson L, Huang XF,
Tornell J and Bohlooly-Y M (2006). G protein-coupled receptor 12
deficiency results in decreased energy expenditure, dyslipidemia and
obesity in mice. Biochemical and Biophysical Research Communications
348:359–366. (ERA Journal Ranking: B; FoR1=0601; Impact
Factor=2.720)
68. Deng C and Huang XF (2006). Increased density of GABAa receptors in the
superior temporal gyrus in schizophrenia. Experimental Brain Research
168:587–590. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=2.410)
69. du Bois T, Deng C and Huang XF (2006). Fatty acids differentially affect
serotonin receptor and transporter transporter binding in the rat brain.
Neuroscience 139:1397–1403. (ERA Journal Ranking: A; FoR1=1109;
Impact Factor=3.520)
70. Huang XF, Zavitsanou K, Huang X, Yu Y, Wang HQ, Chen F, Lawrence A
and Deng C (2006). Dopamine transporter and D2 receptor densities in
mice prone or resistant to chronic high-fat diet-induced obesity.
Behavioural Brain Research 175:415–419. (ERA Journal Ranking: B;
FoR1=1109; Impact Factor=3.206)
71. Huang XF, Deng C and Zavitsanou K (2006). Neuropeptide Y mRNA
expression levels following chronic olanzapine, clozapine and haloperidol
administration in rats. Neuropeptides 40:213–219. (ERA Journal Ranking:
B; FoR1=0601; Impact Factor=2.176)
72. Huang XF, Zavitsanou K and Deng C (2006). Olanzapine differentially
affects 5-HT2A and 2C receptor mRNA expression in the rat brain.
Behavioural Brain Research 171:355–362. (ERA Journal Ranking: B;
FoR1=1109; Impact Factor=3.206)
73. Newell K, Deng C and Huang XF (2006). Increased cannabinoid receptor
density in the posterior cingulated cortex in schizophrenia. Experimental
Brain Research 172:556–560. (ERA Journal Ranking: B; FoR1=1109;
Impact Factor=2.410)
74. South T and Huang XF (2006). Phenotypic variations between a fatpreferring strain and a macronutrient non-preferring strain of mouse.
Diabetes, Obesity and Metabolism 8:302–310. (ERA Journal Ranking: B;
FoR1=1103)
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75. Weidenhofer J, Yip J, Zavitsanou K, Huang XF, Chahl LA and Tooney PA
(2006). Immunohistochemical Localisation of the NK1 Receptor in the
Human Amygdala. Progress in Neuro-Psychopharmacology and
Biological Psychiatry 30:1313–1321. (ERA Journal Ranking:B; FoR1=17;
Impact Factor=2.891)
76. Deng C and Huang XF (2005). Decreased density of muscarinic receptors in
the superior temporal gyrus in schizophrenia. Journal of Neuroscience
Research 81:883–890. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=3.190)
77. du Bois T, Bell W, Deng C and Huang XF (2005). A High n-6
polyunsaturated fatty acid diet reduces muscarinic M2/M4 receptor binding
in the rat brain. Journal of Chemical Neuroanatomy 29:282–288. (ERA
Journal Ranking: B; FoR1=1109; Impact Factor=1.930)
78. du Bois T, Deng C and Huang XF (2005). Membrane phospholipid
composition, alterations in neurotransmitter systems and schizophrenia.
Progress in Neuro-Psychopharmacology & Biological Psychiatry 29:879–
889. (ERA Journal Ranking: B; FoR1=17; Impact Factor=2.891)
79. Huang XF, Yu YH, Zavitsanou K, Han M and Storlien LH (2005)
Differential expression of dopamine D2 and D4 receptor and TH mRNA
expression in mice prone, or resistant, to chronic high-fat diet-induced
obesity. Molecular Brain Research 135:150–161. (ERA Journal Ranking:
B)
80. Newell K, Zavitsanou K and Huang XF (2005). Ionotropic glutamate
receptor binding in the posterior cingulate cortex in schizophrenia.
NeuroReport 16:1363–1367. (ERA Journal Ranking: B; FoR1=1109;
Impact Factor=2.260)
81. Storlien L, Huang XF, Tapsell LC, Karlsson C, Niklasson M and Carlsson
BC (2005). Lifestyle-gene-drug interactions in relation to the metabolic
syndrome. World Review of Nutrition and Diet 94:84–95.
82. Zavitsanou K, Katsifis A, Yu Y and Huang XF (2005). M2/M4 muscarinic
receptor binding in the anterior cingulate cortex in schizophrenia and mood
disorders. Brain Research Bulletin 65:397–403. (ERA Journal Ranking: B;
FoR1=1109; Impact Factor=2.193)
83. Huang XF, Han M and Storlien LH (2004). Differential expression of 5HT2a and 5-HT2c receptor mRNA in mice prone, or resistant, to high-fat
diet-induced obesity. Molecular Brain Research 127:39–47. (ERA Journal
Ranking: B)
84. Huang XF, Huang X, Han M, Chen F, Storlien LH and Lawrence A (2004).
5-HT2A/2C receptor and 5-HT transporter densities in mice prone or
resistant to chronic high-fat diet-induced obesity: a quantitative
autoradiography study. Brain Research 1018:227–235. (ERA Journal
Ranking: B; FoR1=1109; Impact Factor=2.551)
85. Huang XF, Xin X, McLennan P and Storlien LH (2004). Role of fat amount
and type in ameliorating diet-induced obesity: insights at the level of
hypothalamic arcuate nucleus, leptin receptor, neuropeptide Y and proopiomelanocortin mRNA expression. Diabetes, Obesity and Metabolism
6:35–45. (ERA Journal Ranking: B; FoR1=1103)
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86. Paxinos G, Chai SY, Christopoulos G, Huang XF, Toga AW, Wang HQ and
Sexton PM (2004). In vitro autoradiographic localization of calcitonin and
amylin binding sites in monkey brain. Journal of Chemical Neuroanatomy
27:217–236. (Era Journal Ranking: B; FoR1=1109; Impact Factor=1.930)
87. Zavitsanou K, Garrick T and Huang XF (2004). Selective antagonist
[3H]SR141716A binding to cannabinoid CB1 receptors is increased in the
anterior cingulate cortex in schizophrenia. Progress in NeuroPsychopharmacology & Biological Psychiatry 28:355–360. (ERA Journal
Ranking: B; FoR1=17; Impact Factor=2.891)
88. Zavitsanou K, Andrew K, Filomena M and Huang XF (2004). Investigation
of M1/M4 muscarinic receptors in the anterior cingulate cortex in
schizophrenia, bipolar disorder and major depression disorders.
Neuropsychopharmacology 29:619–625. (ERA Journal Ranking: A*;
FoR1=1115; Impact Factor=6.813)
89. Huang XF, Han M, South T and Storlien LH (2003). Altered levels of
POMC, AgRP and MC4-R mRNA expression in the hypothalamus and
other parts of the limbic system of mice prone or resistant to chronic highenergy diet-induced obesity. Brain Research 992:9–19. (ERA Journal
Ranking: B; FoR1=1109; Impact Factor=2.551)
90. Huang XF, Han M and Storlien LH (2003). The level of NPY receptor
mRNA expression in diet-induced obese and resistant mice. Molecular
Brain Research 115:21–28. (ERA Journal Ranking: B)
91. Zavitsanou K and Huang XF (2002). Selective alterations in ionotropic
glutamate receptors in the cingulate cortex in schizophrenia.
Neuropsychopharmacology 27:826–833. (ERA Journal Ranking: A*;
FoR1=1115; Impact Factor=6.813)
92. Zavitsanou K and Huang XF (2002). Decreased [3H]spiperone binding in the
anterior cingulate cortex of schizophrenia: an autoradiographic study.
Neuroscience 109:709–716. (ERA Journal Ranking: A; FoR1=1109;
Impact Factor=3.520)
93. Wang HQ, Storlien LH and Huang XF (2002). Effects of dietary fat types on
body fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA
expression. American Journal of Physiology, Endocrinology and
Metabolism 282:E1352-E1359. (ERA Journal Ranking: A; FoR1=1116)
94. Lin S, Thomas TC, Storlien LH and Huang XF (2000). Development of
obesity and central leptin resistance in high-fat diet induced obese mice.
International Journal of Obesity and Related Metabolic Disorders 2463924646. (ERA Journal Ranking: A)
95. Xin XG, Storlien LH and Huang XF (2000). Hypothalamic c-Fos-like
immunoreactivity in high fat diet-induced obese and resistant mice. Brain
Research Bulletin 52:235–242. (ERA Journal Ranking: B; FoR1=1109;
Impact Factor=2.193)
96. Lin S, Storlien L and Huang XF (2000). Leptin receptor, NPY, POMC
mRNA expression in the diet-induced obese mouse brain. Brain Research
875:89–95. (ERA Journal Ranking: B; FoR1=1109; Impact Factor=3.206)
97. Storlien LH, Higgins JA, Thomas TC, Brown MA, Wang HQ, Huang XF
and Else P (2000). Diet composition and insulin action in animal models.
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British Journal of Nutrition 83:S85–S90. (ERA Journal Ranking: A;
FoR1=1111; Impact Factor=3.569)
98. Wang HQ, Huang XF, Jenkins A and Storlien L (2000). Down-regulation of
NPY and AgRP mRNA expression by high saturated fat diet is independent
of plasma leptin in mice. Journal of Obesity Research 8:60S.
99. Wang HQ, Storlien L and Huang XF (1999). Influence of dietary fats on cFos-like immunoreactivity in mouse hypothalamus. Brain Research
843:184–192. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=3.206)
100. Lin S and Huang XF (1999). Altered hypothalamic c-fos expression in diet
induced obese mice. Brain Research Bulletin 49:251–259. (ERA Journal
Ranking: B; FoR1=1109; Impact Factor=2.193)
101. Huang XF and Wang HQ (1998). Altered c-fos protein expression in the
brain of obese (ob/ob) mice. Brain Research 799:307–310. (ERA Journal
Ranking: B; FoR1=1109; Impact Factor=3.206)
102. Xin XG and Huang XF (1998). Downregulated Y5 receptor gene expression
in genetically obese mice. NeuroReport 4:737–741. (ERA Journal Ranking:
B; FoR1=1109; Impact Factor=2.260)
103. Lin S and Huang XF (1997). Fasting increases leptin receptor mRNA
expression in lean but not obese (ob/ob) mouse brain. NeuroReport
8:3625–3629. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=2.260)
104. Lloyd A, Dixon G, Huang XF, Ward P, Catts S, Hickie I and Wakefield D
(1997). Molecular biology and the major psychoses. Aust N Z J Psychiatry
31:12–16. (ERA Journal Ranking: B; FoR1=1103; Impact Factor=2.761)
105. Huang XF, Lin S and Zhang R (1997). Upregulation of leptin receptor
mRNA expression in obese mouse brain. NeuroReport 8:1035–1038. (ERA
Journal Ranking: B; FoR1=1109; Impact Factor=2.260)
106. Catts SV, Ward P, Lloyd A, Huang XF, Dixon G, Chahl L, Harper C and
Wakefield D (1997). Molecular biological investigations into the role of the
NMDA receptor in the pathophysiology of schizophrenia. Aust N Z J
Psychiatry 31:17–26. (ERA Journal Ranking: B; FoR1=1103; Impact
Factor=2.761)
107. Huang XF, Koutcherov I, Lin S, Wang HQ and Storlien L (1996).
Localisation of leptin receptor mRNA expression in mouse brain.
NeuroReport, 7:2635–2638. (ERA Journal Ranking: B; FoR1=1109; Impact
Factor=2.260)
108. Sexton PM, Christopoulos G, Huang XF, Toga AW and Paxinos G (1995).
In-Vitro Autoradiographic Localization of Calcitonin Receptors in Monkey
Brain. Journal of Neurochemistry 65:S184. (ERA Journal Ranking: A;
FoR1=1109; Impact Factor=4.206)
109. Christopoulos G, Paxinos G, Huang XF, Toga A and Sexton PM (1995).
Comparative distribution of receptors for amylin and the related peptides
CGRP and calcitonin in rat and monkey brain. Canadian Journal of
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Physiology and Pharmacology 73:1037-1041. (ERA Journal Ranking: B;
FoR1=1115; Impact Factor=1.596)
110. Huang XF and Paxinos G (1995). The human intermediate reticular zone: A
cyto-and chemoarchitectonic study. The Journal of Comparative Neurology
360:571–588. (ERA Journal Ranking: A*; FoR1=0608; Impact
Factor=3.935)
111. Sexton PM, Paxinos G, Huang XF and Mendelsohn FAO (1994). In vitro
autoradiographic localisation of calcitonin binding sites in human medulla
oblongata. The Journal of Comparative Neurology 341:449-463. (ERA
Journal Ranking: A*; FoR1=0608; Impact Factor=3.935)
112. Huang XF, Paxinos G, Halasz P, McRitchie D and Törk I (1993). Substance
P-and tyrosine hydroxylase-containing neurons in the human dorsal motor
nucleus of the vagus nerve. The Journal of Comparative Neurology
335:109-122. (ERA Journal Ranking: A*; FoR1=0608; Impact
Factor=3.935)
113. Huang XF, Törk I and Paxinos G (1993). Dorsal motor nucleus of the vagus
nerve: A cyto-and chemoarchitectonic study in the human. Journal of
Comparative Neurology 330:158-182. (ERA Journal Ranking: A*;
FoR1=0608; Impact Factor=3.935)
114. Huang XF, Törk I, Halliday GM and Paxinos G (1992). The dorsal,
posterodorsal and ventral tegmental nuclei: A cyto-and chemoarchitectonic
study in the human. The Journal of Comparative Neurology 318:117-137.
(ERA Journal Ranking: A*; FoR1=0608; Impact Factor=3.935)

Letters to Editor
115. Hu CH, Pai N, Huang XF and Deng C (2011). Potential control of risperidone
related cognitive deficits by adjunctive aripiprazole treamtment. Journal of
Clinical Psychopharmacology 30:480-481. (ERA journal Ranking: A;
FoR1=1701; Impact Factor=4.716)
116. Chen J and Huang XF (2010). The PI3K/Akt pathway may play a key role in
social isolation-caused schizophrenia, comment re: Increased dopamine
D2(High) receptors in rats reared in social isolation. Synapse 64:486-487.
(ERA journal Ranking: B; FoR1=1109; Impact Factor=2.584)
117. Chen J, Huang XF and Katsifis A (2010). Activation of signal pathways and
the resistance to anti-EGFR treatment in colorectal cancer. Journal of
Cellular Biochemistry 111:1082-1086. (ERA journal Ranking: B;
FoR1=0601; Impact Factor=3.285)
118. Chen J, Gislette T and Huang XF (2010). The role of molecular weight and
viscosity of oat ß-glucan in hypocholesterolemic effect. American Journal of
Clinical Nutrition 92:1538; author reply 1539-40. (ERA journal Ranking: A*;
FoR1=1114; Impact Factor=7.744)
119. Chen J and Huang XF (2010). Comment on: Dietary flavonoids suppress
azoxymethane-induced colonic preneoplastic lesions in male C57BL/Ksjdb/db mice. Chemico-Biological Interactions 185:78; author reply 79-80.
(ERA journal Ranking: C; FoR1=0601)
120. Chen J and Huang XF (2010). Dietary flavonoids suppress azoxymethane-
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121.
122.

123.
124.

125.

induced colonic preneoplastic lesions in male C57BL/Ksj-db/db mice.
Chemico-Biological Interactions 183:276-283. (ERA Journal Ranking: C;
FoR1=0601)
Chen J and Huang XF (2010). Beta-glucan may play an important role in algae
hypocholesterolemia effect. European Journal of Nutrition 49:63-4. (ERA
journal Ranking: B; FoR1=1111; Impact Factor=3.146)
Deng C, Chen J, Hu C-H and Huang XF (2010). What is the mechanism for
aripiprazole’s effect on reducing olanzapine-induced obesity? Journal of
Clinical Psychopharmacology 30:480-481. (ERA Journal Ranking: A;
FoR1=1701; Impact Factor=4.716).
Huang XF and Chen J (2010). Obesity and pancreatic cancer: possible role of
the PI3K/Akt pathway. Surgery 147:596. (ERA journal Ranking: B;
FoR1=1103; Impact Factor=3.793)
Lian J, Huang XF, Pai N and Deng C (2010). Potential control of
antipsychotic-induced hyperprolactinemia and obesity in children and
adolescents by aripiprazole. Progress in Neuro-Psychopharmacology and
Biological Psychiatry 34:1157-1158. (ERA journal Ranking: B; FoR1=17;
Impact Factor = 2.891)
Western-Green K, Huang XF and Deng C (2010). Sensitivity of the Female Rat
to Olanzapine-Induced Weight Gain – Far From the Clinic? Schizophrenia
Research 116:299-300. (ERA journal Ranking: A; FoR1=1109; Impact
Factor=4.945)

126. Chen J and Huang XF (2009). Activation of p53 for the treatment of cancer.
Journal of Cellular Biochemistry 107:567–568. (ERA Journal Ranking: B;
FoR1=0601; Impact Factor=3.285)
127. Chen J and Huang XF (2009). Adiponectin in obesity-associated colon
cancer and its preventive implication. Digestive Diseases and Sciences
54:1810–1811. (ERA Journal Ranking: B; FoR1=1103; Impact
Factor=1.729)
128. Chen J and Huang XF (2009). Adiponectin is not effective against AOMinduced colon cancer but more evidences are required for its role in obesityassociated colon cancer. International Journal of Cancer 125:2483–2483.
(ERA Journal Ranking: A; FoR1=1112; Impact Factor=4.558)
129. Chen J and Huang XF (2009). Beta-Catenin pathway in ulcerative colitisassociated colorectal cancer and therapeutic implication. Journal of
Gastrointestinal Cancer 40:64–65.
130. Chen J and Huang XF (2009). Comment on Effects of adipocyte-secreted
factors on cell cycle progression in HT29 cell. European Journal of
Nutrition 48:505–505. (ERA Journal Ranking: B; FoR1=1111; Impact
Factor=3.146)
131. Chen J and Huang XF (2009). Interleukin-6 promotes carcinogenesis through
multiple signal pathways. Digestive Diseases and Sciences 54:1373–1374.
(ERA Journal Ranking: B; FoR1=1103; Impact Factor=1.729)
132. Chen J and Huang XF (2009). Obesity is a major factor for colon cancer
prognosis. Colorectal Disease 11:538–539. (ERA Journal Ranking: C;
FoR1=1103; Impact Factor=2.438)
133. Huang XF and Chen JZ (2009). Adiponectin and signal pathways in obesityinduced colon cancer. Gut: Journal of the British Society of
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Gastroenterology 58:1169. (ERA Journal Ranking: A*; FoR1=1103; Impact
Factor=9.663)
134. Huang XF and Chen JZ (2009). Neuregulin 1, brain region specificity and
PI3K/Akt in schizophrenia. European Archives of Psychiatry and Clinical
Neuroscience 259:307–308. (ERA Journal Ranking: C; FoR1= 103; Impact
Factor=3.149)
135. Han M, Deng C, Newell KA and Huang XF (2007). Histamine H1 mRNA
expression is decreased in the rat hypothalamus following olanzapine
treatment. Schizophrenia Bulletin 33:317. (ERA Journal Ranking: A;
FoR1=1701; Impact Factor=7.253).

National and International Conference Papers:
136. Morosin T, du Bois TM, Newell KA and Huang XF (2011). The effect of
phencyclidine on neuregulin1 and erbB4 receptor mRNA expression in the
adult rat. Australian Neuroscience Society Society 31th Annual Meeting,
New Zealand, 2011.
137. Pan B, Huang XF, Hu CH, Han M and Deng C (2010). Effects of Typical and
Atypical Antipsychotics on the Expressions of Neuregulin 1 and Erbb4
Receptors. 11th Biennial Australia ASC, 2010.
138. Chen J, Huang XF and Katsifis AQ (2010). Insulin decreases the cytotoxicity
of oxaliplatin in colon cancer cell HT29. Obesity and cancer conference,
Spain, October 2010.
139. Dawson A, Newell KA, Ruthirakumar S and Huang XF (2010). The effect of
perinatal and adolescent brain development disruption from NMDA receptor
antagonism on CB1 receptor levels in the rat prefrontal cortex. Australian
Neuroscience Society 30th Annual Meeting, Sydney, January 2010.
140. Dawson AE, Newell KA and Huang XF (2010). No change in 3H-Ifenprodil
binding sites for the NR2B subunit in the prefrontal cortex in schizophrenia.
Australasian Schizophrenia Conference, Sydney, 2010.
141. Dawson AE, Newell KA, Ruthirakumar S and Huang XF (2010). The Effect
of Perinatal and Adolescent Brain Development Disruption from NMDA
Receptor Antagonism on CB1 Receptor Levels in the Rat Prefrontal Cortex.
Australian Neuroscience Society 30th Annual Meeting, February 2010.
142. du Bois TM, Newell KA, Warren CA and Huang XF (2010). The effects of
phencyclidine on the NMDAR/neuregulin1 signalling complex: implications
for schizophrenia. Australian Neuroscience Society Annual Meeting, Sydney,
January 2010.
143. du Bois TM, Newell KA and Huang XF (2010). NMDA receptor and
neuregulin1 signalling in the perinatal PCP animal model of schizophrenia.
Federation of European Neuroscience Societies Forum, Amsterdam, July
2010.
144. Frank E, Snikeris P, Pathy R and Huang XF (2010). Environmental
enrichment affects PCP-induced behavioural, neurochemical and immune
characteristics related to schizophrenia. Federation of European Neuroscience
Societies Forum, Amsterdam, July 2010.
145. Frank E, Snikeris P, Pathy R and Huang XF (2010). Environmental
enrichment affects PCP-induced behavioural and neurochemical symptoms of
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schizophrenia Australian Neuroscience Society 30th Annual Meeting, Sydney,
January 2010.
146. Frank E, Snikeris P, du Bois TM, Newell KA and Huang XF (2010). Perinatal
Phencyclidine (PCP) Treatment in Schizophrenia Research – Of Mice and
Rats. Australasian Schizophrenia Conference, Sydney, 2010.
147. Handyani D, Chen J, Meyer B and Huang XF (2010). Shiitake mushroom
beta-glucan but not oat beta-glucan prevents body weight gain in rats fed a
high fat diet. Annual Scientific Meeting of Nutrition Society of Australia,
2010.
148. Hu C, Deng C, Huang XF, Chen J and Wang Q (2010). Effects of simvastatin
and 6-hydroxydopamine lesion on histaminergic H1 receptor binding in rat
brains. Abstracts of Australian Neuroscience Socity/Australian Physiological
Society 2010 Joint Meeting; p.118, Sydney, January 2010.
149. Huang XF and Chen J (2010). Diet-induced obese mice are significantly more
susceptible to develop colon cancer than diet-resistant mice after chronic
azoxymethane treatment. Obesity and cancer conference, Spain, October
2010.
150. Chen J, Katsifis A, Hu C and Huang XF (2010). Insulin decreases cytotoxicity
of cycloheximide on HT29 and LS174T colon cancer cell lines via the
PI3K/Akt pathway. 22nd Lorne Cancer Conference, 2010.
151. Lian J, Huang XF, Pai N and Deng C (2010). Reduce the olanzapine-induced
body weight gain with histamine H1 receptor agonist betahistine in rats.
Collegium Internationale Neuro-Psychopharmacologicum XXVII World
Congress, Hongkong, China, June 2010; International Journal of
Neuropsychopharmacology 13 (Supplement S1):99.
152. Lian J, Weston-Green K, Kang K, Huang XF and Deng C (2010). Olanzapine
decreases [3H]SR141716A binding to cannabinoid CB1 receptors in the rat
hippocampus and auditory cortex: a dosage-dependent response. Australian
Neuroscience Society 30th Annual Meeting, Sydney, January 2010.
153. Lian J, Weston-Green K, Kang K, Huang XF and Deng C (2010). Olanzapine
decreases [3H]SR141716A binding to cannabinoid CB1 receptors in the rat
hippocampus and auditory cortex: a dosage-dependent response. Abstracts of
Australian Neuroscience Socity/Australian Physiological Society 2010 Joint
Meeting; p.82, Sydney, January 2010.
154. Han M, Huang XF and Deng C (2010). Effects of Antipsychotic Drugs on
Muscarinic M1 Receptors in the Rat Brain. 11th Biennial Australia ASC,
2010.
155. Newell KA, Dawson AE and Huang XF (2010). Long term reductions in
glutamatergic NMDA and dopaminergic D1 and D2 receptors in the rat brain
following adolescent, but not perinatal, MK-801 treatment. Australian
Neuroscience Society 30th Annual Meeting, Sydney, January 2010.
156. Newell KA., du Bois TM, Warren C and Huang XF (2010). Neuregulin1 and
ErbB4 protein levels are altered in the rat brain following perinatal NMDA
receptor antagonism: implications for schizophrenia. Federation of
European Neuroscience Societies Forum, Amsterdam, July 2010.
157. Pan B, Huang XF, Dedova I and Deng C (2010). An age difference in mu
opioid receptor binding density in the human putamen but no changes in
schizophrenia. Abstracts of Australian Neuroscience Socity/Australian
Physiological Society 2010 Joint Meeting; p.33, Sydney, January 2010.
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158. Pan B, Huang XF, Dedova I and Deng C (2010). An age difference in mu
opioid receptor binding density in the human putamen but no changes in
schizophrenia. Australian Neuroscience Society 30th Annual Meeting,
Sydney, January 2010.
159. Snikeris P, Huang XF and Frank E (2010). Immune factors in the Neuregulin1 knockout mouse model of schizophrenia. Federation of European
Neuroscience Societies Forum, Amsterdam, July 2010.
160. Snikeris P, Huang XF and Frank E (2010). Cytokine alterations in the
Neuregulin-1
knockout
mouse
model
of
schizophrenia.
Psychoneuroimmunology Research Society Meeting, Dublin, June 2010.
161. Snikeris P, Huang XF and Frank E (2010). Immune factors in animal models
of schizophrenia. Australian Neuroscience Society 30th Annual Meeting,
Sydney, January 2010.
162. Warren CR, Newell KA, du Bois TM and Huang XF (2010). Neuregulin1 and
ErbB4 Protein Expression in the Rat Brain Following Perinatal Phencyclidine
Treatment. Australian Neuroscience Society 30th Annual Meeting, Sydney,
January 2010.
163. Weston-Green K, Huang XF, Kang K and Deng C (2010). Olanzapine
decreases cannabinoid CB1 receptors in the hypothalamus and brainstem,
possibly through muscarinic M3 receptor antagonism. Collegium
Internationale Neuro-Psychopharmacologicum XXVII World Congress,
Hongkong,
China,
June
2010;
International
Journal
of
Neuropsychopharmacology 13 (supplement 1):111-112.
164. Weston-Green K, Huang XF and Deng C (2010). The dosage response to the
side-effect of metabolic dysfunction in female rats following olanzapine
treatment. Australian Neuroscience Society 30th Annual Meeting, Sydney,
January 2010
165. Weston-Green K, Huang XF and Deng C (2010). The dosage response to the
side-effect of metabolic dysfunction in female rats following olanzapine
treatment. Abstracts of Australian Neuroscience Socity/Australian
Physiological Society 2010 Joint Meeting; p.82, Sydney, January 2010.
166. Weston-Green K, Huang XF, Lian J and Deng C (2010). Olanzapine-induced
metabolic dysfunction: A role for central muscarinic M3 receptors. Abstracts
of Australian Neuroscience Socity/Australian Physiological Society 2010
Joint Meeting; p.33, Sydney, January 2010.
167. Yu Y and Huang XF (2010). GHS-R mRNA expression levels are increased in
the VMH of diet-resistant mice. Australian Neuroscience Society 30th
Annual Meeting, Sydney, January 2010.
168. Chesworth R, Arnold J, Boucher A, Huang XF, Newell K and Karl T (2009).
A mouse model for the schizophrenia candidate gene neuregulin 1. UNSW
Brain Sciences Symposium, 2009.
169. Beck EJ, Tapsell LC, Tosh SM, Batterham MJ and Huang XF (2009). Dietary
interventions with fibre ingredients-considerations, measurements and
manipulations. Cereal Foods World, 54(4): 16
170. Beck, EJ, Tosh, SM, Tapsell, LC, Batterham, MJ and Huang XF (2008)
Characterisation of a functional ingredient requires multiple assessments.
Cereal Foods World, 54(3) Supplement, A21.
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171. Beck, EJ, Tapsell, LC, Huang, XF and Batterham, MJ\ (2008) Relationships
between 24 hour recalls and fasting measures of hunger and satietysubjective and biochemical indices. Nutrition and Dietetics, 65; (S2) A11.
172. Beck, EJ, Norman, JA., Batterham, MJ, Huang, XF and Tapsell, LC (2007)
Dietetic practice in appetite research – acute meal test studies. Nutrition and
Dietetics, 64; Suppl. 1, S49-51.
173. Beck, EJ, Tapsell, L, Batterham, M and Huang, XF Developing foods with
fibre effects. 2008 International Congress of Dietetics, Yokohama, Japan
(OS-8-1, Sept 8-11).
174. Deng C, Huang XF (2008) Related pathological changes of serotonin 2A,
muscarinic M1 and GABA A receptors in the superior temporal gyrus in
schizophrenia Australian Neuroscience Society.
175. Kesby J, O'Loan J, Deng C, Huang XF, McGrath J, Eyles D and Burne T
(2008) Developmental Vitamin D (DVD) deficiency alters MK-801 induced
locomotion and glutamatergic receptor binding Australian Neuroscience
Society Annual Meeting.
176. Newell K, Dawson A, du Bois TM, Wang Q, Huang XF (2008) The effects of
developmental NMDA receptor antagonism on glutamate and acetylcholine
receptor systems: A preliminary investigation of a two-hit animal model for
schizophrenia Biological Psychiatry.
177. du Bois, TM, Deng C, Han M, Newell KA and Huang XF (2008). Perinatal
NMDA receptor blockade alters D2, NMDA and M1/M4 receptors in later
life: implications for pathological processes of schizophrenia. 1st
Schizophrenia International Research Society Conference, Venice, Italy, 2125 June 2008. Schizophrenia Research, 102(s2): 1-279.
178. Deng C., Huang XF. (2008) Cholecystokinin mRNA expression in the arcute
hypothalamic nuclei in diet-induced obese and obese resistant mice. 6th
Forum of European Neuroscience Abstract Volume 4 (pp. 094.2-094.2),
Geneva, Switzerland, July, 12-16.
179. Huang, X.F. South, T. Beck, E. Batterham, M. Grinter, K. Tapsell L (2008)
Diets high in oat-derived beta -glucan promote negative energy regulatory
pathway of hypothalamic NPY system in chronic diet-induced obesity in
mice, The 2008 Obesity Society Conference, Phoenix, USA, 193.
180. Karl T, Boucher A, Dean B, Huang XF, Arnold J, Schofield P (2008)
Environmental modulation of phenotype in neuregulin 1 mutants
International Journal of Neuropsychopharmacology, 11: 68-69.
181. Huang, X.F., TM du Bois, KA Newell, K Zavitsanou, C Deng (2007) A rodent
model of NMDA receptor hypofunction for the study of schizophrenia.
Neuroscience Bulletin, 23: 81.
182. Huang, X.F., South, T. Zavitsanou, K and Deng, C. A negative association
between the CB1 receptor mRNA expression and high fat intake during the
course of diet-induced obesity in mice. Cannabinoid Signalling in the
Nervous System: 17th Neuropharmacology Conference. USA, 2007.
183. South, T. & Huang, X. The CB1 Receptor as a Target for the Preferential
Reduction of High Fat Diet Intake. In 7th IBRO World Congress of
Neuroscience Conference Proceedings; Melbourne, Australia, 2007; pp 282.
184. Weston-Green, K. L., Deng, C., Han, M. & Huang, X. Effects on
Antipsychotic Drugs on Weight Gain and CB1 Receptors in the Dorsal Vagal
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Complex. In 7th IBRO World Congress of Neuroscience Conference
Proceedings; Melbourne, Australia, 2007; pp 144.
185. Han, M., Deng, C., Zavitsanou, K., Tan, Y. Y. & Huang, X. Effects of
Antipsychotics on Muscarinic M1 Receptor mRNA Expression in the Rat
Brain. In 7th IBRO World Congress of Neuroscience Conference
Proceedings; Melbourne, Australia, 2007; pp 275.
186. Du Bois, T., Deng, C., Hsu, C., Han, M., Li, Y., Tan, Y. Y. & Huang, X.
Effects of Perinatel NMDA Receptor Antagonist Treatment on Dopaminergic
System Development and Behaviour. In 7th IBRO World Congress of
Neuroscience Conference Proceedings; Melbourne, Australia, 2007; pp 234.
187. Huang, X., Du Bois, T., Newell, K. A., Zavitsanou, K., Hsu, C., Eftomovska,
J., Tan, Y. Y. & Deng, C. `Long-Term Consequences of Early Brain
Development Disruption on Neurochemical Balance and Behaviour. In 7th
IBRO World Congress of Neuroscience Conference Proceedings; IBRO:
Melbourne, Australia, 2007; pp 367.
188. Yu, Y., South, T. & Huang, X. The Role of CART Peptide in Obesity
Development and Dietary Intervention. In 7th IBRO World Congress of
Neuroscience Conference Proceedings; Melbourne, Australia, 2007; pp 284.
189. Newell, K. A., Dawson, A., Du Bois, T., Zavitsanou, K. & Huang, X. RegionSpecific CB1 Receptor Changes in the Rodent Brain Following NMDA
Receptor Antagonism. In 7th IBRO World Congress of Neurosciences
Conference Proceedings; Melbourne, Australia, 2007; pp 238.
190. Karl, T., Dean, B., Pavey, G., Tan, Y. Y., Huang, X., Duffy, L. & Schofield, P.
Behavioural Investigation of a Neuregulin 1 Knockout Model in
Schizophrenia. In 7th IBRO World Congress of Neuroscience Conference
Proceedings; Melbourne, Australia, 2007; pp 240.
191. Rahardjo, G., Huang, X., Tan, Y. Y. & Deng, C. The Role of Pyy and H1
Histamine ReceptorExpression in Chronic Diet-Induced Obese and Obese
Resistant Mice. In 7th IBRO World Congress of Neuroscience Conference
Proceedings; Melbourne, Australia, 2007; pp 283.
192. Deng, C., Eftimovska, J., Zavitsanou, K. & Huang, X. Phencyclidine Induces
Apoptosis in the Brain of Neonatel But not Adolescent and Adult Rats. In 7th
IBRO World Congress of Neuroscience Conference Proceedings; Melbourne,
Australia, 2007; pp 364.
193. Deng C, Han M, Huang X-F. Antipsychotic drugs increase food intake and
cannabinoid CB1 receptor mRNA expression in the brain of rats 17th
Neuropharmacology Conference: Cannabinoid Signaling in the Nervous
System Submitted October 31-November 2, 2007 San Diego USA.
194. Deng C, Weston-Green K, Huang XF Dose dependent effects of the atypical
antipsychotic drug olanzapine on weight gain and cholecystokinin levels in
rats 7th Biennial meeting of Chinese Society for Neuroscience Submitted
October 24-28, Hangzhou, China.
195. Huang XF, du Bois TM, Newell KA, Zavitsanou K, Deng C A rodent model of
NMDA receptor hypofunction for the study of schizophrenia 7th Biennial
meeting of Chinese Society for Neuroscience, October 24-28, Hangzhou,
China
196. Karl, T. Duffy, L. Dean, B., Pavey, G., Tan, Y.Y. Huang, X.F. and Schofield,
P.R. (2007) The transmembrane domain neuregulin 1 mutant mouse – a
valuable tool for schizophrenia research? International Congress on
Schizophrenia Research, Colorado, 2007-03-26.
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197. Chao Deng, Mei Han, Kelly A. Newell and Xu-Feng Huang (2007) No
changes in cannabinoid CB1 receptor binding density in the superior temporal
gyrus in schizophrenia, Colorado, 2007-03-26.
198. Kelly A. Newell, Katerina Zavitsanou, Xu-Feng Huang (2007) The posterior
cingulate cortex: a site of altered neural circuitry in schizophrenia and NMDA
hypofunction, Colorado, 2007-03-26.
199. Mei Han, Chao Deng, Kelly Newell, Xu-Feng Huang (2007) Histamine H1
mRNA expression is decreased in the rat hypothalamus following olanzapine
treatment Colorado, 2007-03-26.
200. Xu-Feng Huang, Teresa M. du Bois, Ching-Wen Hsu, Juliana Eftimovska,
Yean Yeow Tan, Katerina Zavitsanou, Kelly A. Newell and Chao Deng
(2007) NMDA receptor hypofunction during early brain development:
relevance to schizophrenia Colorado, 2007-03-26.
201. Batterham, M., Faraji, S., Gillen, L., Huang, X.F., Probst, Y., Quick, C.J., Tan,
S. and Tapsell, L.C. (Ed.) (2006). Procedings of the Nutrition Society of
Australia, V30 in conjuction with the Nutrition Society of New Zealand,
Melbourne, Australia: HEC Press.
202. Deng, C. Weston, K.L., Han, M. and Huang, X.F. (2006) Body weight gain and
altered density of muscarinic M2/M4 receptors in the vagal complex of rats
treated with olanzapine. 5th European Neuroscience Forum. Viena, Austria,
July.
203. Deng, C., Liu, Y. and Huang, X.F. (2006) Parasympathetic innervation of
white adipose tissue in mice. Pro. Aust. Neurosci. The 26th Annual Meeting.
17:140.
204. Du Bois, T.M., Deng, C. and Huang, X.F. (2006) Dietary fatty acids
differentially affect serotonin and muscarinic receptor binding in the rat brain.
Pro. Aust. Neurosci. The 26th Annual Meeting, 17:102.
205. Du Bois, T.M., Deng, C. Tan, YY and Huang, X.F. (2006) Brain development
disruption from PCP causes behavioural deficits in the forced swim test in
later life. 9th Australasian Schizophrenia Conference, 0:15, Fremantle,
Western Australia.
206. Han, M. C. Deng, YY Tan, and Huang, X.F. (2006) Differential effects of
antipsychotics on dopamine transmission in the mesolimbic and nigrostriatal
pathways. International Symposium on Frontiers in Life Sciences: Molecular
basis of disease, prevention and treatment. Qingdao, China, September.
207. Han, M., Deng, C., Tan, Y.Y. and Huang, X.F. (2006) Aripirazole treatment
increases D2 receptor mRNA expression in the ventral tegmental area of rat
brain. Pro. Aust. Neurosci. T130:105
208. Huang, X., Chao, D., Han M., Zavitsanou, K. and Huang, X.F (2006) Central
5-HT2 receptor mRNA expression pattern following chronic olanzapine
treatment in rats. Pro. Aust. Neurosci. F92:139
209. Huang, X.F. Deng, C. and Zavitsanou, K. (2006) Differential regulation of
brain NPY mRNA in rats treated with olanzapine, clozapine and haloperidol.
Pro. Aust. Neurosci. T132:105
210. Huang, X.F. K. Zavitsanou, Y. Yu, C. Deng, X. Huang, F. Chen, and A.
Lawrence (2006) Altered dopamine transporter and D2 receptor binding
sites in the brain of obese-prone and obese resistant mice, Society for
Neuroscience, USA. 60.23.
211. Huang, XF, Deng, C, Yu, YH, Tan, YY, and Zavitsanou, K (2006) Similarity
and differences of typical and atypical antipsychotics influencing brain
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neuropeptide Y gene expression in rats. 6th European Neuroscience Forum.
Viena, Austria, July.
212. Newell, K.A. Zavitsanou, K. and Huang, X.F. (2006) NMDA and muscarinic
M1/M4 receptor binding density is decreased 2 weeks after, but not
immediately after chronic PCP treatment. Pro. Aust. Neurosci. T129:105.
213. Rahardjo, G.L., Tan, Y.Y. and Huang, X.F. (2006) NPY Y2 receptor binding
density is reduced in the nucleus accumbens of mice resistant to diet-induced
obestiy. Pro. Aust. Neurosci. T12:8.
214. Rahardjo, GL, X.F. Huang, PL McLennan, WA Buttemer (2006) Does obeseprone or resistant mouse differ in their feeding, metabolic rate, and peptide
YY regulation? 10th International Congress on Obesity, Sydney, Australia,
September.
215. South T. and XF Huang (2006) High dopamine D2 and cannabinoid CB1
receptor density exists in the reward centres of a fat preferrring strain of
mouse. Pro. Aust. Neurosci. F94:140
216. Tan, Y.Y., Huang, X., Han, M. and Huang, X.F. (2006) Effects of chronic
clozapine treatment on 5-HT2A and 5-HT2C receptor mRNA expression in
the rat limbic system. Pro. Aust. Neurosci. T119:102
217. Gillen LJ, Tapsell LC, Batterham M, Huang XF, Cavanagh R, Kennedy M.
2005 Dietary and clinical risk profiles of a sample of healthy overweight
adults provide targets for dietary advice in an intervention trial. Proceedings
of the Nutrition Society of Australia, Melbourne, Australia, Asia Pac J Clin
Nutr 14 (Suppl): S44
218. Yu, Y.H., South, T. and Huang, X.F. (2006) AdipoR1 mRNA expression levels
are increased in the VMH of mice prone to diet-induced obesity. Pro. Aust.
Neurosci. F95:140
219. Zavitsanou K, Nguyen V, Han M, KatsIFis A, Huang XF (2006) Effects of
typical and atypical antipsychotic drugs on rat brain muscarinic receptors.
Pro. Aust. Neurosci. T128:104.
220. Zavitsanou K, Nguyen V, Newell K, Ballantyne P, Huang, XF (2006)
Increased [3H]MK801 binding in the cingulate cortex of the rat after a single
injection of phencyclidine. Pro. Aust. Neurosci. T118:102.
221. Mackey de Paiva L, Gillen, LJ, Tapsell LC, Batterham M, Huang XF,
Cavanagh R, Kennedy M. Relationships between clinical data and baseline
eating behaviours in a sample of overweight volunteers for a dietary
intervention trial. Proceedings of the Nutrition Society of Australia,
Melbourne, Australia, Asia Pac J Clin Nutr 2005; 14:S44.
222. Gillen LJ, Tapsell LC, Batterham M, Huang XF, Cavanagh R, Kennedy M.
Dietary and clinical risk profiles of a sample of healthy overweight adults
provide targets for dietary advice in an intervention trial. Proceedings of the
Nutrition Society of Australia, Melbourne, Australia, Asia Pac J Clin Nutr
2005;14:S44.
223. Rahardjo, G, Buttemer W, Huang, XF (2005) Progressive change on oxygen
consumption and energy intake during development of diet-induced obesity
in mice. ASSO. 64-65Perth.
224. Zavitsanou, K., A. Katsifis, F. Mattner, Y. Yu, X.F. Huang (2005)
Investigation of [3H]pirenzipine and [3H]AF-DX 384 binding to muscarinic
receptors in the anterior cingulate cortex in schizophrenia and mood
disorders. Pro. Aust. Neurosci. 25:34.
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225. South T. and XF Huang (2005) Development of a fat preferring mouse model
reveals an ineffective melanocortin defensive response. Pro. Aust. Neurosci.
25:113.
226. Newell, K.A. and X.F. Huang (2005) Increased NMDA receptor density in the
posterior cingulate cortex in schizophrenia. Pro. Aust. Neurosci. 25:124.
227. Huang, XF, Chen, F. Wang, HQ, Huang, X. Yu, YH, K, Zavitsanou, A.
Lawrence (2005) Differential response of dopamine transporter in mice
resistant to diet-induced obesity. Pro. Aust. Neurosci. 25:241.
228. Huang, X.F., M. Han, YH Yu, X. Huang and K. Zavitsanou (2005) Differential
expression of dopamine D2 and D4 receptor mRNA expression in the brain of
chronic high-fat diet-induced obese mice. Society for Neuroscience, USA.
75.18 USA.
229. Huang, X.F., Deng C., Wang, H, Huang, X., and K. Zavitsanou (2005)
Olazapine's effects on hypothalamic 5-HT2A and 5-HT2C receptor mRNA
expression. Society for Neuroscience, USA. 567.15.
230. Huang, X.F., Deng C., Wang (2005) Reversibility of altered LR, NPY, POMC
and AgRP in cDIO mice . Pro. Chinese Neurosci. 135.
231. Deng, C. and X.F. Huang (2005) Increased density of GABAa receptors in the
superior temporal gyrus in schizophrenia. Pro. Chinese Neurosci. 173.
232. Deng, C. and XF Huang (2005) Decreased density of muscarinic M1 and
M2/M4 receptors in superior temporal gyrus in schizophrenia. Pro. Aust.
Neurosci. 25:125.
233. Zavitsanou, K. and X.F. Huang and N. Solowij (2004) SignIFicant correlations
between cannabinoid and serotonin/glutamate receptor densities in the
anterior cingulate cortex in schizophrenia: a site of functional interactions.
14th International Cannabinoid Research Society Conference. Naples, Italy.
234. Huang, X.F., Huang, X. Han, M., South, T., Lawrence, A. and Chen, F. (2004)
Reduced 5-HTT binding density in the limbic structures of mice resistant to
diet-induced obesity. Proceeding of Australian Neuroscience Society, Martin,
P. Eds. Pp123.
235. Yu, Y., M. Han, and X.F. Huang (2004) Increased D4 receptor mRNA
expression in the VMH of diet-induced obese mice. Pro. Aust. Neurosci.
24:123.
236. Newell, K., K. Zavitsanou, and X.F. Huang (2004) Alterations in the serotonin
and cannabinoid systems in the posterior cingulate cortex in schizophrenia.
Pro. Aust. Neurosci. 24:138.
237. Han, M., K. Zavitsanou, K. Newell, and X.F. Huang (2004) Increased CB1
mRNA in the cortical areas of mice prone to diet-induced obesity. Pro. Aust.
Neurosci. 24:113.
238. Huang, X., M. Han, T. South, F. Chen, A. Lawrence and X.F. Huang (2004)
Reduced 5-HTT binding density in the limbic structures of mice resistant to
diet-induced obesity. Pro. Aust. Neurosci. 24:123.
239. Huang, X.F., M. Han, K. Newell and K. Zavitsanou (2003) A low level of Y1
and Y5 gene expression may contribute to the prevention of chronic high
energy diet-induced obesity. Pro. Aust. Neurosci. 21:228.
240. Zavitsanou, K. and X.F. Huang (2003) Increased cannabinoid CB-1 receptor
binding in the anterior cingulate cortex in Schizophrenia. Pro. Aust. Neurosci.
21: 346.
241. Zavitsanou, K. PB Ward and X.F. Huang (2002) Changes in
neurotransmitter/antipsychotic drug binding sites in the anterior cingulate
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cortex in schizophrenia: Clues for abnormal neural circuitry. Australasian
Schizophrenia Conference. 7:57.
242. Zavitsanou, K. and Huang, X.F. (2002) Increased NMDA and AMPA receptor
densities in the anterior cingulated cortex in schizophrenia. Proceeding of the
Australian Neuroscience Society. 2002, pp166.
243. Newell, K, B. Klose, K. Zavitsanou, M. Han, and X.F. Huang (2002) Effects of
clozapine and haloperidol on motor activity in chronic phencyclidine mouse
model. Australasian Schizophrenia Conference. 7:115.
244. Huang, X.F., X Xin, and HQ Wang (2002) Reversibility of altered LR, NPY,
POMC and AgRP in chronic diet induced obese mice. Society for
Neuroscience. Florida, US.
245. Dixon, G., Huang, X.F. Newell, K. and Harper, C. (2002) Reduced numbers of
paravlbumin-positive neurons in the posterior cingulated cortex in
schizophrenia. Proceeding of the Australian Neuroscience Society, pp138.
246. Bell, W. Zavitsanou, K., Sarris, M., and Huang, X.F (2000) Alterations of
membrane phospholipid composition in the anterior cingulate cortex. Pro.
Aust. Neurosci. 19:135
247. Zavitsanou, K., Bell, W., and Huang, X.F (2000) Autoradiographic
characterization of [3H]spiperone binding sites in the anterior cingulate
cortex of schizophrenia patients and controls. Pro. Aust. Neurosci. Soc.
12:94.
248. Huang, X.F (2000) Leptin receptor and its related neuropeptides in response to
dietary fat types in obesity. Pro. Aust. Neurosci. Soc. Symposium. 11:18.
249. Xin, X., X.F. Huang, Lin, S. and Storlien, L.H. (2000) Hypothalamic NPY
mRNA expression is not critically involved in the development of dietinduced obesity in C57 mice. Pro. Aust. Neurosci. Soc. 11:176.
250. Wang, H.Q., L. Storlien, and X.F. Huang (2000) Alpha-melanocortin
stimulating hormone-like immunoreactive neurons in response to saturated,
n-3 and n-6 polyunsaturated fat diet. Pro. Aust. Neurosci. Soc. 11:172.
251. Bell Warren and X.F. Huang (2000) Influence of n-3 PUFA diet on
hypothalamic alpha-melanocortin stimulating-like immunoreactive neurons.
Pro. Aust. Neurosci. Soc. 11:179
252. Lin, S., Huang, X.F., Wang, H., Xin., Glueska, Z. and Bell, W. (2000) Leptin
receptor and its related neuropathways in the development of obesity.
Proceeding of the Australian Neuroscience Society, Melbourne, Australia,
pp18.
253. Bell, W., Glueska, Z. and Huang, X.F. Differential effects of fish oil
concentration on high saturated fat diet induced obesity and alpha-MSH-LI
neuron distribution. Proceeding of the Australian Neuroscience Society,
Melbourne, Australia, pp179.
254. Huang, X.F (1999) Obesity: Fatty acid subtype influences in neuropeptide gene
and protein expression. Society for Neuroscience. 25:415 USA
255. Huang, X.F., H.Q. Wang, and LH Storlien (1999) Influence of dietary fats on
hypothalamic regulatory centers related to diet-induced obesity in mice.
Society for Obesity Research.
256. Xin, X.G. L.H. Storlien, S. Lin, and X.F. Huang (1999) High fat diet-induced
obese and resistant mice differ in their serum leptin and hypothalamic
neuronal activity. Society for Obesity Research.
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257. Lin, S. T. Thomas, L. Storlien, X.G. Xin and X.F. Huang (1999) Three stages
of high fat diet-induced obesity and leptin resistance in C57 mice. Society for
Obesity Research.
258. Huang, X.F., S. Lin, H.Q. Wang, X. Xin (1999) Obesity: fatty acid subtype
influences in neuropeptide gene and protein expression. Soci. Neurosci. USA
259. Xin, X., HQ Wang, and X.F. Huang (1999) Intracerebroventricular injection of
leptin reverse the altered hypothalamic neural activity in the genetic obese
mice. Pro. Aust. Neurosci. Soc. 151
260. Huang, X.F., S. Lin, H.Q. Wang, X. Xin, Y. Zhang, Y. Ge, J. Xia (1998)
Hypothalamic neural activity in diet induced and genetic obese mouse brain.
Soci. Neurosci. 28:1120USA
261. Wickham, J. M. Brown, Steele, J. and X.F. Huang (1998) Anatomical
segmentation within should joint musculature. Australian. Conference of
Science and Medicine in Sport
262. Wickham, J. M. Brown, Steele, J. and X.F. Huang (1998) Muscles within
muscles: segmental muscle activation during shoulder joint tasks. Australian
Conference of Science and Medicine in Sport
263. Huang, X.F (1996) Leptin mRNA expression in the central nervous system.
Society for Obesity. 5:26
264. Huang, X.F., G. Dixon, S.V. Catts, P.B. Ward, D. Wakefield, G. Paxinos, and
A. Lloyd (1995) Characterisation and localisation of alternative spliced
isoforms of the NMDA R1 mRNA in the human hippocampus. Soci.
Neurosci. 21:1836 USA
265. Huang, X.F., G. Dixon, S.V. Catts, P.B. Ward, D. Wakefield, G. Paxinos, and
A. Lloyd (1995) Characterisation of the NMDA receptor complex in the
human hippocampus. Proceedings of the Australian Society for Psychiatric
Research. Perth, Dec
266. Christopoulos, G., G. Paxinos, X.F. Huang, A. W. Toga, and P. M. Sexton
(1995) In vitro Autoradiographic localisation of calcitonin receptors in
monkey brain. Proc. Aust. Neurosci. Soc. 6:163
267. Dixon, G, X.F. Huang, and A. Lloyd (1995) A protocol for molecular and
cellular studies of human brain tissue for neuropsychiatric research. Soci.
Neurosci. USA, 21:239
268. Chadda, N., P. Carrive, X.F. Huang, A.W. Toga, P. Sexton, and G. Paxinos
(1995) Chemoarchitecture of the hippocampal formation of the Rhesus
Monkey. Pro. Aust. Neurosci. Soc. 6:163
269. Huang XF, Dixon G, Catts SV, Ward PB, Wakefield D and Lloyd A (1995).
The NMDA Receptor Complex in the Hippocampus in Schizophrenia.
Schizophrenia Research 15:60-60.
270. Huang, X.F., G. Dixon, Di Girolamo, S.V. Catts, P.B. Ward, D. Wakefield, G.
Paxinos, and A. Lloyd (1994) Heterogeneous distribution of NMDA mRNA
in the human hippocampal formation and entorhinal cortex. Soc. Neurosci.
20:493 USA
271. Catts, S.V., N. Di Girolamo, P.B. Ward, G.J. Dixon, X.F. Huang, and D.
Wakefield (1994) N-methyl-D-aspartate (NMDA) receptor mRNA expression
in human and rat brain. Proc. Aust. Neurosci. Soc. 5:247
272. Huang, X.F. and G. Paxinos (1994) Hypothalamic nuclei in the human and
monkey brains: A comparative study based on acetylcholinesterase
histochemistry. Proc. Aust. Neurosci. Soc. 5:228
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273. Halasz, P., X.F. Huang, and G. Paxinos (1994) Three-dimensional computer
reconstruction of the monkey amygdala. Proc. Aust. Neurosci. Soc. 5:227

5. Some publications in high impact journals or having high citations:
• Beck E, Batterham M, Tapsell L, Tosh S, Huang XF (2009) Oat ß-glucan increases
postprandial cholecystokinin levels, decreases insulin response and extends
subjective satiety in overweight subjects, Molecular Nutrition & Food Research.
53, (10), 1343-1351. IF= 3.439 (A* journal). This paper reported on ARC-Linkage
funded dietary intervention tests for potentiating effects of dietary fibre on body
metabolism. It showed soluble fibre (beta-glucan) affects satiety hormones.
• Huang XF and J Chen (2009) Obesity, the PI3K/Akt signal pathway and colon
cancer. Obesity Review, 10: 610-616. IF= 7.821 (A* journal). This review
summarized existing knowledge, made critical hypotheses and pointed out a key
therapeutic target addressing the link between obesity and bowel cancer.
• Beck, E.; Tapsell, L.; Batterham, M.; Huang, XF, (2010) Oat beta-glucan
supplementation does not enhance the effectiveness of an energy-restricted diet in
overweight women. British Journal of Nutrition, 2010, 103, 1212-1222 (A
journal). This is a human clinical trial study, which demonstrated the beneficial
effect of beta-glucan (soluble fiber) for body metabolism.
• Huang XF and Chen JZ (2009) Adiponectin and signal pathways in obesityinduced colon cancer, Gut, 2009; Vol. 58, 1169; IF=10.0 (A* journal). This paper
draws together a concept of how adiponectin as a cytokine plays a key role in
prevention of obesity-associated colon cancer.
• Rahardjo GL, XF Huang and C Deng (2007) Decreased plasma PYY accompanied
by an elevated PYY and Y2 receptor binding sites in the medulla oblongata of
diet-induced obese mice, Endocrinology, 148:4704-4710. IF=5.313 (A* journal).
This paper for the first time proved involvement of a new pathway between gut
PYY signal and medulla in autonomic centre regulation of diet-induced obesity.
• Huang XF, Xin X, McLennan P and Storlien LH (2004) Role of fat amount and
type in ameliorating diet-induced obesity: insights at the level of hypothalamic
arcuate nucleus, leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA
expression. Diabetes, Obesity and Metabolism. 6(1) 35-45. IF= 3.44. This paper
provides a better understanding of dietary fat type and amount affecting specific
neurotransmitters regulating energy balance (cited 33 times, ISI).
• Wang, H.Q., L.H. Storlien, X.F. Huang (2002) Effects of dietary fat types on body
fatness, leptin, and ARC leptin receptor, NPY, and AgRP mRNA expression.
American Journal of Physiology, Endocrinology and Metabolism. 282:1352-1359,
IF=3.6 (A* journal). This paper addresses the interaction between nutrition and
genes focusing on n-3 and n-6 PUFA and saturated fat and key hypothalamic
neurotransmitters (cited 75 times, ISI).
• Lin, S, Storlien, L, and Huang, X.F. (2000) Leptin receptor, NPY, POMC mRNA
expression in the diet-induced obese mouse brain, Brain Research, 875:89-95. This
paper investigated the regulatory relationship between peripheral signal (leptin and
central control molecules, leading to high citations (cited 86 times).
• Lin, S., TC Thomas, LH Storlien and X.F. Huang (2000) Development of obesity
and central leptin resistance in high-fat diet induced obese mice. International
Journal of Obesity and Related Metabolic Disorders. 24639-646, IF= 3.6 (A
journal). This paper reported for the first time that central leptin resistant is a key
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•

feature of chronic high-energy diet-induced obesity, leading to high citations (cited
120 times, ISI).
Huang XF, I. Koutcherov, S. Lin, H.Q. Wang and L. Storlien (1996) Localisation
of leptin receptor mRNA expression in mouse brain. NeuroReport. 7:2635-2638.
This paper identified for the first time the location of the letpin receptor in the
hypothalamus receiving fat signals, leading to high citations (cited 92 times, ISI).

VII. Successful Grants in Supporting My Research
In total, I have been awarded $5,170,301 in research funding in the last 16 years at
UoW. I was the 1st Chief Investigator for 82% of funded grants.
NHMRC Funding
1. Huang, XF and C Deng, 2010 NHMRC ID635231: Schizophrenia: Prevention
and treatment of atyipical antipsychotic drug-induced obesity, 2010–2012,
$399,250
2. Mei Han (Postdoc) and XF Huang (Supervisor), 2010 NHMRC ID:635245, for
NHMRC training fellowship, Understanding the role of neurgulin-1 genetic
polymorphisms in patients with schizophrenia, 2010–2013, $334,171
3. Huang, XF and K. Newell, 2009 NHMRC project, ID:573426: The effects of
phencyclidine on the NMDA receptor/neuregulin1 signalling complex:
implications for schizophrenia, 2009–2011, $417,000
4. Yinghua Yu (Postdoc) and XF Huang (Supervisor) 2009 for NHMRC training
fellowship, Evaluation of functional protein molecules in treating obesity,
ID:573441, 2009–2012, $334,171
5. Huang, et al., NHMRC Equipment grant: Molecular Pathology Laboratory, 2008,
$10,000
6. Karl, T, J Arnold, XF Huang, I McGregor, NHMRC project, 2008 ID493301: The
role of cannabis in an Nrg1 animal model of genetic vulnerability to
schizophrenia. 2008–2010, $449,800
7. Tapsell, Huang, Batterham NHMRC Project ID514631, PUFA as a protective
agent in the dietary management of obesity 2005–2007, $377,375
8. Huang, XF, NHMRC Target identification of chemical coded neural networks for
treating obesity. 2005–2007, $254,250
9. Huang, Deng, Zavitsanou, NHMRC Equip. ProgRes C10 digital microscope
camera system. 2004, $5,000
10. Huang, XF, NHMRC Project Obesity induced by high-energy diet: Central
influences in prevention, 2002–2005, $220,000
11. Huang XF, NHMRC equipment grant: Dedicated radioactive laboratory
equipment. 2008, $5,480
12. Huang, XF, et al., NHMRC Equip. Digital Photo Lab. 1999, $7,000
13. Huang, XF, NHMRC Project Gene expression of leptin receptor in lean, obese and
diabetic mouse Brain. 1997, $143,596
ARC-Linkage Project Funding
14. Huang, Tapsell, Batterham, ARC-Linkage Project ID: 0561586, Functional
properties of a whole grain in weight management. 2006, $225,444
15. Huang, XF,ARC-small Brain regulation of energy balance. 2000, $10,500
16. Huang, XF, ARC/Small Expression of NMDA, 1998, $10,000
17. Huang, XF, ARC-small Molecule, chemical and weight control. 1997, $5,500
Neuroscience Institute of Schizophrenia and Allied Disorder Funding:
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18. Huang, XF, Neuropathology of Schizophrenia; Schizophrenia Research Institute
Funding, 2008–2010 ($140,000 × 3yrs). $420,000
19. Huang, XF, NISAD Equip. Beta-imager. 2004, $200,000
20. Huang, Tan, NISAD Project Neuropathology of Schizophrenia. 2005, $330,000
21. Huang, Deng, Zavitsanou, NISAD/UoW Beta-imager analysis of drug binding
efficacy for treating schizophrenia. 2005, $20,000
22. Huang, Zavitsanou, NISAD Project Schizophrenia: Antipsychotic compound and
neural MPC. 2003–2007, $213,591
23. Huang, Morris NISAD Project Schizophrenia and Neuropathology. 1999,
$110,000
AstraZeneca pharmaceutical company of Sweden funding
24. Huang, XF, AstraZeneca Project Differential expressed genes in the late stage of
obesity. 2003, $157,000
25. Huang, XF, AstraZeneca Project Development of obese mouse model. 2003,
$25,000
26. Huang, XF, AstraZeneca Project Cause or consequence genes of obesity. 2006,
$100,000
University Research Council and Research Partnership Scheme funding
27. Huang, XF and P Craig, URC Research Partnership Scheme, Development of a
functional food combination to achieve synergistic satiety effects for the
prevention of obesity. 2010, $40,000
28. Huang XF and C Deng. The role of histamine, NYP and melanocortin systems in
the development and prevention of olanzapine-induced obesity; URC near miss
grant. 2009, $15,000
29. Huang URC. New initiative of research strength. 2007, $40,000
30. Huang, XF. RIBG, Molecular Pathology Infrastructure. 2009, $73,000
31. Huang, XF. iiMH/UOW Assist in grant preparation, $2,000
32. Astheimer, Huang et al. RIBG Beta and Gamma Radiation Counters. 2005,
$45,000
33. Else, Huang, et al. RIBG GC for fatty acid analyses. 2005, $35,474
34. Huang, et al. RIBG Acquisition system for physiology, 1999, $36,375
35. Huang, XF. URC, Hybridisation oven, 1998, $4,700
36. Huang, Zhang. URC Neural networks in weight control. 1996, $6,850
37. Huang, XF. Metabolic Research Centre, Neural networks and Metabolism. 1996,
$2,293
Australia Nuclear Science and Technology Organisation funding
38. Huang XF and A Katsifits, AINSE, Peripheral Benzodiazapine as an Early
Marker for Obesity and Inflammation: Implications for Development of Type II
Diabetes Mellitus and Cancer, 2009, $14,000
39. Deng, Huang et al. AINSE Project PCP induced apoptosis in a rat model. 2005,
$21,000
National Food – Smart Food funding:
40. Huang, et al. NCCEF Dietary protein and weight control. 2003, $50,481

VIII. PhD, Masters and Honours Students and Research Fellows
Experience and Success in Supervising Research Fellows and Students (PhD, Master,
Honours and Research topic students): Table 1 summarises the various levels of fellows
and students who have worked with me at the University of Wollongong since 1996. I
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have supervised eight Research Fellows since 1999, ten PhD completions since 1997, as
well as four Masters completions and 16 Honours completions since 1996. In addition,
seven Visiting Research Fellows or Professors have worked in my laboratory since
1998. Many honours students after training from my centre were awarded PhD
scholarships to continue their neuroscience research, while other students were accepted
in Medical Schools (Sydney, Tasmania, Wollongong Universities). Among my PhD
graduates, three are currently NHMRC Post-doctoral Fellows. It is common for PhD
students finishing their research projects in my laboratory to have published three to
five peer reviewed articles as the 1st author. Much of this work has been well-cited (for
example, Dr Lin has now been cited 121 times).

Table 1. Primary Supervision/Co-Supervision of PhD, Masters
Honours and Research Fellow Research Projects
Degree
Name
PhD, Masters and Honours Completion
1
PhD
S. Lin
2
PhD
C Xin
3
PhD
J Wickham
4
PhD
K Newell
5
PhD
T South
6
PhD
M Han
7
PhD
T du Bois
8
PhD
YH Yu
9
PhD
E Beck
10
PhD
Christopher Magee
11
MSc
Somayeh Jafarj
12
MSc
G Rahardjo
13
MSc
W Zhang
14
MS
G. Tuess
15
Hon
Koutcherov
16
Hon
A Howki.
17
Hon
M Hassi.
18
Hon
W Bell
19
Hon
D Burn
20
Hon
K Newell
21
Hon
T South
22
Hon
B Klose
Hon
T du Bois
23
24
Hon
CW Hsu
25
Hon
K Westo
26
Hon
J Eftimo
27
Hon
D Weir
28
Hon
N Piyaratna
29
Hon
D Manassa
30
Hon
Asya

Year

Completion

1997
1997
1997
2003
2004
2006
2005
2005
2006
2006
2007
2005
1997
2006
1997
1998
1999
1999
2000
2001
2002
2002
2004
2006
2006
2006
2006
2008
2008
2008

2000
2000
2001
2007
2008
2009
2008
2009
2009
2009
2008
2008
1998
2009
1997
1998
1999
1999
2000
2001
2002
2002
2004
2006
2006
2006
2006
2008
2008
2008
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Senior research/Research fellows (SRF/RF)
31
RF
R Morris
32
SRF
K Zavitsanou
33
RF
G Dixon
34
RF
YY Tan
35
SRF
C Deng
36
RF
L Frank
Visiting Research Fellows
37
A/Pr
YL Ge
38
Dr
Y Xia
39
Dr
M Han
40
Dr
X Huang
41
Dr
YH Yu
42
Dr
YX Lin
43
Dr
YL Li

1999
2000
2001
2005
2003
2009

1999
2004
2001
2008
2010
2010

1998
1999
2002
2003
2003
2003
2006

1998
1999
2004
2004
2004
2005
2006

IX. PhD, Master and Honours Theses Examination
•
•
•
•
•
•
•
•
•
•
•

Honours thesis, Title: Amelioration of hyperthermia-induced birth defects through
folic acid administration, Michael Conor Bulman, Thesis for Bachelor of Science
(Honours), 2002
Honours thesis, Title: Leptin kinetics and skin blood flow during rewarming,
Cassandra Dale Haley, Bachelor of Science (Honours), 2003
Honours thesis, Title: Does the speed of muscle belly displacement correlate to
muscle fibre type Ms Laurel Snelson, Honours Project, 2003
PhD thesis, Title: The role of hypothalamic neuropeptides in feeding behavior and
obesity, Michelle Joan Hansen, Thesis for the degree of Doctor of Philosophy,
2003
Honours thesis, Title: Tissue distribution of dietary phytoestrogen compounds in
rats: method development, effects of genders and dietary competition, Tim Murray,
BMS Honours, 2003
PhD thesis, Title: The role of PYY in regulating energy balance and glucose
homeostasis, Dana Boey, PhD thesis, Garvan Medical Research Institute, 2004
Honours thesis, Title: The effects of dietary calorie restriction on biochemical and
physiological parameters in mice, Sally Faulks, Thesis for Bachelor of Science
(Honours), 2004
Honours thesis, Title: Description of dietary habits of people with and without
schizophrenia, Deepa Ghedia, Honours, 2004
PhD Thesis, Title: Neuropeptide Y and obesity by Dana Boey Garvan Institute of
Medical Research, 2004
Honours thesis, Title: Molecular analysis of membrane phospholipids species
using a body mass comparison in mammals, Jessica Nealon, Thesis for Bachelor of
Science (Honours), 2006
Honours thesis, Title: Investigating the consequences to the neuregulin1/ErbB4
signalling pathway following perinatal disruption to the NMDA receptor:
implications for schizophrenia. S. Ruthirakumar, Thesis for Bachelor of Science
(Honours), 2008.
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•

PhD Thesis, Title: Phenotypic characterisation of germline and conditional
deletion of the NPY Y1 and Y5 receptors in mice, by Ms Natalie Mitchell, 2010,
Garvan Medical Research Institute
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A growing number of studies have identified chronic sleep restriction as a potential risk factor for obesity. This could have
important implications for how obesity is prevented and managed, but current understanding of the processes linking chronic
sleep restriction to obesity is incomplete. In this paper, we examined some of the pathways that could underlie the relationship
between chronic sleep restriction and obesity. This involved exploring some of the potential environmental, health, behavioral, and
sociodemographic determinants of chronic sleep restriction, which require further investigation in this context. Three pathways
that could potentially link chronic sleep restriction to obesity were then examined: (1) altered neuroendocrine and metabolic
function, (2) impaired glucose regulation, and (3) waking behavior. The selected pathways linking chronic sleep restriction to
obesity reviewed in this paper are presented in a schematic representation; this may be used to guide future research in this area.
This area of research is important because it may lead to more eﬀective interventions and strategies to combat the present obesity
epidemic.

1. Introduction
Obesity has increased at an alarming rate in recent decades,
and it is currently estimated that between 25% and 30% of
adults in countries such as the US and Australia are obese [1–
3]. Obesity is a major health issue as it contributes to conditions such as diabetes, cardiovascular disease, osteoarthritis,
and some metabolic-related cancers [3, 4]. Obesity has
a multifactorial etiology comprising a range of genetic,
metabolic, environmental, behavioral, and social/cultural
factors [5]. However, the rapid rise in obesity suggests
that the present epidemic is the result of recent social and
environmental changes, with high fat diets and increasingly
sedentary lifestyles identified as two of the main causes [3, 6].
There are, however, other factors that may be contributing to the present obesity epidemic which need to be
addressed. One factor that is receiving increased attention
is chronic sleep restriction (<7 hours sleep a night). This
is based on a number of recent epidemiological studies

reporting that shorter sleep durations are associated with
overweight and obesity in adults; see Cappuccio et al. [7]
for a review. Some longitudinal data also indicate that
short sleep predicts weight gain over a period of several
years [8–12]. Furthermore, several laboratory-based studies
have demonstrated that sleep restriction aﬀects hormones
involved in regulating energy balance, in a manner that is
consistent with weight gain [13–18]. Interestingly, Chaput
et al. [19] recently examined the relative contribution of
nine risk factors for obesity (e.g., diet, physical activity, and
sleep duration) over a six-year period. They found that
sleep duration along with low calcium consumption and
high disinhibition and restraint eating behavior significantly
predicted weight gain; energy intake and physical activity
were not significant predictors of weight gain.
These findings suggest that chronic sleep restriction
could be a possible risk factor for obesity, and this may
have implications for obesity management and prevention.
However, our understanding of the relationship between

2
chronic sleep restriction and obesity is incomplete as the processes through which chronic sleep restriction contributes to
obesity, and the extent and magnitude of these eﬀects, remain
unclear. Furthermore, an important gap in the literature is
that the causes, or determinants, of chronic sleep restriction
have been largely overlooked. In this area of research, chronic
sleep restriction has tended to be viewed as a result of
behavioral sleep curtailment or an underlying sleep disorder
[20]. This is a problem because the causes of chronic
sleep restriction are likely to be complex and encompass
many factors. These need to be identified and understood
because they could influence the nature of the relationship
between sleep and obesity and would likely have treatment
implications.
Therefore, the purpose of the present paper is to integrate
two important bodies of literature and examine (1) the
determinants of chronic sleep restriction and (2) selected
pathways linking chronic sleep restriction to obesity. This
paper is not intended to provide a comprehensive review
of these areas, as the relationship between chronic sleep
restriction and obesity is likely to be complex and involve
a multitude of processes. Instead, we focus on the factors
and pathways that we feel are most important based on
our assessment of the available literature. For example,
we explore the following three potential pathways linking
chronic sleep restriction to obesity: (1) neuroendocrine and
metabolic pathways, (2) glucose regulation, and (3) waking
behaviour.
It is also acknowledged that the association between
chronic sleep restriction and obesity is likely to be bidirectional since obesity could also contribute to chronic sleep
restriction (e.g., sleep apnea). However, this paper focuses
primarily on chronic sleep restriction as a possible cause of
obesity. We conclude the paper by presenting a schematic
representation that integrates these pathways and provides
an important framework that is currently lacking in the
literature; this can be used to guide future research in this
area.

2. Determinants of Chronic Sleep Restriction
Chronic sleep restriction is generally defined as habitual
sleep durations that are less than 7 hours, but more than
4 hours, a night [21]. It is distinct from acute total sleep
deprivation which refers to an absence of sleep over a
minimum of 24 hours; this is neither a common nor chronic
condition in humans. Chronic sleep restriction has become
more common in recent decades, having more than doubled
in the US since the 1960s [22, 23]. Approximately onethird of adults in the US currently report chronic sleep
restriction and similar figures have been observed in other
countries [24–26]. Chronic sleep restriction is increasingly
recognized as a health concern because it is associated with
motor vehicle and industrial accidents, health conditions
such as hypertension, diabetes, obesity, and depression, and
increased mortality [21, 27, 28].
Previous research investigating the link between chronic
sleep restriction and obesity has not adequately addressed
the underlying causes of chronic sleep restriction. Many
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studies have either overlooked the causes of chronic sleep
restriction or viewed chronic sleep restriction as the result of
voluntary sleep curtailment [20]. However, the determinants
are likely to be complex and vary considerably between
individuals. These need to be examined because the nature
of the relationship between chronic sleep restriction and
obesity could depend on, or vary according to, the precise
cause of chronic sleep restriction. The potential to modify
sleep duration to aid obesity prevention and management
may also depend on the precise factor(s) that contribute to
chronic sleep restriction. Therefore, the remainder of this
section identifies some key determinants of chronic sleep
restriction that require investigation in this context.
Sleep duration is influenced by a combination of genetic,
health, sociodemographic, environmental, and behavioral
factors; so there are likely a multitude of factors that could
potentially contribute to chronic sleep restriction. Data
from large-scale population studies have recently identified
factors associated with chronic sleep restriction in adults at
a population level. Most of these studies have been crosssectional, but they do provide an insight into the factors that
could be important predictors of chronic sleep restriction.
In particular, sociodemographic factors such as increased
age, lower education level, lower income, ethnicity, and
nonmarried status have been identified as strong predictors
of chronic sleep restriction [24, 25, 29–31]. Health behaviors
such as smoking, excessive alcohol consumption, lower levels
of physical activity, increased television viewing, shift work,
long working hours, and increased time commuting to and
from work have also been associated with shorter sleep
durations [24, 25, 30–34]. Several studies also demonstrate
that physical and mental health status strongly predict sleep
duration. For example, chronic diseases such as diabetes or
cardiovascular disease [24, 25, 29–31] and mental health
conditions such as stress, depression, and sleep disorders
(e.g., insomnia) have been associated with reduced sleep
[35, 36]. Dramatic changes in our physical environments
in recent decades may also be contributing to chronic sleep
restriction. For example, it is argued that we increasingly live
in a 24-hour society that is characterized by more artificial
light; this has the potential to disrupt natural circadian
rhythms and adversely aﬀect sleep [37].
There are, therefore, many sociodemographic, behavioral/lifestyle, health, and environmental factors that could
contribute to chronic sleep restriction. Importantly, the
precise causes of chronic sleep restriction are likely to vary
considerably between individuals. Some individuals may voluntarily limit the amount they sleep in order to meet work,
social, or family demands, whilst others engage in behaviors
such as cigarette smoking and excessive alcohol consumption
that adversely impact on sleep duration. In other individuals,
an underlying health condition, medication use, or factors
associated with a low socioeconomic status could be the
primary cause(s) of chronic sleep restriction.
If chronic sleep restriction is to be targeted as a
modifiable risk factor for obesity, there is a need to better
understand the underlying factors contributing to chronic
sleep restriction in diﬀerent populations. This is important
for two main reasons. First, the nature and magnitude of
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the relationship between chronic sleep restriction and obesity
may depend on the underlying causes of chronic sleep
restriction; this could influence the mechanisms or pathways
linking chronic sleep restriction to obesity and also how
susceptible an individual is to the eﬀects of sleep restriction.
Second, the potential to modify sleep through interventions
may diﬀer based on the specific cause(s) of chronic sleep
restriction. For example, factors such as mental health
problems and sleep disorders may require interventions from
specialist practitioners. In contrast, factors such as work
hours could be targeted by behavioral interventions that do
not necessarily aim to reduce work hours (as this could
have adverse consequences, such as a loss of income), but
rather attempt to minimize the impact of work hours on
sleep patterns. This could perhaps be achieved by addressing
factors such as television viewing and time spent commuting
to and from work which may be limiting sleep duration in
people who work long hours [33, 34]. Thus it is important
that research investigating the relationship between chronic
sleep restriction and obesity examines the determinants of
chronic sleep restriction.

3. Hypothesised Pathways Linking Chronic
Sleep Restriction to Obesity
There are many processes or pathways through which
chronic sleep restriction could contribute to obesity and it is
not feasible to address all of these in a single review. Instead
we focus on the following three hypothesized pathways linking chronic sleep restriction to obesity: (1) neuroendocrine
and metabolic pathways, (2) glucose regulation, and (3)
waking behaviour. There is potential overlap between these
pathways, but for the purposes of clarity, we discuss each of
them separately.
The concept of energy balance is important in this
context. A constant body weight depends on a balance
between energy intake (diet) and energy expenditure (basal
metabolic rate, physical activity, and thermogenesis). Under
normal conditions energy balance is maintained by a complex regulatory system that involves multiple physiological
pathways in the body which act on neural circuits to maintain
body weight within a narrow range [38–40]. For example,
the adipose tissue hormones leptin and adiponectin, the pancreatic hormone insulin, and the gastrointestinal hormones
ghrelin, peptide YY3–36 (PYY), and glucagon-like peptide-1
(GLP-1) all act on hypothalamic circuits to influence energy
balance. A chronic positive energy balance occurs when
energy intake exceeds expenditure over a prolonged period
of time; this has the potential to aﬀect the processes involved
in regulating body weight and can lead to obesity over time
[39, 40].
3.1. Hypothesis 1. Sleep Restriction Alters Neuroendocrine and
Metabolic Functioning. In a landmark series of experimental
studies, Spiegel and colleagues [16–18, 41] demonstrated
that short-term sleep restriction alters some neuroendocrine
and metabolic hormones that are involved in the regulation
of energy balance. In particular, six consecutive nights of
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sleep restriction (four hours sleep per night) were associated
with increases in sympathetic nervous system (SNS) activity,
evening cortisol levels and growth hormone levels (GH),
and reductions in thyroid stimulating hormone (TSH), and
leptin [16, 17, 41]. A follow-up study found that sleep
restriction (four hours sleep per night) over two nights
led to an 18% reduction in leptin and a 28% increase
in ghrelin [18]. The increase in the leptin-to-ghrelin ratio
corresponded with a 24% increase in hunger and a 23%
increase in appetite that was mainly for energy dense foods.
Other research groups have obtained similar results. For
example, Guilleminault et al. [13] found that seven nights of
sleep restriction (five hours sleep per night) led to a reduction
in leptin rhythm amplitude. Schmid et al. [15] also found
that a single night of 4.5-hour sleep led to an increase in
ghrelin levels. Finally, Magee et al. [14] observed that two
consecutive nights of five hours sleep led to a significant
reduction in PYY levels and a corresponding decrease in
satiety levels.
The profile of these hormonal changes is suggestive of
increased energy intake, reduced energy expenditure and
weight gain. For example, leptin, which is released in proportion to adipose tissue amount, acts on hypothalamic circuits
to reduce energy intake and increase energy expenditure
[42]. Insulin has many roles but also acts on hypothalamic
circuits to reduce energy intake and increase energy expenditure [42, 43]. The reductions in leptin and insulin observed
with sleep restriction are therefore suggestive of increased
food intake and reduced energy expenditure. Ghrelin is
released primarily from the stomach when nutrient levels are
low and acts on hypothalamic pathways to stimulate food
intake [44, 45]. The PYY3–36 molecule is released from the
gastrointestinal tract in response to ingested nutrients and
acts on the hypothalamus to reduce food intake [46, 47].
Therefore, the elevations in ghrelin and reductions in PYY
observed with sleep restriction may be predictive of increased
food intake.
Similarly, the increases in evening cortisol and GH levels
may also be suggestive of weight gain. The elevation in
GH levels observed by Spiegel et al. [41] was the result
of an extended period of nocturnal GH secretion. This
may have increased the amount of exposure of peripheral
tissues to GH; if prolonged this could impact on glucose
regulation in a way that leads to obesity (this is discussed in
more detail below) [41]. However, GH has been shown to
promote lean tissue and reduce the accumulation of adipose
tissue [48]. The precise implications of the increases in GH
observed with sleep restriction are therefore unclear and
require further investigation.
The elevations in cortisol following sleep restriction suggest greater activity of the hypothalamic-pituitary-adrenal
gland (HPA) axis. This could reflect increased stress levels
as the HPA axis plays an important role in regulating the
stress response [49]. Importantly, elevated cortisol levels
have been shown to promote increased food intake and the
accumulation of visceral fat in humans [50]. Similarly, since
TSH normally functions to stimulate basal metabolic rate,
the reductions in TSH with sleep restriction are suggestive
of a reduction in energy expenditure.
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The findings reviewed above indicate that short-term
sleep restriction under controlled laboratory conditions
alters neuroendocrine and metabolic hormones in a manner
that is consistent with weight gain and obesity. However, we
only have partial understanding of these mechanisms and
there are a number of issues that remain to be addressed.
First, it is not clear which brain mechanisms link sleep
restriction with the observed alterations in metabolic and
neuroendocrine functioning. The activation of the SNS
with sleep restriction is one possibility since increased SNS
activity inhibits the release of leptin from adipose tissue
and may inhibit insulin release [51]. Increased SNS activity
also inhibits vagal nerve activity, which could account
for the rise in ghrelin level observed with sleep loss [52,
53]. However, increased SNS activity is typically associated
with reductions in energy intake and increased energy
expenditure over time [54]. Since this pattern is predictive
of weight loss, increased activation of the SNS may not be
the predominant mechanism through which sleep restriction
alters energy balance and leads to weight gain. Instead, other
mechanisms involving disruptions in the functioning of the
suprachiasmatic nucleus (SCN) or activation of the HPA axis
could be more important.
The SCN is located in the anterior hypothalamus and
regulates the circadian rhythms of several physiological
systems, including sleep, and the secretion of hormones
involved in energy balance regulation [55]. Alterations
in hormones such as leptin, cortisol, and TSH and GH
observed with sleep restriction could therefore be the result
of disrupted SCN output. As noted earlier, the increases
in cortisol secretion observed with sleep restriction suggest
increased activation of the HPA-axis, which is indicative of
the stress response. The stress response serves an important
adaptive purpose by supplying extra energy to body tissues
in anticipation of a fight or flight response [49, 50, 56].
This leads to the release of cortisol which through a series
of feedback loops signals the HPA axis to reduce cortisol
secretion [57]. However, chronic or frequent stress can
desensitise the HPA axis such that cortisol remains elevated;
over time this can lead to an increase in visceral body fat since
cortisol promotes fat accumulation and also inhibits the
release of leptin [49, 50, 58]. Activation of the HPA axis may
also explain the increased SNS activity observed with sleep
restriction. Thus it is possible that the physiological changes
observed with sleep restriction are the result of increased
HPA axis activity and/or altered SCN output, which have a
cascading eﬀect on a number of physiological systems.
The second important consideration is that it is not clear
whether the physiological eﬀects of sleep restriction observed
under laboratory conditions over a period of a few days are
equivalent to prolonged (or chronic) sleep restriction as it
occurs in free-living individuals. In particular, it is feasible
to assume some degree of physiological adaptation to the
eﬀects of sleep restriction, but one can only speculate on the
extent and nature of this adaptation. Moreover, the eﬀects
of sleep restriction as observed in laboratory-based settings
may diﬀer to the eﬀects of chronic sleep restriction in free
living adults. These are all important considerations because,
as noted above, the causes of chronic sleep restriction
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could diﬀer considerably between individuals and the impact
of sleep restriction on energy balance may depend on
the underlying cause of chronic sleep restriction. Finally,
few studies have examined whether sleep restriction alters
components of energy expenditure. Schmid et al. [59]
demonstrated that sleep restriction led to a reduction in
physical activity under free-living conditions, but there were
no significant changes in food intake, hunger and appetite,
and levels of leptin and ghrelin. This suggests that sleep
restriction might alter energy expenditure but this requires
further investigation in studies that also examine other
components of energy expenditure such as basal metabolic
rate or nonexercise activity thermogenesis. This is important
because examining both sides of the energy equation (i.e.,
energy intake and expenditure) will be critical to understanding the processes through which sleep restriction promotes
obesity.
3.2. Hypothesis 2. Sleep Restriction Alters Glucose Regulation.
Another potential pathway linking chronic sleep restriction
to obesity could involve disruptions in the regulation of
glucose levels; this may also have implications for diabetes,
which are discussed by Spiegel et al. [60]. Alterations in
glucose regulation have been linked with weight gain and
obesity. For example, Boulé et al. [61] found that lower blood
glucose concentrations at the end of an oral glucose tolerance
test (OGTT) predicted weight gain over a 6-year period.
These results were explained according to the Glucostatic
Theory of Appetite Control, which postulates that glucose
plays an important role in the regulation of satiety and
appetite [62]. In particular, reduced glucose utilization in
important regions of the brain leads to perception of hunger
and increased food intake, whereas higher glucose utilization
in these same areas promotes a decrease in hunger and a
cessation of eating [62].
Sleep restriction has been shown to aﬀect glucose levels
in humans. Spiegel et al. [17] found that six nights of sleep
restriction led to a 30% reduction in glucose eﬀectiveness
(i.e., noninsulin dependent glucose utilization) and a 40%
reduction in glucose utilization following intravenous glucose administration. These results have been supported by
cross-sectional and prospective data. For example, Chaput et
al. [63] found that habitually short sleepers had higher levels
of fasting plasma glucose and insulin concentrations and
lower blood glucose concentrations at the end of an OGTT.
Chaput et al. [64] also found that individuals reporting
short sleep had increased glucose area below fasting glucose
concentrations; this is indicative of reactive hypoglycemia
and predicted diabetes/impaired glucose tolerance at six-year
followup.
Thus it is possible that chronic sleep restriction contributes to obesity by disrupting the regulation of glucose in
a manner that promotes increased food intake. Chronic sleep
restriction could potentially exert these eﬀects via activation
of the SNS or disruptions in hormones such as cortisol or GH
[63]. As with the neuroendocrine pathways discussed above,
there is a need for more longitudinal data examining whether
prolonged sleep restriction does promote fat accumulation
and lead to obesity by impairing glucose regulation.
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Figure 1: Schematic representation of the pathways linking chronic sleep restriction to obesity.

3.3. Hypothesis 3. Sleep Restriction Aﬀects Waking Behaviour.
The third hypothesis discussed in this paper is that chronic
sleep restriction contributes to obesity by aﬀecting waking
behavior, and in particular promoting patterns of behavior
that cause weight gain. It is well documented, for example,
that consumption of food with a high-energy content
and sedentary behavior (e.g., television viewing, physical
inactivity) are strong risk factors for obesity [6]. Chronic
sleep restriction could lead to obesity by promoting these
behaviors and this has received some empirical support.
Nedeltcheva et al. [65] for example, recently examined
the eﬀects of 14 consecutive days of sleep restriction
on food intake, energy expenditure, and neuroendocrine
hormones. In contrast to the studies conducted by Spiegel
and colleagues [16–18], which involved a mild form of
calorie restriction, Nedeltcheva et al. [65] provided food to
participants ad libitum. Their results indicated that sleep
restriction led to an increase in calorie consumption that
was attributed to snacking particularly during the night
when the individual would normally have been sleeping
(this is unlikely to reflect the night eating syndrome).
Food intake during meal time remained unchanged with
sleep restriction, as did energy expenditure. The findings
suggest that short sleepers could be more susceptible to
weight gain because they have more time to eat. The
increase in consumption because of greater exposure to food
(rather than increased hunger) suggests that in addition
to the homeostatic factors reviewed above, nonhomeostatic
factors may also be involved in the relationship between
chronic sleep restriction and obesity [66]. Thus, future
studies will need to further investigate both homeostatic and
nonhomeostatic pathways linking chronic sleep restriction to
obesity.
Another plausible behavioral pathway linking chronic
sleep restriction to obesity involves fatigue, since individuals

who get insuﬃcient sleep are more likely to experience
fatigue and daytime sleepiness [67]. It is possible that
individuals engage in behaviors such as consumption of
high-energy drinks or food to counter the eﬀects of fatigue.
Fatigue may also render individuals less likely to engage
in physical activity [68, 69] and more likely to engage in
sedentary behaviors such as television viewing. This pattern
of behavior could also promote a positive energy balance and
may partially account for the association between chronic
sleep restriction and obesity.

4. Integrating the Pathways Linking Chronic
Sleep Restriction to Obesity
Chronic sleep restriction may be an important risk factor for
obesity and could have implications for obesity prevention
and management. However, current understanding of the
processes underlying the relationship between chronic sleep
restriction and obesity is limited. The purpose of the
present paper was not to provide a definitive review of
the literature, but rather to integrate two important aspects
of this relationship which are summarized in Figure 1.
First, we examined potential determinants of chronic sleep
restriction, which have been largely overlooked in the
literature. We hypothesize that chronic sleep restriction
could be the result of a range of factors including mental
health status, lifestyle/behavioral factors, chronic disease,
and sociodemographic status. It is important that these are
examined further because the precise causes of chronic sleep
restriction, and the potential to modify these in therapeutic
settings, are likely to diﬀer considerably between individuals.
Second we examined the following three potential pathways
through which chronic sleep restriction could potentially
promote weight gain and obesity: (1) metabolic and neuroendocrine functioning, (2) glucose regulation, and (3)
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waking behaviour. These pathways have the potential to
promote a positive energy balance and may explain the
mechanisms linking chronic sleep restriction to obesity. The
first challenge for researchers will be to demonstrate that
chronic sleep restriction does impact on these and other
pathways not examined in this paper. This is important
because the eﬀects of short-term sleep restriction may not
correspond with the eﬀects of chronic sleep restriction, as
there may be some form of physiological adaptation over
time. Thus, more long-term prospective studies examining
the associations between changes in sleeping patterns, body
composition, and the pathways identified in Figure 1 are
needed. There is also a need to investigate whether the magnitude of the association between chronic sleep restriction
and obesity, and the underlying pathways, varies according
to the causes of chronic sleep restriction.
It should be noted that the association between chronic
sleep restriction and obesity is likely to be bidirectional and
circular, and this is depicted in Figure 1. Therefore, although
the primary purpose of this paper was to review evidence
indicating that chronic sleep restriction contributes to obesity, it is also possible that obesity contributes to chronic sleep
restriction. For example, symptoms of obesity such as pain
and discomfort and comorbid conditions such as obstructive
sleep apnea have been shown to impair and disrupt sleep. As
a result, there is a need for more experimental or prospective
research to delineate the magnitude of the eﬀect of chronic
sleep restriction on obesity.
A final consideration is that it is not clear whether
chronic sleep restriction can be modified through interventions, and whether these changes are eﬀective in preventing
and managing obesity. Research addressing these issues will
be important in determining not only the pathways linking
chronic sleep restriction to obesity but also whether chronic
sleep restriction is a risk factor that can be modified to treat
and prevent obesity. Currently there is a 12-month randomized controlled trial being conducted in the US (clinicaltrials.gov register number NCT00261898) that is examining
whether increasing sleep duration in obese individuals who
report short sleep aﬀects body weight and other related variables (e.g., glucose regulation, neuroendocrine hormones).
This study may provide clarification as to whether chronic
sleep restriction can be targeted as a modifiable risk factor
for obesity, but the results of this study have not yet been
published. This area of research is significant given that the
obesity epidemic continues to grow and poses a number of
major health, social, and economic problems; targeting the
amount we sleep could be an important step in combating
this health problem.
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Epidemiological evidence shows an inverse relationship between dietary fibre intake and body weight gain. Oat b-glucan, a soluble fibre alters
appetite hormones and subjective satiety in acute meal test studies, but its effects have not been demonstrated with chronic consumption. The
present study aimed to test the effects in women of two different doses of oat b-glucan on weight loss and hormones associated with appetite
regulation. In a 3-month parallel trial, sixty-six overweight females were randomised into one of three 2 MJ energy-deficit diets: a control and
two interventions including 5 – 6 g or 8 – 9 g b-glucan. Anthropometric and metabolic variables (blood glucose level, insulin, total cholesterol
(TC), LDL, HDL, TAG and leptin), together with markers of appetite regulation (cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1),
ghrelin, peptide YY (PYY) and PYY3-36) were measured at baseline and at 3 months. After 3 months, all groups lost weight (P,0·001) and
showed a reduced waist circumference (P,0·001). The study sample also showed reductions in TC, LDL, HDL, leptin, PYY, GLP-1 values
(all P, 0·001) and an increase in CCK levels (P,0·001). No significant differences were noted between the groups for all outcome values
except PYY levels (P¼ 0·018). In broad terms, the addition of oat b-glucan did not enhance the effect of energy restriction on weight loss in
mildly overweight women, although wide variations in observed results suggests that individual responsiveness may be an issue.
b-D -Glucan: Weight loss: Weight control: Appetite hormones

Large bodies of epidemiological data show an inverse
relationship between dietary fibre intake and body
weight(1 – 5) so that the logic and simplicity of including fibre
in an energy-controlled diet remains tantalising. As a component of food, fibres are found in a fermentable (soluble)
or non-fermentable (insoluble) form, but early research has
been unable to show benefits from including either form in
short term (3 –4 weeks) ad libitum diets(6). This was also the
case when the form of fibre was mixed linkage b-glucan, a
soluble fibre delivered by oats(7), well recognised for its
cholesterol(8) and glucose lowering(9) actions. In order to
better expose the advantages apparent from epidemiological
studies, more work is required in understanding the physical
features of fibre, the food delivery system, and how these
may work together to affect mechanisms associated with
weight management, such as satiety, particularly over longer
periods of time.
It is accepted that soluble fibre, by its viscous nature will
not only increase upper gastrointestinal transit time, but also
stimulate cholecystokinin (CCK) that will increase peristalsis(10). The effects of other hormones are less clear, but the
ileal brake formed by undigested foods in the distal gut
(occurring with high fibre foods), in addition to the fermentation of soluble fibres in the large bowel are all seen as positive

benefits of fibre. Meal studies are able to expose these mechanisms of action. This is done via assessment of biochemical
markers and subjective measures of satiety, in addition to
monitoring subsequent food intake after consumption of the
test food. Studies of b-glucan have identified doses as low
as 2 g may elicit acute lowering of glycaemia(11), while
others suggest a minimum of 4 g(10) may be required for
other gastrointestinal effects, such as those causing the release
of appetite hormones. However, meal test studies only define
an acute situation in very controlled conditions.
In addition to the time factor, the food delivery system
requires consideration. For example, the clinical effectiveness
of fibres such as b-glucan may be reduced in certain foods. It
has been shown that in bread making, endogenous enzymes in
the bread reduce the viscosity of the b-glucan thereby decreasing its clinical effectiveness(12,13). However, a recent satiety
study(14) looking at high-dose (10 g) b-glucan and appetite
hormones has showed that a lower viscosity drink (with
viscosity lowered using b-glucanases) increased the levels of
certain appetite hormones such as CCK and glucagon-like
peptide-1 (GLP-1) compared with the high viscosity version
of the same drink. Nevertheless, such contrasts once again
do not define what may happen when soluble fibres are
consumed over time, as a change in hormones over a few hours

Abbreviations: CCK, cholecystokinin; GLP-1, glucagon-like peptide-1; HBG, high-dose b-glucan; MBG, mid-dose b-glucan; PYY, peptide YY; RMANOVA,
repeated-measures ANOVA; RTE, ready-to-eat; VAS, visual analogue scales.
* Corresponding author: Eleanor J. Beck, fax þ 61 2 4221 4844, email eleanor@uow.edu.au
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does not necessarily translate to appetite and weight changes
over a longer period of time.
The present study describes a 3-month randomised controlled dietary intervention trial, designed to review the
specific effects of b-glucan from oat bran incorporated in
an energy-restricted meal plan. The primary outcome was
a difference in weight reduction between the control group
and intervention groups. Secondary outcomes included a variety of biochemical measures linked with satiety or change
in body weight, subjective satiety measures and perceived
satisfaction with the product. Biochemical measures included
fasting glucose, insulin, cholesterol, LDL, HDL, TAG,
leptin, CCK, GLP-1, ghrelin, peptide YY (PYY) and
PYY3-36. We hypothesised that the subjects receiving
b-glucan would lose more weight than the subjects on the
control diet, and that changes in appetite hormones may
be detected due to mechanisms linking the satiety with
ingestion of b-glucan.

Experimental methods
Subjects and recruitment
This was a 3-month parallel randomised controlled trial with
female subjects, based on evidence that they may exhibit
greater acute hormone changes with fibre intake(15). There
were three arms to the study with all the groups receiving
advice on energy restriction and all the subjects receiving
cereal products to include in their diets. The control group
had relatively high fibre products with no oat b-glucan,
while the intervention groups had similar products with
added b-glucan at a moderate (MBG; 5–6 g/d) and at a high
(HBG; 8–9 g/d) level. A sample size of twenty subjects per
group was based on data from a previous study showing a
1·8 kg difference between a group supplemented with
b-glucan and a control group, where both groups were consuming a energy-deficient diet(16). For a power of 80 %, seventeen subjects would be required in each group for this change
to be significantly different at an a level of 0·05 and recruiting
at least twenty subjects would allow for dropouts. Inclusion
criteria advertised in local media were 19– 45 years of
age (pre-menopausal), BMI range from 25–32 kg/m2, nonsmokers, no known food allergies and of general good
health. The present study was conducted according to the
guidelines laid down in the Declaration of Helsinki and all
procedures involving human subjects were approved by the
University of Wollongong, Human Ethics Committee
(HE06/311). Written informed consent was obtained from
all the subjects. The trial was registered with the Australian
Clinical Trials Registry (ACTRN12607000126415).
The first seventy-seven of 215 enquiries were screened
resulting in randomisation of sixty-six subjects, using a computer-generated sequence using random permuted blocks
(Fig. 1). All the subjects, but not dietitians were blinded to
their randomisation status within the trial. The subjects
attended the study centre for a total of five times. Visits
included collection of background dietary data using a validated diet history interview(17) and instruction on completion
of a 3-d weighed food record, collection of fasting blood
samples at baseline together with dietary education, two
follow-up dietary visits and collection of fasting blood
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samples at 3 months. All the subjects had their height,
weight and waist circumference recorded at each visit to the
centre. The subjects were also contacted by telephone on
one occasion in between the monthly visits to provide dietary
review and support. Visual analogue scales (VAS) related to
appetite(18), food records and the Baecke Physical Activity
Questionnaire(19) were all completed at baseline, half-way
through the study and within the final week of the study.
For the VAS, the subjects recorded their feelings on individual
forms at six different time points throughout the day: immediately before each of the three main meals and 2 h after each of
these meals. Markings by participants were measured in
millimetres. All nutritional analysis was performed using
FoodWorks 2007, version 5 (Xyris Software, Brisbane,
QLD, Australia) with nutrient contents of study foods added
as required.
Dietary intervention
A basal metabolic requirement for energy was calculated for
each subject using the Schofield equation using BMI equal
to 25 kg/m2. A low activity factor (1·3) was chosen to estimate
energy requirements and then 2000 kJ was subtracted from this
level to a calculated weight loss of 0·5 kg/week. Intervention
diets were designed to control for all macronutrients with
the only variation in total fibre, primarily b-glucan such that
a typical diet, as described in Table 1 only varied in the
trial products given. Product development for cold and hot
cereals as well as additional snack items took place in a
pilot processing plant by qualified cereal food technologists.
The source of b-glucan was a commercially available oat
bran with 22 % b-glucan. The subjects were instructed to eat
the cereal provided at breakfast (ready-to-eat (RTE) cereal
or porridge) and two snack items at afternoon tea (choice
of two muesli bars, two cereal snack packs or one muesli
bar and one cereal snack pack). Product consumption was
evaluated for overall satisfaction, and positive and negative
symptoms were observed using questionnaires at the completion
of the study.
Products were tested for molecular weight, solubility,
viscosity and both soluble and total b-glucan using methods
described by Tosh et al. (20). The amount of b-glucan in the
control products was negligible (,0·2 g/serving). b-Glucan
contents of the products, including soluble b-glucan are
included in Table 2. The b-glucan in the RTE cereal and
snack products had a higher solubility than the other products,
with solubility improved by extrusion (porridges not
extruded). The molecular weight of b-glucan extracted from
all of the products showed only limited decreases due to
effects of processing; highest where there was least processing
(muesli bars and porridge) and lower in the extruded products
(RTE cereal and cereal snack). The cereal and porridge
samples with lower b-glucan contents (MBG samples) produced lower viscosity extracts (Table 2). The viscosity profiles
of the HBG muesli bar and the HBG porridge had extracts
with very similar viscosity profiles despite their differences
in total b-glucan content. This is due to the greater solubility
of the b-glucan in the muesli bar. The HBG RTE cereal
had the greatest viscosity due to its high b-glucan and high
solubility. All of the intervention products showed physicochemical characteristics which would be expected to produce
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Fig. 1. Flow diagram of participation in the study. MBG, mid-dose b-glucan; HBG, high-dose b-glucan.

bioactivity. These products should have increased viscosity in
the upper digestive tract which should modify the digestion
and absorption rates of the nutrients.
Clinical indices
Fasting blood samples at 0 and 3 months were collected
using Sarstedte Monovette blood collection tubes. Glucose,
insulin, total cholesterol, HDL, LDL and TAG analysis was
performed at an accredited pathology laboratory (Southern
IML Pathology, Wollongong, NSW, Australia). A further
sample was collected into tubes containing potassium
EDTA (to achieve a concentration of 0·5–2 mg EDTA/ml
of blood after collection). Both the tubes contained dipeptidyl
peptidase IV (Millipore, Billerica, MA, USA) to level of
10 ml/ml of blood. One tube also contained aprotinin equivalent to 0·6 trypsin inhibitor units per ml of blood (Aprotinin

from bovine lung Sigma Aldrich A1153 dissolved in
normal saline with 0·9 % benzyl alcohol) for analyses of
CCK and PYY3-36. Together with the dipeptidyl peptidase
IV inhibitor, the second tube contained 240 ml of complete
protease inhibitor cocktail (Roche, Castle Hill, NSW, Australia) made to 25 £ concentration in distilled water. Final concentrations met the recommendations for the manufacturers’
protocols for assays described later. The blood samples
were then centrifuged at 48C for 15 min at 1500 g. The
plasma was stored at 2 808C until further analysis could be
completed.
Ghrelin, leptin, GLP-1 and total PYY were analysed using
a Lincoplexe Human Gut Hormone Panel (catalogue no.
HGT-68K) according to manufacturer’s instructions.
CCK analysis used Phoenix Peptidese RIA (RK-069-04)
for CCK octapeptide (CCK 26-33). The standard RIA protocol
was applied but without extraction of the peptides before the
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Table 1. Food serves for typical dietary study participant
Food group

Serve size

Number of serves/d

Breads/cereal/starchy vegetables
Other vegetables
Fruit
Milk/alternatives
Meat/alternatives
Fats
Control or intervention products

1 slice bread or 1/2 cup pasta or 1 medium potato
1/2 cup cooked ¼ 1 cup raw
1 piece fresh or 3/4 cup canned
150 ml light/200 ml skim, 100 g low-fat yoghurt
30 g meat/45 – 60 g fish/20 g low-fat cheese
1 tsp oil or margarine or 1 tbsp avocado
Portion controlled pre-packed

4 serves
2·5 cups cooked or 5 cups raw
2 pieces
2 – 3 serves
3 – 4 serves
3–4
Cereal þ 2 snacks (muesli bar or snack pack of cereal)

tsp, tea spoon; tbsp, table spoon.

assay. PYY3-36 analysis utilised a human specific RIA sourced
from Linco (PYY-67HK) using the standard protocol.

British Journal of Nutrition

Statistical analysis
Data for all anthropometry, blood analysis, VAS measurements and dietary intake were entered into SPSS for windows,
version 15.0 (SPSS 15.0, Chicago, IL, USA). Repeated
measures ANOVA (RMANOVA) using the general linear
model with group (control, MBG and HBG) as the betweensubjects factor, was used to identify primary changes in
each parameter over time and also differences between the
groups. Post hoc analysis using Bonferroni adjustments was
reviewed to detect specific differences between the control
and intervention groups. Log (base 10) transformations were
also used as appropriate. Regression analysis was used to
identify correlations between group anthropometric and biochemical indices. One-way ANOVA was used to review
VAS and Baecke questionnaire results at various time points
identifying any differences between the groups.

Results
Baseline data
Final numbers in each group were sixteen controls, twenty-one
MBG and nineteen HBG (Fig. 1). There were two withdrawals
from each of the MBG and HBG groups, but six were from the
control group. Fifty-six subjects were included in the final data
analysis. Some subjects did not complete all forms or blood
was unable to be drawn for certain tests, so numbers in each
calculation varied.

At baseline, there were no significant differences between
group anthropometric and metabolic measures (Table 3).
The subjects were overweight but overall they were not hyperlipidaemic (mean cholesterol 5·03 (SD 1·07) mmol/l). The only
baseline biochemistry measure which showed significant
differences between the groups was the fasting blood glucose
level (P¼0·046), where the level for the HBG group was
lower than that of the other two treatments (Table 3).
Review of food records and diet histories at baseline indicated relatively well-matched groups. No significant differences were noted between energy, fibre, protein, fat or
carbohydrate overall (Table 4). The only significant difference
at baseline was the amount of MUFA consumed (P¼ 0·025),
where post hoc analysis using Bonferroni adjustments
showed significantly less MUFA in the MBG group (24·8
(SD 9·8) g) compared with the control (32·5 (SD 8·0) g). The
MUFA intake of the HBG group (28·8 (SD 6·8) g) was between
these two levels.

Dietary intervention
Evaluation of the food records at mid-way through the study
and at the end indicated little variation between the groups
for macronutrient intakes at each time point with no significant differences between the groups. Review of the overall
dietary composition of baseline diets compared with the
mid-point of the study and the 3-month end-point showed a
decrease in percentage energy from fat and an increase in
the percentage energy from protein and carbohydrate (Table 4).
General compliance with a weight reduction regimen was
identified by overall weight loss (described later) and
energy restriction detailed in the food records. Total energy

Table 2. b-Glucan and total fibre content of study products (allowing for moisture and fruit content, calculated for serve size)

Sample

Description

Control
Control
Control
Control
MBG
MBG
HBG
HBG
HBG
HBG

RTE cereal
Porridge
Extruded snack
Muesli bar
RTE cereal
Porridge
RTE cereal
Porridge
Extruded snack
Muesli bars

Soluble b-glucan
(g per serve)

Total b-glucan
(g per serve)

Viscosity of extract
(mPa £ s)

Total fibre
content (g)

Negligible
Negligible
Negligible
Negligible
2·3
1·2
3·5
1·7
1·4
0·9

Negligible
Negligible
Negligible
Negligible
3·9
3·0
4·8
4·4
2·1
1·7

Not done
Not done
Not done
Not done
14·6
19·0
83·9
58·9
54·5
57·0

4·0
1·2
0·6
2·9
7·4
6·6
10·1
9·7
4·4
4·6

RTE, ready-to-eat; MBG, mid-dose b-glucan; HBG, high-dose b-glucan.
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Table 3. Baseline characteristics of study subjects
(Mean values and standard deviations)
Control (n 16)

MBG (n 21)

HBG (n 19)

Variable

Mean

SD

Mean

SD

Mean

SD

P

Age (years)
Weight (kg)
BMI (kg/m2)
Waist (cm)
Fasting blood glucose (mmol/l)
Fasting insulin (mU/l)
Cholesterol (mmol/l)
LDL (mmol/l)
HDL (mmol/l)
TAG (mmol/l)

37·1
77·0
29·2
83·8
4·7
10·7
5·2
3·2
1·6
1·3

5·6
7·8
2·2
5·7
0·6
4·3
0·7
0·5
0·4
0·4

37·7
80·9
29·3
85·1
4·9
11·1
5·0
2·9
1·6
1·1

6·0
8·2
2·2
8·0
0·5
5·8
1·1
1·0
0·3
0·5

37·4
77·6
29·3
82·4
4·5
12·1
4·9
2·7
1·7
1·0

5·5
6·5
2·1
5·6
0·4
4·8
1·3
0·9
0·3
1·0

0·96
0·17
0·86
0·29
0·05*
0·57
0·73
0·17
0·63
0·55
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MBG, mid-dose b-glucan; HBG, high-dose b-glucan.
* Significant value was measured using ANOVA.

intake was significantly lower at the mid-point (mean 6308
(SD 1068) kJ) of the trial and the end-point (mean 6000
(SD 1163) kJ) (P,0·001) compared with the baseline (mean
8725 (SD 1703) kJ) using RMANOVA with fibre level as the
between-group effect and time as the within-subject variant.
There was no interaction effect over time (P¼0·192) indicating all the groups followed the energy-restricted diet to the
same extent.
Dietary compliance with the study products measured by
review of 3-d food records indicated that the use of breakfast
cereal was very high (90 % consumed), while compliance with
the snacks was reasonable (74 % consumed). Differences in
dietary fibre intakes between the groups could be accounted
for by the difference in fibre between the groups’ product
supply. This includes both soluble (b-glucan) and insoluble
fibre from the products. The groups achieved a significant
difference in the amounts of dietary fibre consumed at midpoint (P,0·001, RMANOVA) and the last week of the
study (P, 0·001, RMANOVA; Table 4). There was limited
change in the control group, indicating that the products supplied to the subjects (which especially in the case of the cereal
were relatively high fibre) replaced foods of similar fibre
content.
The only dietary variation between the groups was the monounsaturated fats which varied at baseline also. The levels were
not different at mid-point and at 3 months, but rather the
change from baseline produced an interaction effect for time £
group (Table 4). Therefore, all anthropometric and biochemical
results were also checked for correlation with the monounsaturated fat levels.
There were no significant differences in activity scores
between the groups at any time point, indicating that changes
in physical activity were not a factor in influencing other
results.
Clinical indices
Almost all anthropometric and biochemical indices changed
over time, although there were no significant differences
between the groups for any measured clinical parameter
over time (Table 5). The average weight loss for the study
sample of 4·1 kg was significant (P, 0·001; ranging from a

0·2 kg gain to a 14·9 kg loss). However, this is less than the
anticipated 6–6·5 kg designed for the energy-restricted diet.
It is also less than the change in kilojoule intake demonstrated
in the food records would predict. The weight loss was not significantly different between the groups (P¼0·921). Waist
measurements decreased significantly (P,0·001).
Fasting blood glucose results did not decrease, however,
fasting insulin decreased significantly compared with baseline
(P, 0·001). However, no differences between the groups were
identified (P¼0·184; Table 5). Log transformation of insulin
data showed the difference from baseline to 3 months was
still significant (P¼ 0·001) but not related to the intervention
(P¼0·113).
Regression analysis indicated that weight loss significantly
predicted waist change (P¼0·001), leptin (P¼0·007), blood
glucose level (P¼0·031) and insulin (P¼0·052). However,
the predictions, other than the expected waist change
(R 2 0·480) were relatively weak (R 2 0·130, 0·084 and 0·069,
respectively). Adjusting changes in these parameters for
weight loss, failed to identify any significant differences
between the groups.
Lipid results were examined overall, between the groups
and also reviewing data for those subjects who had elevated
lipids at baseline. The reduction in total cholesterol was not
significantly different between the groups, with mean
decreases of 0·19 (SD 0·79), 0·31 (SD 0·55) and 0·56 (SD
0·61) mmol/l for the control, MBG and HBG, respectively
(P¼0·239). The general trend was as expected with the greatest decrease in cholesterol with the highest dose of b-glucan.
Overall, there was a significant decrease in cholesterol over 3
months (P, 0·001).
For all the subjects, HDL levels significantly decreased over
time (P, 0·001), LDL significantly decreased (P¼0·028) and
TAG did not change (P¼0·353). Although the LDL results for
RMANOVA did not show an overall effect between the
groups, post hoc Bonferroni adjustments indicated a trend to
differ between the control and high dose of b-glucan
(P¼0·077) with the greatest decrease in LDL in the HBG
group (Table 5). No significant (P,0·05) differences were
detected between the groups for the other lipid parameters.
Large standard deviations existed within all the datasets
limiting the significance of results, especially hormonal
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Table 4. Reported energy and macronutrient intakes at baseline, mid-point and at 3 months, with P values for repeated-measures ANOVA between groups
(Mean values and standard deviations)
Baseline
Control

MBG

Mid-point
HBG

Control

MBG

3 months
HBG

Control

MBG

HBG

P-values

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Group

Time

Interaction

Energy
(kJ)
Protein
(%E)
CHO
(%E)
Total fat
(%E)
SFA
(%E)
PUFA
(%E)
MUFA
(%E)
Total
fibre
(g)

9229

1419

8394

2122

8213

1284

6060

910

6480

1080

6008

1060

6090

1089

6193

1226

5496

1108

0·106

, 0·001*

0·192

18·6

3·5

18·5

5·1

17·6

5·6

20·6

2·7

21·3

3·7

21·8

6·1

19·3

3·6

20·6

3·7

21·3

3·7

0·411

, 0·001*

0·363

42·9

6·5

42·0

16·4

42·1

8·8

50·3

7·7

44·7

8·8

47·5

8·1

50·3

11·2

45·2

4·3

49·3

10·4

0·217

, 0·001*

0·842

34·9

19·0

32·1

10·1

34·3

9·1

22·6

8·8

27·0

8·9

23·5

7·2

22·4

7·9

26·9

6·5

22·7

8·4

0·321

, 0·001*

0·062

13·3

3·8

12·7

5·0

14·5

3·8

8·4

3·2

9·5

4·0

8·7

3·3

8·6

3·8

9·7

2·5

7·9

3·2

0·547

, 0·001*

0·217

4·6

1·4

4·4

1·7

5·2

1·8

3·7

1·6

4·2

0·6

3·5

1·2

3·6

1·6

4·0

1·3

3·8

1·3

0·458

, 0·001*

0·202

13·1

3·2

10·9

4·1

13·0

3·1

8·1

4·4

10·0

3·7

8·9

3·0

7·7

3·0

9·8

3·0

9·0

3·8

0·645

, 0·001*

0·006*

21·9

4·6

21·2

6·0

20·5

6·8

24·2

5·4

28·0

4·2

34·1

6·9

21·6

4·5

27·4

5·6

33·0

3·9

, 0·001*

, 0·001*

, 0·001*
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Variable

E, energy; CHO, carbohydrate.
* Significant values were measured using repeated-measures ANOVA.
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Table 5. Changes in clinical indices overtime and between control, mid-dose b-glucan (MBG) and high-dose b-glucan (HBG) groups
(Mean values and standard deviations)
All groups

Control

Mean change
Changes in clinical indices

78·4
83·8
4·72
11·37
5·03
2·91
1·65
1·11
53·4
20 620
47·95
85·80
73·23
218

Mean
2 4·1
2 4·1
0·02
2 2·68
2 0·37
2 0·23
2 0·14
2 0·09
2 6·4
2 7130
2 6·9
2 12·0
6·1
177

Mean change

Baseline

HBG
Mean change

Baseline

Mean change

SD

P*

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

3·1
2·8
0·47
3·75
0·65
0·2
0·48
0·43
29·5
5720
9·3
26·2
21·0
170

, 0·001
, 0·001
0·586
, 0·001
, 0·001
, 0·001
0·028
0·353
0·217
, 0·001
, 0·001
0·015
0·195
, 0·001

77·6
83·8
4·75
10·74
5·21
1·59
3·23
1·27
45·4
18 690
49·6
92·4
71·4
186

7·8
5·7
0·57
4·29
0·73
0·38
0·47
0·40
21·0
9340
16·7
32·1
11·7
167

2 4·0
2 4·0
2 0·01
2 3·16
2 0·19
0·24
2 0·13
2 0·05
2 6·9
2 7050
2 7·7
2 5·6
2·5
219

2·4
2·6
0·41
4·59
0·79
0·10
0·54
0·29
18·7
6470
9·5
11·8
18·2
147

80·9
85·3
4·89
10·92
5·02
1·64
2·89
1·06
65·0
20 300
50·3
89·1
71·0
245

8·23
7·9
0·46
5·70
1·07
0·27
0·99
0·49
72·9
9160
15·0
19·7
19·8
159

2 4·3
2 0·8
0·03
2 1·42
2 0·31
2 0·16
2 0·08
2 0·13
2 9·3
2 5340
2 8·0
2 23·4‡
10·1
139

3·7
3·16
0·43
3·11
0·55
0·19
0·50
0·26
33·9
4820
8·9
31·5
18·4
171

76·6
82·0
4·52
12·40
4·91
1·70
2·67
1·03
47·2
22 610
43·8
77·1
77·3
210

6·5
5·5
0·37
4·83
1·30
0·33
0·92
0·98
29·6
6510
14·6
32·9
25·1
171

2 3·9
2 3·4
0·15
2 3·40
2 0·56
2 0·3
2 0·23
2 0·01
0·0
2 9430
2 5·0
2 1·3‡
8·9
186

2·9
2·5
0·55
3·50
0·61
0·25
0·42
0·72
33·8
5390
9·7
19·6
25·8
187

P†
0·921
0·476
0·420
0·184
0·239
0·091
0·692
0·688
0·957
0·078
0·493
0·018
0·807
0·253

Cho, cholesterol; GLP, glucagon-like peptide; PYY, peptide YY; CCK, cholecystokinin.
* P values for ANOVA for change from 0 to 3 months.
† P values for repeated-measures ANOVA for changes between groups.
‡ P# 0·05 when compared to control using Bonferroni adjustments. No significant difference existed between MBG and HBG.
§ Results for CCK were higher than usually measured. Peptides were not extracted before analysis and this may have affected absolute results, however, as this is a repeated-measures analysis, trends can still be detected if they
exist.
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Weight (kg)
Waist (cm)
Glucose(mmol/l)
Insulin (mmol/l)
Cho (mmol/l)
HDL (mmol/l)
LDL (mmol/l)
TAG (mmol/l)
Ghrelin (pg/ml)
Leptin (pg/ml)
GLP (pg/ml)
PYY (pg/ml)
PYY3-36 (pg/ml)
CCK (pg/ml)§

Baseline data

Baseline

MBG
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changes. The decrease in leptin levels for the study sample
was significant over time (P, 0·001) and regression analysis
indicated the association with decreasing body weight
(P¼0·007). Between the groups, the differences approached
significance (P¼0·078) with the greatest decrease in leptin
identified in the HBG group, even with the same body
weight change.
Total PYY levels decreased significantly over time
(RMANOVA, P¼0·015), and this was significantly different
between the groups (P¼0·041). Post hoc Bonferroni adjustments indicated that the control group produced significantly
different effects compared with both the MBG (P¼0·021)
and HBG (P¼0·050) groups, where the smallest decrease
in PYY was seen in the HBG group. The greatest change
was in the MBG group so this would not seem related to
dose of b-glucan. Even though levels of total PYY decreased
in all the groups those for PYY3-36 increased, although the
latter were not statistically significant (P¼0·195). PYY3-36
levels increased more with the inclusion of b-glucan in the
diet (8 –10 pg/ml increase compared with 2·5 pg/ml in the
control), but this was not significant between the groups
(P¼0·807).
There was a significant decrease in GLP-1 over time
(P,0·001) but no differences between the groups
(P¼0·567). Ghrelin levels did not significantly alter over
time (P¼0·217) and there were no between-group effects
(P¼0·632). CCK results seemed elevated most likely due to
a lack of extraction of peptides, however, as this was a
repeated-measures analysis, results were included. CCK
levels increased significantly over time (P,0·001) but there
was no group effect (P¼0·969) with all the groups increasing
the CCK levels at equal rates.
All variables were reviewed adjusting for weight loss and
monounsaturated fat, but other than the correlations described
previously, no significant trends were noted. The large standard deviations indicated that individual fluctuations are
more varied than any overall effect of increased b-glucan.
Subjective satiety
VAS results were reviewed for individual time points to
compare any differences which may have existed between
the control and test groups (ANOVA). No significant differences were identified between the groups at any time point
tested – that is all individuals showed similar hunger/fullness
at the same test points (data not shown).
Product evaluation
The majority of subjects in the intervention groups reported
some negative physical symptoms from the products (52 %
for MBG and 63 % for HBG), although this was less than
the numbers experiencing positive symptoms (67 % for
MBG and 85 % for HBG). Negative symptoms included
abdominal pain and changes in bowel patterns (both increased
and decreased stool frequency). Positive associations with the
study products included ‘feeling more full, for longer’,
‘healthy snacking avoiding unhealthy snacking’, ‘less peaks
and lows’ in intake, ‘more regular bowel movements’ and
‘increased energy’. The products were also evaluated from
an organoleptic perspective using questionnaires with Likert
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scales. Overall, all the RTE cereal products received favourable evaluations. The porridges overall were disliked and
were consumed at a minimal level.
Discussion
Within the context of the present study, regardless of the diet
subjects were on, they lost weight, with the expected changes
in waist circumference, fasting insulin(21), lipids(22) and
leptin(23). Even though weight loss was modest, the change
of 5 % if maintained even at 3–4 % would most likely
decrease the incidence of development of type 2 diabetes in
this moderately overweight group, but at risk group(24). The
waist circumference of the group as a whole decreased significantly and as a measure of abdominal adiposity indicated
decreased risk of insulin resistance, glucose intolerance and
dyslipidaemias(25,26). The fact that the subjects were only
moderately overweight with limited progression towards
metabolic syndrome, most likely limited the ability of the
study to differentiate subtle differences that may have existed
between the groups. Nevertheless, energy restriction alone
remained effective for weight loss.
Much of the research with b-glucan as a functional ingredient focuses on improvements in parameters, such as glycaemic
control and hypercholesterolaemia. The research here used
healthy subjects whose ‘healthy overweight’ status ensured
some elevated lipids but minimal insulin resistance. Greater
effects may have been seen in a population with diabetes
with greater metabolic dysfunction. Effects of b-glucan in a
more overweight or obese sample with or without energy
restriction cannot be inferred from the present study. The
change in cholesterol, greatest for the HBG group may have
been more exposed with more subjects, but this was a secondary outcome measure. Some literature on non-hypercholesterolaemic or mildly hypercholesterolaemic individuals tends to
show limited response to b-glucan, so that the borderline significance of results would be expected, particularly given the
observed weight loss. Greater than 10 % decrease in the
HBG group together with evidence from other studies(27)
still provides support for oat b-glucan as a dietary intervention
agent in the management of hypercholesterolaemia. The
observed decrease in HDL levels was unexpected, but the
reported consumption of saturated fats was notably higher
than polyunsaturated fats (Table 4), so the background diet
may not have been favourable.
With the modest weight loss demonstrated here, there were
still significant changes in PYY and GLP-1. Additionally,
there was an overall decrease in PYY while maintaining
or perhaps increasing the fractions involved with satiety
PYY3-36. It has been postulated that PYY has a role in the
aetiology of human obesity due to negative correlation with
BMI and the fact that injection of the active fraction of
PYY, PYY3-36 decreases food intake in human subjects(28).
PYY is secreted in the same gut endocrine cells as GLP-1;
both inhibit gastric emptying and promote satiety and are
released in response to food. GLP-1 having an additional or
additive role in its regulation of blood glucose via increasing
insulin sensitivity(29).
The observed relationship between changes in hormones
and weight loss was perplexing. Nevertheless, recent research
has shown that with a very large weight loss, as seen in
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surgical interventions for obesity, fasting levels of PYY
increase but GLP-1 decreases, suggesting a less easily defined
relationship between the two hormones and that they are not
co-dependent(30). Studies using hypoenergetic diets to induce
weight loss have identified a decrease in GLP-1 response to
dietary stimulus with weight loss(31).
In clinical trials, fasting PYY and often PYY3-36 have been
shown to be decreased in obesity. Roth identified decreased
PYY3-36 in obese children, which increased with weight loss
and showed that this increase was predictive of successful
weight maintenance(32). Pfluger et al. (33) found no difference
in fasting PYY3-36 between lean and obese subjects, however,
identified a 30 % decrease in fasting total PYY when obese
subjects lost approximately 5 % of their body weight. The
results from the present study broadly mimic these results
with an overall decrease in PYY, but an increase or at least
maintenance in PYY3-36. Animal studies in our laboratory
(unpublished results) have indicated an increase in PYY3-36
with increasing doses of b-glucan, and the trend in the present
study warrants further investigation.
The group effect noted in fasting PYY, where both MBG
and HBG results are different from the control, is difficult
to interpret, given the smallest decrease was in the HBG
and the largest decrease in the MBG. Other results which
show similar trends (MBG a greater difference in one direction compared with the control or HBG such as with leptin)
do not show significant correlations with the PYY results so
it is difficult to infer a mechanism based on a U-shaped
curve, where a certain dose would produce negative results
but a greater dose would achieve desired outcomes. For
example, in the present study no correlations existed with
monounsaturated fat intake that was highest in the MBG
group, so that the differences may just be statistical aberrations, in part created by the large variations in responses.
Similarly, the larger change in leptin in the HBG group
with the same weight loss seems positive, but the smallest
change was with the MBG group and no dietary correlations
exist.
We found a high overall acceptance of the high doses of
fibre and good maintenance of the solubility, molecular
weight and viscosity of the b-glucan after processing. No
differences were identified with the subjective measures of
satiety. The use of VAS is most likely to be accurate in a
controlled situation such as in acute meal test studies in a
laboratory situation(18). So it is perhaps not surprising that
small differences from month to month are unlikely to be
quantified by the subjects using the scales.
Despite attention to product attributes that theoretically
affect satiety and tight dietary controls, the present study
failed to confirm direct effects of set levels of b-glucan on
weight loss in an energy-restricted diet. Epidemiological
evidence strongly suggests that high fibre diets have positive
effects on weight control(34). Separating out the effects of a
single fibre remain a difficult task within an human intervention trial, and it would seem the major outcomes in the present
study are similar to another recent intervention trial with
soluble fibre(35) that also could not find an intervention
effect with respect to weight loss. The lack of positive results
such as these could certainly be used to support the notion that
‘fibre’ is not just an indigestible ingredient in a food but is a
part of healthy diet that includes wholegrains, fruits and

vegetables perpetuating good health. However, there are a
number of confounding variables in the present study, which
warrant consideration.
First the current trial was only of 3 months duration. Studies
identifying positive effects of fibre, such as decreased weight
gain usually last for a number of years(4). A 3-month intervention may not be long enough to separate out the differences
between the subjects’ desire to comply and the actual effects
of the dietary intervention. This difference is more likely to
be obvious if the subjects were to follow a particular eating
pattern over a longer timeframe. In a recent study, researchers
have found that regardless of the dietary intervention, subjects
who reported greater compliance with a weight loss regimen
have lost a greater amount of weight(36). The authors conclude
that strategies to increase adherence may be more important
than dietary composition.
Second, the present study included products for the control
group, which were still relatively high in fibre. Only the
amounts of b-glucan varied within the diet. It seems likely
that the effect of any one ingredient, even if positive, will
be relatively small and hence showing a statistical difference
between the groups will be difficult, especially over only
3 months. The numbers of subjects identified as necessary to
detect a difference in the present study was based on the
work of Solum(16), who used an energy-restricted diet with
overweight women to determine the possible benefits of
fibre supplementation. Control subjects used placebo tablets,
while the intervention group had approximately 6 g of fibre
sourced from grains and citrus fruit fibres. Over 12 weeks,
the intervention group lost 1·8 kg more. The way the subjects
consumed the fibre in the Solum study (capsules with water
just before each meal) may have affected the outcomes. The
overall greater weight loss of 6·7 and 8·5 kg for the control
and intervention groups, respectively in this supplement
study shows that adding food items to a dietary regimen
(as in the currently reported study) may decrease weight loss
to some degree. However, insisting subjects ate particular
breakfast and afternoon tea items may have increased energy
consumption at times when the subjects may have chosen to
eat less in a non-directed environment.
Finally, it is difficult to control the intake of human
subjects. Although food records and subjective discussions
with the subjects indicated high compliance with consumption
of study products overall, the subjects were less compliant
with the energy restriction as evidenced by the modest
weight loss. The greatest number of subjects withdrew from
the control group, which could infer the greatest difficulty
with compliance and a positive benefit of b-glucan, but this
is unable to be confirmed within the constraints of the ethical
requirements of the intervention trial.
In summary, although the groups experienced general
improvement in measures such as fasting insulin and cholesterol, associated overall with weight loss, no effects seem
specifically related to b-glucan dose. Most likely, some differences would have been realised if the study continued in the
longer term, as generally, the subjects with higher fibre intakes
will maintain weight more easily. However, within the timeframes of an intervention trial, and realistically, the time
frames individuals may pursue a ‘weight loss diet’, there
were no discernable differences between a regular energyrestricted diet and that which contained significant b-glucan.
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Editors,
We read with great interest Henderson and colleagues’ paper in your journal (2009;
29:165–169),

which

reported

that

aripiprazole

reduced

olanzapine-induced

overweight/obesity and hyperlipidemia in a 10-week placebo-controlled double-blind
crossover study. This and their previous studies 1,2 provide a new way for controlling
olanzapine- and clozapine-induced weight gain/obesity using another atypical
antipsychotic, even without reducing the original olanzapine and clozapine doses,
which is important particularly for treatment of refractory schizophrenia patients. The
key issue is what are the mechanisms that underlie aripiprazole’s effects on body
weight? Henderson et al. proposed that aripiprazole’s low histaminergic antagonism
and 5-HT 2C agonist activity may contribute to its effect on reducing olanzapineinduced weight gain 1. Several meta-analytical studies have indicated an association
between histamine H1 antagonism properties in antipsychotic drugs and obesity sideeffects

3,4

. Consistent with these findings, both olanzapine and clozapine are potent

H1 antagonists 5. A recent study found that, correlated with body weight gain,
olanzapine treatment significantly down-regulated H1 receptor binding and mRNA
expression in the rat hypothalamus, however, aripiprazole did not affect H1 receptor
expression 6. These results suggest that aripiprazole’s effects in reducing olanzapineand clozapine-induced weight gain/obesity should not be via H1 receptors, although
histaminergic antagonism is a main cause of olanzapine- and clozapine-induced
weight gain/obesity. We agree that 5-HT 2C receptors may play a role, however, it
should also be noted that aripiprazole has only a moderate affinity to 5-HT 2C
receptors 7. Aripiprazole was developed as a potent dopamine D2 partial-agonist, 5HT 1A partial agonist, and also 5-HT 2A antagonist 7. A recent study has reported that
both aripiprazole and olanzapine affect 5-HT 1A receptor expression, but these changes

2

are not correlated with body weight 8. On the other hand, like aripiprazole, olanzapine
and clozapine are 5-HT 2A antagonists

5

. Recent studies have suggested that

aripiprazole is not a simple partial agonist, but a functionally selective drug that can
act as a D2 agonist or D2 antagonist in different brain regions

9,10

. We suggest that

aripiprazole’s D2 agonistic property may account partly for the effect of aripiprazole
in reducing olanzapine-induced overweight /obesity. Atypical antipsychotics such as
olanzapine may increase appetite through the dopamine-mediated reward pathway 11.
Dopamine D2 agonists have been reported to reduce food intake by acting in
hypothalamic areas

12

. Another possible mechanism of aripiprazole may be via the

activation of the PI3K/Akt pathway. The PI3K/Akt pathway plays an important role
in cellular proliferation, growth and metabolism

13

. Over-expression of the pathway

causes cancer but defects in the pathway could induce metabolic disorders. The
PI3K/Akt pathway plays a key role in the action of insulin via control of Glu4, which
transports glucose into the cells

14

. The activity of the PI3K/Akt pathway in insulin-

mediated Glu4 activation is impaired in olanzapine-induced obesity

15

. Aripiprazole

may have an effect on the activation of the PI3K/Akt pathway via its agonistic effect
on D2 receptors. In fact, D2 receptor agonist (bromocriptine) has been reported to
increase the PI3K/Akt pathway activity 16. It is possible that aripiprazole can restore
the impairment of the PI3K/Akt pathway in insulin-mediated Glu4 activation caused
by olanzapine so that the side-effect of weight gain is reduced. Further studies on
these mechanisms will improve our understanding and management of atypical
antipsychotic-induced weight gain/obesity.

3
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Abstract
Aripiprazole has been used eﬀectively to treat schizophrenia in the clinic ; however, its mechanisms of
action are not clear. This study examined how short- and long-term aripiprazole treatment aﬀects dopaminergic transmission in mesolimbic and nigrostriatal pathways. For comparison, the eﬀects of haloperidol and olanzapine treatment were also examined. Aripiprazole signiﬁcantly increased D2 receptor
mRNA expression and decreased tyrosine hydroxylase (TH) mRNA expression in the ventral tegmental
area (VTA) after 1- and 12-wk treatment, but had no eﬀect in substantia nigra (SN) and nucleus accumbens
(NAc). Aripiprazole also decreased dopamine transporter (DAT) binding density in NAc (for 1- and 12wk treatment) and VTA (1-wk treatment). In contrast, haloperidol signiﬁcantly increased D2 receptor
binding density and decreased DAT binding density in NAc and caudate putamen (CPu) after 1- and 12wk treatment, and it also decreases DAT binding in VTA after 12-wk treatment. Olanzapine had less
widespread eﬀects, namely an increase in D2 receptor mRNA in VTA after 12-wk treatment and decreased
DAT binding in NAc after 1-wk treatment. These results suggest that aripiprazole has selective eﬀects on
the mesolimbic dopaminergic pathway. Selectively reducing dopamine synthesis in VTA is a possible
therapeutic mechanism for the long-term eﬃcacy of aripiprazole in controlling schizophrenia symptoms
with reduced extrapyramidal side-eﬀects.
Received 2 October 2008 ; Reviewed 4 November 2008 ; Revised 16 December 2008 ; Accepted 30 December 2008 ;
First published online 10 February 2009
Key words : Antipsychotics, dopamine D2 receptor, dopamine transporter, tyrosine hydroxylase, ventral
tegmental area.

Introduction
Aripiprazole is a newly introduced antipsychotic
drug, with clinical eﬃcacy to control both positive and
negative symptoms, which has been recommended as
a ﬁrst-line therapy for the treatment of schizophrenia
(Cassano et al. 2007 ; DeLeon et al. 2004). An advantage
of aripiprazole over existing antipsychotics is a
favourable safety and tolerability proﬁle, including a
low incidence of extrapyramidal symptoms (EPS)
compared with typical antipsychotics (such as haloperidol), and a low incidence of weight gain and other
Address for correspondence : Dr C. Deng, School of Health Sciences,
University of Wollongong, Wollongong, NSW 2522, Australia.
Tel. : +61 2 4221 4934 Fax : +61 2 4221 5945
Email : chao@uow.edu.au

metabolic syndromes compared with other atypical
antipsychotics (such as olanzapine) (DeLeon et al.
2004). However, the mechanisms underlying its clinical eﬃcacy and improved safety and tolerability are
not well understood. A unique pharmacology of aripiprazole has been proposed to explain its favourable
clinical proﬁle : unlike other antipsychotics, aripiprazole has both partial agonist and antagonist activity at the dopamine D2 receptor (Hirose et al. 2004 ;
Shapiro et al. 2003). It is also a partial agonist to 5-HT1A
receptors and a partial antagonist to 5-HT2A receptors,
a so-called dopamine and 5-HT stabilizer. However,
there is evidence that at therapeutic doses, aripiprazole exhibits low levels of 5-HT1A and 5-HT2A receptor occupancy and activity (Wolﬀ et al. 2003 ;
Wood & Reavill, 2007), and acts predominantly on
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dopamine D2 receptors (Urban et al. 2007 ; Wood &
Reavill, 2007).
Dopaminergic neurons have two major projections
which are derived from the mesencephalon : the mesolimbic pathway, in which the ventral tegmental area
(VTA) projects to nucleus accumbens (NAc), and the
nigrostriatal pathway, in which the substantia nigra
(SN) projects to caudate putamen (CPu). Blockade of
dopamine D2 receptor activity in the mesolimbic
pathway is the main mechanism of antipsychotic drug
action (Kapur & Mamo, 2003). On the other hand,
the EPS side-eﬀects of typical antipsychotics (such as
haloperidol) relates to blockade of D2 receptors in the
SN–striatal pathway (Stephen & Stahl, 2003). Whether
aripiprazole exerts its eﬀects solely through partial
agonism on D2 receptors (Burris et al. 2002 ; Wood &
Reavill, 2007) or due to functionally selective activity
at D2 receptors (Lawler et al. 1999 ; Mailman, 2007 ;
Shapiro et al. 2003 ; Urban et al. 2007) is controversial.
Aripiprazole is a partial agonist at human D2L
receptors coupled to the inhibition of forskolinstimulated cAMP accumulation (Burris et al. 2002). It
has been suggested that aripiprazole is not simply a
partial agonist, but a drug with functional selectivity,
exerting eﬀects diﬀerentially depending on the cellular
location of the targeted receptor (Shapiro et al. 2003).
For example, it acts as an agonist on pre-synaptic D2
autoreceptors, whereas it also acts as an antagonist at
post-synaptic D2 receptors (Kikuchi, 1995 ; Shapiro et al.
2003). Recently aripiprazole has been found to act as a
potent partial agonist at D2 receptor-mediated signalling responses, such as the potentiation of arachidonic
acid release, and as a weak partial agonist using
MAPK (mitogen-activated protein kinase) phosphorylation, but lacked agonist activity on receptor internalization (Urban et al. 2007). These results support
aripiprazole as being a functionally selective D2 receptor ligand rather than a simple partial agonist
(Mailman, 2007).
As mentioned above, aripiprazole has less EPS sideeﬀects, which could be attributed to its partial agonism
at D2 receptors, in which some signals to postsynapses can be persistently generated although the
post-synaptic D2 receptors are fully occupied (Hirose
et al. 2004). However, it is possible that aripiprazole
is not only limited to straightforward receptor–drug
interaction but, may also have diﬀerential eﬀects on
the mesolimbic and nigrostriatal dopaminergic pathways.
In-vivo microdialysis studies have found that acute
aripiprazole treatment increases dopamine release
in the medial prefrontal cortex and hippocampus
(Bortolozzi et al. 2003 ; Zocchi et al. 2005) and elevates

3,4-dihydroxyphenylacetic acid (the major metabolite
of dopamine) in the medial prefrontal cortex and
striatum (Jordan et al. 2004). The dopamine transporter
(DAT) regulates the re-uptake of free dopamine from
the intra-synaptic cleft. It is the primary mechanism
for inactivation of dopamine following its release into
the synapse (Iversen, 1971). DAT binding density may
therefore reﬂect levels of free dopamine in the intrasynaptic cleft. However, it is unclear whether aripiprazole, particularly chronic treatment, aﬀects DAT
binding density. Furthermore, although aripiprazole
has been reported to reduce dopamine synthesis and
tyrosine hydroxylase activity (TH ; a rate-limiting
enzyme for the synthesis of dopamine) in reserpinetreated rodents through action at pre-synaptic dopamine autoreceptors (Kikuchi, 1995), it is unclear
whether aripiprazole aﬀects TH mRNA expression.
Therefore, in the present study, we examined the
selective eﬀects of short-term (1-wk) and chronic
(12-wk) aripiprazole treatment on D2 receptor and TH
mRNA expression, and binding densities of D2 receptor and DAT in the mesolimbic and nigrostriatal dopaminergic pathways. For comparison, the eﬀects of
haloperidol and olanzapine treatment were also examined.

Methods
Animals and experimental procedures
Sprague–Dawley rats (220–250 g) were obtained from
the Animal Resource Center (Perth, Australia). Upon
arrival, rats were housed individually in environmentally controlled conditions (temperature 22 xC, 12h light/dark cycle, lights on 07:00 hours), and had
ad-libitum access to water and standard laboratory
chow diet. After 1 wk adaptation to the new environment, they were treated with aripiprazole (2.25 mg/
kg.d ; Otsuka, Japan), olanzapine (1.5 mg/kg.d ;
Eli Lilly, USA), haloperidol (0.3 mg/kg.d, Sigma,
Australia), or vehicle (control) (Han et al. 2008a). The
daily dosage was divided into three equal amounts
and all rats were treated three times a day (06:00, 14:00,
22:00 hours) orally by specially prepared drug pellets
as described previously (Han et al. 2008b ; Huang et al.
2006). Each drug group was randomly subdivided
into short-term (1-wk, n=5) and chronic (12-wk, n=5)
treatment groups. Rats were sacriﬁced 48 h after the
last drug treatment. All experimental procedures were
approved by the Animal Ethics Committee, University
of Wollongong, and complied with the Australian
Code of Practice for the Care and Use of Animal for
Scientiﬁc Purposes.

Aripiprazole aﬀects dopaminergic transmission
Histology
All rats were sacriﬁced by carbon dioxide asphyxiation between 07:00 and 09:00 hours, in order to
minimize the variation of circadian mRNA expression.
Brains were immediately removed and frozen in
liquid nitrogen. Coronal brain sections (14 mm) were
cut at x17 xC a cryostat and thaw-mounted onto
polysine-coated slides. For in-situ hybridization, sections were immediately ﬁxed in ice-cold phosphate
buﬀer containing 4 % paraformaldehyde. Acetylation
was carried out in 0.25 % acetic anhydride in 0.1 M
triethanolamine buﬀer (pH 8.0) for 10 min. Sections
were then dehydrated in ethanol and stored at x20 xC
until use. For autoradiography, the sections were
stored at x20 xC after cutting until use without ﬁxation. Identiﬁcation of neuroanatomical structures was
according to a standard rat brain atlas (Paxinos &
Watson, 1997).
In-situ hybridization
The protocol followed that previously described
(Huang et al. 2006). Brieﬂy, the speciﬁc antisense hybridization probes for the D2 receptor were :
5k-cat gat aac ggt gca gag ttt cat gtc ctc agg gtg ggt aca
gtt gcc-3k
(NM010077, encoding bases 853–900),
5k-gac cca ttg aag ggc cgg ctc cag ttc tgc ctc tcc aga tca
tca tc-3k
(NM010077, encoding bases 157–203),
and for TH :
5k-tgg gtc agg gtg tgc agc tca tcc tgg acc ccc tct aag gag
cg-3k
(NM009377, encoding bases 1437–1480).
No sequences bearing signiﬁcant homology to the designed probes were found in the Gene Bank (NCBA).
All oligonucleotide probes were terminally labelled
with 10-fold molar excess of [35S]dATP (speciﬁc activity 1000 Ci/mmol, Amersham, UK) and terminal
transferase (Promega, USA), and puriﬁed over a
MicroSpin G-50 column (Amersham). The probe concentration was 107 cpm of 35S-labelled probes in 750 ml
hybridization solution. Hybridization was performed
by incubating sections in hybridization buﬀer [50 %
deionized formamide, 4r SSC, 10 % dextran sulfate,
1r Denhardt’s solution, 0.2 % sheared salmon sperm
DNA, 0.1 % long-chain polyadenylic acid, 0.012 %
heparin, 20 mM sodium phosphate (pH 7.0), 106/75 ml
labelled probe and 5 % DTT] at 37 xC for 16 h. Nonspeciﬁc hybridization was determined by including
100-fold molar excess of non-labelled probes in the
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respective hybridization solution. After hybridization,
sections were washed in 1r SSC buﬀer at 55 xC for
3r20 min followed by 1 h incubation in 1r SSC buﬀer
at room temperature. Finally, sections were dipped
sequentially in Milli-Q water, 70 % ethanol and 95 %
ethanol before air-drying and exposure to Hyperb-max ﬁlm (Amersham). After exposure (4 wk for D2
receptor and 2 wk for TH) in-situ hybridization ﬁlms
were developed using standard procedures. The sections containing positive signals were dipped in the
emulsion solution (Amersham) and exposed (6 wk for
D2 receptor and 4 wk for TH). This allows further
examination of positive signals at cellular level and
conﬁrmation of the results from the ﬁlm. As in our
previous work (Huang et al. 2006), all ﬁlms were
analysed using a computer-assisted image analysis
system, Multi-Analyst, connected to a GS-690 Imaging Densitometer (Bio-Rad, USA). Quantiﬁcation of
mRNA expression levels in various brain regions were
performed by measuring the average density of each
region. Values were then compared against a 14Clabelled autoradiographic standard (Amersham).
D2 receptor binding
Sections were preincubated in 50 mM Tris–HCl,
120 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
0.1 % ascorbic acid buﬀer (pH 7.4) for 30 min at room
temperature to remove endogenous ligands. Sections
were then incubated at room temperature for 1 h in
the same buﬀer containing 5 nM [3H]raclopride (speciﬁc activity 60.1 Ci/mmol ; PerkinElmer, USA). Nonspeciﬁc binding was determined in the presence of
10 mM butaclamol. The sections were then washed
2r5 min in ice-cold buﬀer and rinsed brieﬂy in icecold distilled water. Sections were then dried under a
stream of cold air.
DAT binding
Sections were preincubated in 50 mM Tris–HCl containing 120 mM NaCl and 0.1 % BSA (pH 7.4) for
20 min at 4 xC and then incubated for 2 h in the same
buﬀer containing 15 nM [3H]WIN 35,428 (speciﬁc
activity 85.6Ci/mmol ; PerkinElmer). Non-speciﬁc
binding was determined in the presence of 50 mM
benztropine. The sections were washed 2r1 min in
ice-cold buﬀer. After a brief rinse in ice-cold distilled water, the slides were rapidly dried under a
stream of cold air.
Autoradiographic images were produced using a
Beta image camera (BioSpace, France) as previously
described (Deng & Huang, 2005). The exposure time
was 3.5 h at a high-resolution setting. A series of
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sections with a known amount of ligand was used as a
standard in all scans. Quantitative analysis of these
images was performed with b-Image Plus (version 4 ;
BioSpace). The density of the binding signal was ﬁrst
expressed in counts per minute per square millimetre
(cpm/mm2) of area selected and was then converted
into femtomoles of radioligand bound per milligram
tissue equivalent (fmol/mg TE) by comparing with
the standard.

(a)

Bregma –4.92 mm

VTA

*
(b)

(e)

Statistical analysis
The data was analysed statistically using SPSS version
15.0 software (SPSS Inc., USA). Data for each brain
area were analysed by two-way ANOVA (drug treatmentrtreatment duration), followed by Tukey–
Kramer–HSD post-hoc analyses. Pearson’s correlations
were used to assess the relationships between D2 receptor mRNA expression, TH mRNA expression, D2
receptor binding and DAT binding.

(c)

Control

(f )

Control

(d)

Aripiprazole

(g)

Aripiprazole

Results
D2 receptor mRNA expression
Diﬀerential expression of D2 receptor mRNA was observed in NAc core (NAcC), NAc shell (NAcS), CPu,
SN and VTA. Examples of D2 receptor mRNA expression are presented in Fig. 1.
CPu. There were signiﬁcant eﬀects of drug treatment
(F3,32=5.712, p=0.003) and treatment duration (F1,39=
7.066, p=0.012) on D2 mRNA expression in CPu, but
no signiﬁcant interaction between the two factors
(F3,32=0.697, p=0.561). After 1-wk treatment, only the
aripiprazole group (237.9¡2.5 nCi/g TE) had signiﬁcantly higher D2 receptor mRNA expression compared
to the control group (206.7¡10.7, p=0.031 ; Fig. 2 d).
However, after 12-wk treatment, no signiﬁcant diﬀerence in D2 receptor mRNA expression was observed
between the aripirazole and control groups (p=0.471 ;
Fig. 2 d). Olanzapine and haloperidol groups also did
not signiﬁcantly diﬀer from controls in D2 receptor
mRNA expression (all p>0.300 ; Fig. 2 d).
VTA. There were signiﬁcant eﬀects of drug treatment
(F3,32=11.243, p=0.000) and treatment duration
(F1,39=4.770, p=0.036) on D2 mRNA expression in
VTA. However, there was no signiﬁcant interaction
between the two factors (F3,32=2.350, p=0.091). Compared to the control group, aripiprazole treatment signiﬁcantly increased the level of D2 receptor mRNA
expression in the 1-wk (aripiprazole 256.8¡6.3 vs.
control 203.1¡10.6, p=0.008 ; Fig. 1 b–d and Fig. 2 b)

Fig. 1. (b–d ) D2 receptor mRNA expression and (e–g) tyrosine
hydroxylase (TH) mRNA expression in the ventral tegmental
area (VTA) after 1-wk aripiprazole treatment. (a) The
schematic diagram is adapted from a rat brain atlas (Paxinos
& Watson, 1997). (b) Low magniﬁcation ﬁlms of D2 receptor
mRNA expression. (c, d ) High magniﬁcation emulsion
autoradiographs of D2 receptor mRNA expression in VTA.
(e) Low magniﬁcation ﬁlms of TH expression. ( f, g) High
magniﬁcation emulsion autoradiographs of TH mRNA
expression in VTA. * Indicates where high magniﬁcation
autoradiographs were taken. Scale bars : (b, e), 2 mm ; (c, d,
f, g), 50 mm.

and 12-wk (aripiprazole 254.2¡10.2 vs. control 205.1¡
5.1, p=0.002 ; Fig. 2 b) treatment groups. However,
compared to controls, olanzapine and haloperidol had
signiﬁcantly increased D2 receptor mRNA expression
only in the 12-wk treatment groups (olanzapine
246.7¡5.7 vs. control 205.1¡5.1, p=0.008 ; haloperidol
244.4¡9.1 vs. control, p=0.013 ; Fig. 2b) but not in the
1-wk treatment groups (all p>0.299 ; Fig. 2 b). There
were no signiﬁcant eﬀects of drug treatment on D2 receptor mRNA expression in NAcC (Fig. 2a), NAcS,
and SN (Fig. 2 e).
TH mRNA expression in VTA and SN
There was a signiﬁcant eﬀect of drug treatment on the
level of TH mRNA expression in VTA (F3,32=14.5,
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Fig. 2. Expression of (a, b, d, e) D2 receptor mRNA and (c, f ) tyrosine hydroxylase (TH) mRNA in rats treated with either
aripiprazole (Ari), olanzapine (Olz), haloperidol (Hal), or vehicle (Con). NAcC, Nucleus accumbens core ; CPu, caudate
putamen ; SN, substantia nigra ; VTA, ventral tegmental area. Compared to control : * p<0.05, ** p<0.01, *** p<0.001. %, 1-wk
treatment ; &, 12-wk treatment.

p=0.000), but no signiﬁcant eﬀect of treatment period
(F1,39=1.2, p=0.287). There was also no interaction
between the two factors (F3,32=0.7, p=0.554). Compared to the control group, TH mRNA expression
levels were signiﬁcantly decreased in the aripiprazole
group after 1-wk (aripiprazole 319.6¡8.4 vs. control
460.3¡22.0, p=0.001 ; Figs 1 e–g, 2 c) and 12-wk (aripiprazole 312.1¡8.4 vs. control 422.2¡19.9, p=0.024 ;
Fig. 2 c) treatment. However, olanzapine and haloperidol treatment did not diﬀer from controls in TH
mRNA expression levels in VTA (Fig. 2 c). There was
no signiﬁcant eﬀect of drug treatment on TH mRNA
expression in SN (F3,32=2.3, p=0.092 ; Fig. 2 f ). It is
interesting that in the VTA, D2 receptor mRNA expression was negatively correlated with TH mRNA
expression (r=x0.449, p=0.004 ; Fig. 3 a).
D2 receptor binding
Examples of D2 receptor binding are presented in
Fig. 4c.
NAcC and NAcS. There were signiﬁcant eﬀects of drug
treatment on D2 receptor binding densities in NAcC
(F3,32=16.827, p=0.000) and NAcS (F3,32=12.572,
p=0.000) ; however, there were no eﬀects of treatment
duration in NAcC (F1,39=0.054, p=0.817) and NAcS
(F1,39=0.062, p=0.805). There was also no signiﬁcant

interaction between the two factors in the NAcC
(F3,32=1.199, p=0.326) and NAcS (F3,32=2.226, p=
0.104). Compared to the control group, only haloperidol treatment signiﬁcantly increased binding densities in these brain areas after 1- and 12-wk treatment
in these brain regions (NAcC, 1 wk : haloperidol 89.4¡
4.1 fmol/mg TE vs. control 69.4¡2.1, p=0.003 ; 12 wk :
haloperidol 85.5¡4.7 vs. control 68.2¡1.9, p=0.005 ;
Fig. 5 a. NAcS, 1 wk : haloperidol 79.9¡2.5 vs. control
65.2¡3.7, p=0.030 ; 12 wk : haloperidol 79.1¡1.8 vs.
control 58.9¡2.1, p=0.002).
CPu. There was a signiﬁcant eﬀect of drug treatment
on D2 receptor binding density in CPu (F3,32=8.318,
p=0.000), but no eﬀect on treatment duration (F1,39=
1.622, p=0.212). There was also no signiﬁcant interaction between the two factors in CPu (F3,32=0.195,
p=0.899). Compared to the control group, only haloperidol treatment signiﬁcantly increased binding
densities after 1- and 12-wk treatment (1 wk : haloperidol 146.9¡5.0 vs. control 120.4¡4.6, p=0.008 ;
12 wk : haloperidol 143.9¡8.1 vs. control 109.2¡4.6,
p=0.020 ; Fig. 5 b).
However, haloperidol treatment had no eﬀect on D2
receptor binding density in SN or VTA (Fig. 5 c).
Furthermore, aripiprazole and olanzapine treatments
did not aﬀect D2 receptor binding in any of these brain
regions examined (Fig. 5a–c).
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there was a tendency for binding to be decreased after
12-wk olanzapine treatment (olanzapine 30.3¡2.7 vs.
control 36.0¡3.8, p=0.109 ; Fig. 5 d).
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CPu. There was a signiﬁcant eﬀect of drug treatment
(F3,32=5.338, p=0.004), but no eﬀect of treatment duration (F1,39=0.258, p=0.615) on DAT binding in CPu.
There was also no signiﬁcant interaction between the
two factors (F3,32=1.335, p=0.280). As shown in Fig.
5 e, compared to the controls, haloperidol signiﬁcantly
decreased DAT binding density after 1- and 12-wk
treatment (Fig. 5 e). However, aripiprazole and olanzapine treatments did not aﬀect DAT binding in CPu
(Fig. 5 e).

D2 receptor mRNA expression (nCi/g tissue TE)

Binding density of DAT (fmol/mg TE)
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Binding density of D2 receptor (fmol/mg TE)
Fig. 3. (a) A signiﬁcant negative correlation was found
between D2 receptor and tyrosine hydroxylase (TH) mRNA
expression in the ventral tegmental area. (b) A signiﬁcant
negative correlation was found between the binding densities
of D2 receptor and dopamine transporter in the nucleus
accumbens core.

DAT binding
Examples of DAT binding are presented in Fig. 4 d, e.
NAcC. There was a signiﬁcant eﬀect of drug treatment
(F3,32=12.057, p=0.000), but no signiﬁcant eﬀect of
treatment period (F1,39=1.578, p=0.218) on DAT
binding in NAcC. There was also no signiﬁcant interaction between the two factors (F3,32=0.789, p=0.509).
Compared to the control group, DAT binding density
was signiﬁcantly decreased in the 1- and 12-wk
aripiprazole and haloperidol groups (Fig. 5 d). However, in the olanzapine group, a signiﬁcant diﬀerence
was observed only after 1-wk treatment (olanzapine 29.7¡3.7 vs. control 41.2¡7.1, p=0.018), although

VTA. There were signiﬁcant eﬀects of drug treatment
on DAT binding in VTA (F3,32=4.214, p=0.013) and no
eﬀect of treatment period (F1,39=0.044, p=0.836).
However, a signiﬁcant interaction between drug treatment and treatment period was observed (F3,32=5.731,
p=0.003). After 1-wk treatment, the aripiprazole
group (10.1¡0.6 fmol/mg TE) had signiﬁcantly lower
DAT binding density compared to the control group
(13.7¡0.7 fmol/mg TE, p=0.03 ; Fig. 5 f), but was
not signiﬁcantly diﬀerent from the other groups.
After 12-wk drug treatment only the haloperidol
(9.7¡0.7 fmol/mg TE) group had signiﬁcantly lower
DAT binding density than controls (12.5¡0.5, p=
0.048) (Fig. 5 f). However, there were no eﬀects of drug
treatment and treatment period on DAT binding in
NAcS and SN.
Discussion
This study has showed that aripiprazole has selective
eﬀects on mesolimbic vs. nigrostriatal dopaminergic
pathways. Aripiprazole signiﬁcantly increased D2 receptor mRNA expression in VTA and CPu compared
to controls after 1- and 12-wk treatment, but not in
SN and NAc. Aripiprazole also signiﬁcantly downregulated TH mRNA expression in the VTA, but not in
SN, compared to controls. It is interesting that D2 receptor mRNA expression is negatively correlated with
TH mRNA expression in the VTA. Aripiprazole also
decreased DAT binding sites in NAc (both 1- and 12wk treatment) and VTA (1-wk treatment). In contrast,
haloperidol had a signiﬁcant inﬂuence on mesolimbic
and nigrostriatal dopaminergic pathways. Haloperidol treatment increased D2 receptor binding in CPu
and NAc after 1- and 12-wk treatment, but decreased
DAT binding in CPu and NAc (1- and 12-wk treatment), as well as VTA (12-wk treatment). Olanzapine
had less widespread eﬀects compared to the other two

Aripiprazole aﬀects dopaminergic transmission
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Fig. 4. Autoradiographic images taken using a Beta image camera (BioSpace, Paris) showing the high binding density of (c)
D2 receptor and (d, e) dopamine transporter in the nucleus accumbens core (NAcC), nucleus accumbens shell (NAcS), caudate
putamen (CPu) and ventral tegmental area (VTA) in the rat brain. Maps (a) and (b) are adapted from a standard rat brain atlas
(Paxinos & Watson, 1997).

(b)

D2 receptor binding density
(fmol/mg TE)

(a)
D2–NAcC

100

* *
* *

80

160

*
* *

120

D2–VTA

30

20

60
80
40

10

40

20

0

0

0
Con

Ari

Olz

Con

Hal

Ari

Olz

DAT–NAcC

80

*
* *

*

* **

20

* *
* *

40

0
Con

Ari

Olz

Hal

Hal

*

10

*

5

20

0

Olz

DAT–VTA

15

60

40

Ari

(f )
DAT–CPu

80

60

Con

Hal

(e)

(d )
DAT binding density
(fmol/mg TE)

(c)
D2–CPu

0
Con

Ari

Olz

Hal

Con

Ari

Olz

Hal

Fig. 5. The binding densities of (a–c) D2 receptor and (d–f ) dopamine transporter (DAT) in rats treated with aripiprazole (Ari),
olanzapine (Olz), haloperidol (Hal) and vehicle (Con) in the nucleus accumbens core (NAcC), caudate putamen (CPu) and
ventral tegmental area (VTA). Compared to control : * p<0.05, ** p<0.01. %, 1-wk treatment ; &, 12-wk treatment.

treatments, namely an increase in DAT binding in
NAcC (1-wk treatment only) and D2 receptor mRNA
expression in VTA (12-wk treatment only).
A series of short-term (4–6 wk) and longer term (26
or 52 wk) clinical trails have revealed that aripiprazole
not only has signiﬁcant short- but also long-term eﬃcacy in the treatment of positive and negative symptoms of schizophrenia (Cassano et al. 2007 ; DeLeon

et al. 2004 ; Kane et al. 2007 ; Kasper et al. 2003 ; Travis
et al. 2005). Compared with placebo, aripiprazole improved symptoms of schizophrenia as early as 1 wk
after treatment (Travis et al. 2005), and this eﬃcacy
lasted up to 52 wk (Kasper et al. 2003). It has been
suggested that the partial agonism of dopamine D2
receptors is one of the mechanisms underlying the
therapeutic eﬀects of aripiprazole (Wood & Reavill,
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2007). However, it is worth noting that another D2 receptor partial agonist (preclamol) also decreases positive and negative symptoms of schizophrenia, but its
eﬀects only last for 1 wk (Lahti et al. 1998). Therefore,
the partial agonism of dopamine D2 receptors cannot
completely explain the long-term eﬃcacy of aripiprazole. TH mRNA expression in VTA was decreased in the aripiprazole group in the present study.
Since TH is the rate-limiting enzyme for the synthesis
of dopamine, this indicates a reduction of dopamine
synthesis in this brain region. The selective eﬀects of
aripiprazole on reducing dopamine production found
in the present study may provide a mechanism to explain its long-term eﬃcacy.
A reduction in dopamine synthesis may be mediated by D2 autoreceptors (Wolf & Roth, 1990). Previously, in-vivo studies have found that aripiprazole
has potent agonist activities at dopamine autoreceptors (Kikuchi, 1995). Aripiprazole may act on
these D2 autoreceptors in the VTA to reduce chronic
dopamine synthesis, and continual treatment of aripiprazole would reduce dopamine release. Although a
single low-dose (0.3 mg/kg) administration of aripiprazole increases dopamine release (Zocchi et al.
2005), a higher dose (2–40 mg/kg) decreases or has no
eﬀect on extracellular levels of dopamine in the rat
cortex and striatum (Jordan et al. 2004 ; Zocchi et al.
2005). It follows that in our experiment, aripiprazole
treatment (2.5 mg/kg.d) for 1 or 12 wk should decrease dopamine release. As a compensatory mechanism, D2 autoreceptor synthesis in the VTA may be
increased in response to the decrease of dopamine
synthesis and release caused by aripiprazole treatment. Consistent with this, an increase in D2 receptor
mRNA expression was observed in VTA of the aripiprazole group. In fact, a negative correlation between D2 receptor mRNA and TH mRNA expressions
was found in this brain region. This suggests that aripiprazole may achieve its pharmacological eﬀects by
reducing dopamine production in VTA. Moreover,
since the eﬀects of aripiprazole on D2 receptor mRNA
and TH mRNA expression have been observed after
1- and 12-wk treatment, our theory may well explain
its fast eﬀects (1 wk) on improving symptoms and its
long-term eﬃcacy maintenance. It is interesting that
aripiprazole had no eﬀect on D2 receptor mRNA expression and D2 receptor binding in NAc. It is possible
that aripiprazole reaches its long-term eﬃcacy by reducing dopamine levels in the VTA–NAc pathway,
but not directly through blocking post-synaptic D2 receptors in the NAc.
In this study, like haloperidol, olanzapine increased
D2 receptor mRNA expression in VTA after 12-wk

treatment, but it did not change in TH mRNA expression. Since olanzapine has relatively low aﬃnity
for D2 receptors but high aﬃnity for 5-HT2A, 5-HT2C
and M1 receptors (DeLeon et al. 2004), it has been
suggested to achieve its pharmacological eﬀects
through its actions on these neurotransmission systems (Tyson et al. 2004). In fact, we have previously
found that chronic olanzapine treatment downregulated 5-HT2A receptor mRNA expression in NAc
(Huang et al. 2006) and up-regulated muscarinic M1
receptor mRNA expression in the hippocampus (Han
et al. 2008b).
It is an exciting ﬁnding that aripiprazole has diﬀerential eﬀects on the VTA–NAc pathway compared to
the SN–CPu pathway. Aripiprazole did not aﬀect the
expression of D2 receptor mRNA or TH mRNA in SN.
This result suggests that there are no changes in dopamine synthesis in SN, which may be due to the fact
that D2 autoreceptors in VTA are about 10-fold more
sensitive to dopamine and D2 receptor agonists than
those in SN (Roth, 1979). Although 1-wk aripiprazole
treatment slightly increased D2 receptor mRNA expression in CPu compared with controls, this diﬀerence disappeared after 12-wk treatment. It is also
interesting that 1- and 12-wk aripiprazole treatment
did not aﬀect D2 receptor binding in CPu in this study.
Therefore, the absence of changes to dopaminergic
transmission in the SN–CPu pathway following
chronic treatment of aripiprazole may partially explain why aripiprazole does not cause serious EPS
after long-term treatment in the clinic. However, a recent human PET study using [18F]Fallypride has
shown that aripiprazole occupies a very high percentage of the D2/D3 receptor in all brain regions investigated (including the putamen, caudate nucleus,
thalamus, amygdala, and interior temporal cortex)
(Grunder et al. 2008). Therefore, the more robust actions in mesolimbic dopamine neurons may be possibly due to the fact that the same amount of receptor
binding of aripiprazole (a partial agonist) may cause
diﬀerent functional consequences in the nigrostriatal
system.
It is important to note that a series of studies have
shown aripiprazole is a functionally selective D2 receptor ligand (Lawler et al. 1999 ; Mailman, 2007 ;
Shapiro et al. 2003 ; Urban et al. 2007). The selective
eﬀects of aripiprazole on the mesolimbic and nigrostriatal systems might be due to its properties of functional selectivity. For example, as discussed in the
Introduction, aripiprazole can act as a potent partial
agonist at D2 receptor-mediated signalling responses,
such as the potentiation of arachidonic acid release, and as a weak partial agonist at MAPK

Aripiprazole aﬀects dopaminergic transmission
phosphorylation, but lacks agonist activity on receptor
internalization (Urban et al. 2007). It is possible that
aripiprazole may act as a potent agonist at dopamine
D2 autoreceptors in VTA to reduce dopamine synthesis, but as a weak agonist (or even short of agonist
activity) in SN, therefore it modulates dopaminergic
transmission mainly in the VTA–NAc pathway but
not the SN–CPu pathway.
In contrast, haloperidol aﬀected the mesolimbic and
nigrostriatal pathways by blocking D2 receptors.
Haloperidol signiﬁcantly increased D2 receptor binding density in NAc and CPu after 1- and 12-wk treatment, which is in agreement with previous reports
(Gross et al. 1991 ; Prosser et al. 1988 ; Sawa & Snyder,
2002 ; Stephen & Stahl, 2003). Some studies have also
found that haloperidol (at a dose of 1.5–4 mg/kg) increases D2 receptor mRNA expression in the striatum
(Damask et al. 1996 ; Rogue et al. 1991) ; however, the
present study did not observe any changes in D2 receptor mRNA expression in CPu. Although haloperidol increased D2 receptor mRNA expression in VTA
after 12-wk treatment, it did not cause any change in
TH mRNA expression. These results conﬁrm previous
ﬁndings that haloperidol improves schizophrenia
symptoms by blocking D2 receptors in NAc, while
causing EPS side-eﬀects by blocking D2 receptors in
CPu after chronic treatment (Kapur et al. 2000 ; Vohora,
2007). In this study, olanzapine did not aﬀect D2 receptor binding or expression of D2 mRNA and TH
mRNA in the CPu, which is consistent with a PET
study showing that olanzapine had lower D2 receptor
blockade compared to haloperidol in the striatum
(Xiberas et al. 2001). One study observed that olanzapine increased D2 receptor density in the striatum
of rats ; however, much higher doses of olanzapine
(5.0 mg/kg.d compared to 1.5 mg/kg.d in this study)
were used (Tarazi et al. 2001). These results supported
the observation that olanzapine does not cause EPS at
common clinical dosages (Vohora, 2007).
Consistent with the changes of D2 receptor and
TH mRNA expression, selective eﬀects of aripiprazole
treatment on DAT binding densities were also observed in mesolimbic and nigrostriatal pathways.
Since DAT mediates the re-uptake of free dopamine
from the synaptic cleft (Iversen, 1971), decreased DAT
density in NAc could be explained by decreased D2
synthesis in this nucleus as discussed above. In contrast, haloperidol treatment reduced DAT binding
densities in NAc and CPu. Although aripirazole and
haloperidol reduced DAT binding density, they might
act through diﬀerent mechanisms. Haloperidol has
previously been reported to reduce the reuptake
transport of dopamine in the striatum (McElvan &
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Schenk, 1992 ; Meiergerd et al. 1993). In addition, a
negative correlation between D2 receptor binding
density and DAT binding density was found in NAcC
in this study (Fig. 3 b). These results further suggest
that haloperidol may control schizophrenia symptoms
by D2 receptor blockade in NAc, and produce EPS by
D2 receptor blockade and prolonged free dopamine
reuptake in CPu. Olanzapine decreased DAT density
in NAc only, which suggests that olanzapine might
prolong dopamine activity in NAc.
DAT binding densities in VTA were decreased only
after 1-wk aripiprazole treatment, but returned to a
normal level after 12-wk treatment. It is interesting
why only short-term treatment of aripiprazole aﬀected
DAT binding density. In contrast haloperidol had
long-term eﬀects on DAT binding in VTA. One possible explanation is the speciﬁc proﬁle of aripiprazole
as a selective D2 receptor partial agonist. It was reported that D2 receptor agonists may increase the reuptake of dopamine via stimulating D2 autoreceptors,
but this eﬀect could be reversed by D2 receptor antagonists (Meiergerd et al. 1993 ; Parsons et al. 1993).
Since aripiprazole has dual D2 partial agonist and antagonist properties, it is possible that its dual eﬀects
may reach a balance after long-term treatment. However, haloperidol only has D2 antagonist properties
and needs long-term action to reduce DAT binding
density in VTA.
In the literature, the dosages of aripiprazole, haloperidol, and olanzapine vary signiﬁcantly in the animal studies. Similar doses to that used in this study
have been used previously in the literature and have
been shown to be pharmacologically and behaviourally eﬀective. For example, aripiprazole has been
used at doses ranging from 2 to 3 mg/kg (Kalinichev
et al. 2005 ; Li et al. 2005 ; Schwabe & Koch, 2007).
Haloperidol has frequently been utilized at a dose
of 0.3 mg/kg (Pouzet et al. 2003 ; Wiley, 2008), while
olanzapine treatments ranging from 1.2 mg/kg
(Arjona et al. 2004 ; Huang et al. 2006) to 2.0 mg/kg
(Cooper et al. 2005) have been used in rats. These
selected doses all share a D2 occupancy of y70–80 % in
rats (Kapur et al. 2003 ; Natesan et al. 2006). Furthermore, antipsychotics were administrated orally three
times a day in this study. We have shown previously
that the doses of the drugs and treatment (at three
times a day) used in this study aﬀected central receptor systems relative to their pharmacological proﬁles
(Han et al. 2008a, b ; Huang et al. 2006), indicating
the eﬀectiveness of these treatments. Since rats were
sacriﬁced 48 h after the last drug treatment, we could
not completely rule out a possible drug withdrawal
response observed 2 d after the last aripiprazole
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treatment ; however, it is unlikely. It has been shown
that aripiprazole has a long elimination half-life
(60–70 h) and exerts its eﬀects on D2/D3 receptors for
almost 1 wk after the last dose in humans (Grunder
et al. 2008). Unfortunately, there is no data available
on its half-life in rats. It is understandable that aripiprazole may have a diﬀerent half-life in rats from
that in humans ; however, even assuming a 4- to 6-fold
faster half-life of aripiprazole in rats, it may still have
eﬀects 1.5 d after the last treatment in rats. Further
studies are necessary to measure the half-life of aripiprazole in rats (particularly in the brain) and to
investigate changes of TH and D2 receptor mRNA expression a short period (e.g. a few hours) after the last
aripiprazole treatment.
In conclusion, the present results suggest that aripiprazole, unlike other antipsychotics, has selective
eﬀects on dopaminergic pathways, in which both
short- and long-term treatment predominantly modulates the dopaminergic neurotransmission in the mesolimbic but not nigrostriatal pathways. Selectively
reducing dopamine synthesis in VTA (but not SN)
is the possible therapeutic mechanism for long-term
eﬃcacy of aripiprazole in controlling schizophrenia
symptoms with less extrapyramidal side-eﬀects.
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Abstract
Cannabis contains over 70 unique compounds and its abuse is linked to an increased risk of developing
schizophrenia. The behavioural proﬁles of the psychotropic cannabis constituent D9-tetrahydrocannabinol
(D9-THC) and the non-psychotomimetic constituent cannabidiol (CBD) were investigated with a battery of
behavioural tests relevant to anxiety and positive, negative and cognitive symptoms of schizophrenia.
Male adult C57BL/6JArc mice were given 21 daily intraperitoneal injections of vehicle, D9-THC (0.3, 1,
3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg). D9-THC produced the classic cannabinoid CB1 receptormediated tetrad of hypolocomotion, analgesia, catalepsy and hypothermia while CBD had modest
hyperthermic eﬀects. While sedative at this dose, D9-THC (10 mg/kg) produced locomotor-independent
anxiogenic eﬀects in the open-ﬁeld and light–dark tests. Chronic CBD produced moderate anxiolytic-like
eﬀects in the open-ﬁeld test at 50 mg/kg and in the light–dark test at a low dose (1 mg/kg). Acute and
chronic D9-THC (10 mg/kg) decreased the startle response while CBD had no eﬀect. Prepulse inhibition
was increased by acute treatment with D9-THC (0.3, 3 and 10 mg/kg) or CBD (1, 5 and 50 mg/kg) and
by chronic CBD (1 mg/kg). Chronic CBD (50 mg/kg) attenuated dexamphetamine (5 mg/kg)-induced
hyperlocomotion, suggesting an antipsychotic-like action for this cannabinoid. Chronic D9-THC decreased
locomotor activity before and after dexamphetamine administration suggesting functional antagonism of
the locomotor stimulant eﬀect. These data provide the ﬁrst evidence of anxiolytic- and antipsychotic-like
eﬀects of chronic but not acute CBD in C57BL/6JArc mice, extending ﬁndings from acute studies in other
inbred mouse strains and rats.
Received 15 December 2008 ; Reviewed 5 January 2009 ; Revised 27 July 2009 ; Accepted 6 August 2009
Key words : Antipsychotic, anxiolytic, cannabidiol, mouse, D9-tetrahydrocannabinol.

Introduction
The population risk for schizophrenia is increased by
cannabis use (Henquet et al. 2005 ; Moore et al. 2007).
This increase is reported to be greater in people with
a predisposition to psychosis (Henquet et al. 2005).
D9-tetrahydrocannabinol (D 9-THC), the most abundant
* Address for correspondence : L. E. Long, Ph.D., Schizophrenia
Research Institute, 384 Victoria Rd, Darlinghurst NSW 2010,
Australia.
Tel. : +61 2 9399 1265 Fax : +61 2 9295 8689
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of the >70 cannabis constituents, produces the
euphoric eﬀects sought by recreational users, and
produces psychotomimetic symptoms such as altered
perception and disrupted working memory. Schizophrenia patients show increased susceptibility to these
eﬀects (D’Souza et al. 2005). D9-THC has partial agonist
eﬃcacy at cannabinoid CB1 and CB2 receptors and
exerts many of its central eﬀects via inhibition of
neurotransmitter release by presynaptic CB1 receptors.
Cannabidiol (CBD), another cannabis constituent,
does not produce the psychotropic eﬀects of D9-THC
and antagonizes the eﬀects of CB1/CB2 receptor
agonists (Pertwee, 2008). Interestingly, consumption of
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cannabis with little or no CBD content is associated
with increased incidence of psychotic symptoms
(Morgan & Curran, 2008 ; Rottanburg et al. 1982),
suggesting that CBD may partially attenuate the
psychotomimetic eﬀects of D9-THC or other cannabis
constituents. The therapeutic potential for CBD is
supported by observations of its antipsychotic-like
(Leweke et al. 2000 ; Zuardi et al. 2006a) and anxiolyticlike eﬀects (Crippa et al. 2004, 2009) after acute oral
administration in healthy volunteers. While preliminary data in treatment-resistant schizophrenia patients
suggest that CBD monotherapy is not eﬀective (Zuardi
et al. 2006b), regular oral CBD administration reduces
psychotic symptoms in Parkinson’s disease suﬀerers
(Zuardi et al. 2008).
Reports of CBD eﬀects in rodents are currently restricted to acute studies : CBD exerts anxiolytic-like
(Campos & Guimaraes, 2008 ; Guimaraes et al. 1994 ;
Moreira et al. 2006 ; Onaivi et al. 1990 ; Resstel et al.
2006) and antipsychotic-like (Long et al. 2006 ; Moreira
& Guimaraes, 2005 ; Zuardi et al. 1991) eﬀects in mice
(Swiss, ICR) and rats (Wistar). Interestingly, CBD induces c-fos expression in the rat nucleus accumbens
but not the dorsal striatum, in a pattern similar to that
of clozapine (Guimaraes et al. 2004). To accurately
model the eﬀects of regular cannabis use in humans
and to determine the potential for lasting clinical
eﬃcacy of cannabinoids such as CBD, chronic rodent
behavioural studies are necessary. Furthermore, since
a majority of mutant mouse models are generated
on a C57BL/6J or mixed C57BL/6Jr129SvJ genetic
background, studies in C57BL/6J mice are crucial for
further research.
This study therefore aimed to directly compare the
acute and chronic eﬀects of D9-THC and CBD in
C57BL/6J mice using a multi-tiered battery of schizophrenia- and anxiety-relevant behavioural tests. CBD
eﬀects were compared to the well-characterized eﬀects
of D9-THC in the classic cannabinoid CB1 receptor
agonist ‘tetrad’. Following this, mice were assessed
using a comprehensive multi-tiered battery of behavioural models relevant to positive (spontaneous hyperactivity), negative (social withdrawal, anxiety) and
cognitive (disrupted learning and working memory,
impaired sensorimotor gating) symptoms of schizophrenia during repeated treatment with D9-THC or
CBD. The antipsychotic eﬀect of chronic CBD on druginduced psychotomimetic behaviour was assessed
using acute challenges with the non-competitive
NMDA antagonist MK-801 and the catecholaminergic
stimulant dexamphetamine (Dex). To enable comparison of the eﬀects of repeated treatment, a followup study on acute anxiolytic and potentially anti-

psychotic-like eﬀects of CBD was conducted, using
doses that were behaviourally active in the chronic
study.
Methods
Animals
Test animals were 119 male C57BL/6JArc mice (aged
12–14 wk). Standard social interaction opponents
were 12 male A/JArc mice (aged 9–10 wk) (Animal
Resources Centre, Australia). Mice were maintained
under a 12-h light/red light cycle (lights on 07:00
hours) and pair-housed in Macrolon cages (1144B :
Tecniplast, Australia) containing paper tissues
(Kimwipes1, Kimberley-Clark, Australia) as nesting
material with ad libitum access to water and standard
irradiated mouse feed (Gordon’s Specialty Stockfeeds,
Australia). Chronic experiments were performed in
four sets of 22–24 mice over 8 wk, with treatment randomized and counterbalanced across sets. Follow-up
acute experiments with CBD were performed in a
single set of 29 mice. Research and animal care procedures were approved by the Garvan Institute/
St Vincent’s Hospital Animal Experimentation Ethics
Committee in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientiﬁc
Purposes.
Drug treatment
D9-THC and CBD (THC Pharm GmbH, Germany)
were suspended in a 1 : 1 : 18 mixture of ethanol :
Tween-80 : saline. Dex and MK-801 (Sigma, Australia)
were dissolved in saline. Dose ranges of D9-THC and
CBD were based on previous studies (Boucher et al.
2007 ; Long et al. 2006). Drugs were injected at a volume of 10 ml/kg.
For chronic treatment, mice received 21 consecutive daily intraperitoneal (i.p.) injections of vehicle
(1 : 1 : 18 ethanol : Tween-80 : saline), D9-THC (0.3, 1, 3 or
10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) (n=10). On
day 7 all mice were injected with MK-801 (0.5 mg/kg
i.p.) 35 min after cannabinoid injection. On day 21 all
mice were injected with Dex (5 mg/kg i.p.) 45 min
after cannabinoid injection.
Follow-up experiment
After observing key eﬀects of chronic CBD we investigated the acute behavioural eﬀects of CBD at relevant doses. Separate groups of age-matched male
C57BL/6JArc mice received an i.p. injection of vehicle
or CBD (1 or 50 mg/kg) (n=9–10). Mice were tested in
the elevated plus maze (EPM) (5 min) followed by
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Table 1. Chronic test biography of C57BL/6JArc mice
Day Test
x2
x1
0
1
3
5
7
12
14
15
16
17
18
19
20
21

Time

Prepulse inhibition acclimatization

07:00–10:00
16:00–19:00
Prepulse inhibition acclimatization
07:00–10:00
16:00–19:00
Prepulse inhibition (baseline)
07:00–10:00
16:00–19:00
Body temperature, catalepsy, open ﬁeld, 07:00–11:00
tail ﬂick, prepulse inhibition
15:00–19:00
Body temperature, catalepsy
07:00–10:00
Body temperature, catalepsy
07:00–10:00
Body temperature, catalepsy, MK-801
07:00–11:00
and prepulse inhibition
15:00–19:00
Body temperature, catalepsy
07:00–10:00
Body temperature, catalepsy, tail ﬂick
07:00–10:00
Open ﬁeld
07:00–10:00
Y-maze
07:00–12:00
Light–dark, elevated plus maze
07:00–13:00
Social interaction, prepulse inhibition
07:00–11:00
15:00–19:00
Passive avoidance training
07:00–11:00
Passive avoidance retention test, tail ﬂick 07:00–11:00
Dex and open ﬁeld
07:00–15:00

D9-THC, D9-tetrahydrocannabinol ; CBD cannabidiol, Dex,
dexamphetamine.
Ninety mice were tested over a period of 8 wk. Mice were
injected with either vehicle or D9-THC (0.3, 1, 3 or 10 mg/kg
body weight) or CBD (1, 5, 10 or 50 mg/kg) once daily for
21 d (n=10). On day 7, all mice were injected with MK-801
(0.5 mg/kg) and on day 21 all mice were injected with
Dex (5 mg/kg). The test schedule shows the order in which
tests were completed. Test order and age at commencement
of testing was standardized to avoid diﬀerential impact
of repeated testing on the behavioural parameters
investigated. Tests involving an aversive stimulus
(i.e. electric footshock in passive avoidance) were
performed after tests of anxiety-like behaviour such as the
elevated plus maze to avoid confounds related to the stress
response of the mice.

open-ﬁeld (OF) testing of Dex-induced locomotor
activity (45 min), in which all mice received an injection of Dex (5 mg/kg i.p.) 45 min after vehicle or CBD
injection (in a manner identical to the Dex-induced OF
testing after chronic CBD).
Behavioural testing
Injections commenced at the start of the light cycle
(07:00 hours). On behavioural testing days injections
were staggered within the light cycle to standardize
intervals between injection and testing (Table 1). Mice
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were returned to the home cage following injection
and behavioural testing. Environmental odours were
removed from test apparatus between trials with 70 %
ethanol.
In conducting behavioural testing for schizophrenia, experiments need to target the range of behavioural domains that are aﬀected in the disorder
(Powell & Miyakawa, 2006). Furthermore, behavioural
testing batteries over one or more days have previously yielded informative data on anxiety-related
behaviour (Karl et al. 2008), sensory and motor function (Metz & Schwab, 2004) and defensive behaviour
(Griebel et al. 1999). Ethical considerations prompted
us to investigate more than one behavioural domain in
each group of mice, and during repeated treatment,
the order of behavioural testing proceeded from least
to most aversive, such that tests involving an aversive
stimulus (i.e. electric footshock in passive avoidance)
were performed after tests of anxiety-like behaviour
such as the EPM to avoid confounds related to the
stress response of the mice.
Cannabinoid tetrad A : body temperature, catalepsy
and nociception
Mice were assessed for the classical cannabinoid behavioural tetrad of hypothermia, catalepsy, hypolocomotion and nociception (Compton et al. 1993). Body
temperature was measured 5 min before and 30 min
after injection on days 1, 3, 5, 7, 12 and 14 using a lubricated rectal thermometer (SDR Clinical Technology,
Australia). Catalepsy was measured 20 min after injection on days 1, 3, 5, 7, 12 and 14. The hindpaws of the
mouse were placed on the bench and the forepaws
were placed on a bar (0.2 cm diameter) raised 8 cm oﬀ
the bench surface. The latency for the mouse to place
both forepaws on the bench was recorded. Nociception
was measured with the hot-water tail-ﬂick test 45 min
after injection on days 1, 14 and 20. Mice were gently
wrapped in a towel leaving the tail unrestrained. The
tail tip (1.5 cm) was placed in a beaker of water at room
temperature (25 xC) for 10 s then placed immediately
in a water bath at 52 xC. The latency for the mouse to
ﬂick its tail was recorded. Data are reported as the
mean of three consecutive trials performed for each
mouse, with 2-min inter-trial intervals during which
mice were returned to the home cage.
Cannabinoid tetrad B : spontaneous and Dex-induced
locomotor activity
Locomotor activity was measured by placing mice into
an OF activity chamber (Med Associates Inc., USA).
Horizontal (distance travelled) and vertical activity
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(rearing) in central and peripheral zones were
measured (described previously ; Karl et al. 2007). The
ratio of central to total distance travelled (distance
ratio) and time spent in the central zone were taken as
measures of anxiety (Denenberg, 1969). On days 1 and
15 mice were placed in the OF 35 min after injection
and allowed to explore freely for 10 min. On day 21 of
the chronic study, and in the follow-up study, mice
were placed in the OF 30 min after injection and
allowed to explore freely for 15 min before they were
removed, injected with Dex and immediately returned
to the chamber for a further 30 min.
Light–dark (LD) test
Mice were placed into the opening of the dark compartment of the LD test apparatus (described previously ; Karl et al. 2007) and allowed to explore freely
for 10 min. The ratio of distance travelled in the light
compartment to total distance travelled (distance ratio)
and time spent in the light compartment were taken
as measures of anxiety. Mice were tested with the LD
test 30 min after injection on day 17.
EPM
Mice were placed onto the central platform of the EPM
(described previously ; Karl et al. 2007) facing an enclosed arm and allowed to explore freely for 5 min.
Arm entries, time spent in arms and in the central
platform, rearing and head dipping were scored.
Arm entries were recorded when mice entered the arm
with all four paws. Anxiety-related behaviour was
measured by entries into the open arm from the centre,
percentage of time spent on open arms (divided into
inner and outer halves) and the percentage of openarm entries (open-arm entry ratio) (Hogg, 1996 ;
Pellow et al. 1985). Mice were tested in the EPM 45 min
after injection on day 17 and 25 min after injection in
the acute study.
Social interaction (SI)
SI between pairs of rodents is used to measure anxietylike behaviours (File & Seth, 2003 ; Kask et al. 2001).
Furthermore, reduction in SI models aspects of
social withdrawal observed in schizophrenia patients
(Ellenbroek & Cools, 2000 ; Rung et al. 2005). Test mice
and weight-matched A/JArc standard opponents,
with no prior exposure to either the test arena or to
each other, were placed in opposite corners of a grey
perspex arena (35r35r30 cm ; illumination 50 lx) and
allowed to explore freely for 10 min. Frequency and
total duration of the active socio-positive behaviours
general sniﬃng, anogenital sniﬃng, allogrooming,

following and climbing over/under in each test mouse
were recorded manually. Mice were tested for SI
35 min after injection on day 18.
Prepulse inhibition (PPI)
PPI, an operational measure of sensorimotor gating, is
impaired in schizophrenia patients (Braﬀ et al. 2001 ;
Ludewig et al. 2003). Startle reactivity was measured
using SR-Lab startle chambers (San Diego Instruments, USA). Mice were habituated to this apparatus
for 30 min on two consecutive days. The next day,
mice were tested for baseline PPI, and on the following
day chronic drug treatment began. PPI testing commenced 60 min after injection on days 1 and 18 and
55 min after injection on day 7 (20 min after injection
of MK-801). PPI test sessions consisted of 5-min acclimatization to 70-dB background noise followed
by 105 trials presented in a pseudo-random order :
5r70-dB trials (background) ; 5r80-dB trials ; 5r
100-dB trials ; 15r120-dB trials (startle) and 15 sets of
ﬁve trials comprising a prepulse of either 74, 82 or
86 dB presented 32, 64, 128, 256 or 512 ms prior to a
startling pulse of 120 dB (PPI response). Inter-trial
intervals varied randomly from 10 s to 20 s. Responses
to each trial were calculated as average mean amplitudes detected by the accelerometer. Percentage PPI
( % PPI) was calculated as
startle response (120 dB)xPPI response
r100:
startle response (120 dB)
% PPI was averaged across inter-stimulus (prepulsestartling pulse) intervals to produce a mean % PPI for
each prepulse intensity.
Y-maze
The natural tendency of mice to alternate successive
entry choices of arms in a Y-maze (spontaneous alternation) is used as an assessment of memory retention
(Hughes, 2004). Mice were placed into the centre of a
grey perspex Y-shaped maze (30 cmr10 cmr17 cm,
arms joined by a triangular centre section) and allowed to explore freely for 8 min. Diﬀerent patterns on
each arm wall provided intra-maze directionality cues.
Objects (e.g. a camera tripod) at the end of each arm
provided extra-maze directionality cues. Arm entries
(deﬁned when all four paws were inside the arm) were
recorded manually. The spontaneous alternation score
was calculated as the number of novel triplet entries
(three consecutive entries into diﬀerent arms) expressed as a percentage of the maximum possible
triplet entries (Hodges, 1996). Mice were tested 30 min
after injection on day 16.
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Passive avoidance (PA)
In PA, memory retention is indicated by avoidance of
a naturally less aversive dark compartment after it is
paired with an electrical footshock (Bovet et al. 1969).
This hippocampus-dependent learning test is inﬂuenced by fear of highly illuminated areas and aversive
stimuli (e.g. electrical footshock), and by nociception.
Training and retention trials were performed 30 min
after injection on days 19 and 20, respectively, using a
shuttle box system (TSE Systems, Bad Homburg,
Germany). Latency to enter the dark chamber on each
trial was measured (cut-oﬀ time : 300 s) (previously
described ; Karl et al. 2008). Increased latency in the
retention trial indicated memory of the aversive
stimulus (0.4 mA footshock ; 2 s). Due to apparatus
malfunction several mice did not receive a footshock
and were excluded from further analysis.
Statistical analysis
In analyses for all experiments the vehicle group was
compared separately to the D9-THC (THC 0.3, THC 1,
THC 3 and THC 10) and CBD (CBD 1, CBD 5, CBD 10
and CBD 50) groups. Diﬀerences between treatment
groups were analysed with one-way (factor : treatment) or repeated-measures analyses of variance
(ANOVA) [factors : treatment, 5-min block (Dexinduced locomotor activity), prepulse intensity and
trial (PA)]. Main and interaction eﬀects were identiﬁed
when p<0.05. Planned contrasts were used to determine which treatment groups were signiﬁcantly
diﬀerent to vehicle (simple contrasts), to locate diﬀerences between levels of within-subjects factors (polynomial contrasts) and to locate interactions between
levels of treatment groups and within-subjects factors
(special interaction contrasts). Huynh–Feldt corrections for non-sphericity were applied. Degrees of
freedom, F values and p values from ANOVA are
presented in the Results, and p values from planned
contrasts are indicated in the Figures and Tables by
asterisks (* p<0.05, ** p<0.01, *** p<0.001). Data are
presented as mean¡standard error of the mean
(S.E.M.). Analysis was performed using SPSS 16.0 for
Windows (SPSS Inc., USA).
Results
Cannabinoid tetrad A : body temperature, catalepsy
and nociception
Acute D9-THC (10 mg/kg) produced signiﬁcant hypothermia [one-way ANOVA : F(4, 49)=9.3, p<0.001]
and catalepsy [one-way ANOVA : F(4, 43)=6.0, p<
0.001] (Table 2). There was a trend towards an eﬀect of
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acute D9-THC on nociception (one-way ANOVA :
p=0.08). D9-THC (10 mg/kg) had a signiﬁcant antinociceptive eﬀect on day 14 [one-way ANOVA :
F(4, 44)=3.9, p=0.01] (Table 2), but not on day 20.
CBD (1 and 10 mg/kg) induced a hyperthermic
response on day 7 [one-way ANOVA : F(4, 49)=3.5,
p<0.05] but had no eﬀect on catalepsy or nociception
(Table 2).
Cannabinoid tetrad B : spontaneous
locomotor activity
D9-THC decreased overall distance travelled on day 1
[one-way ANOVA : F(4, 49)=3.5, p<0.05] and day 15
[F(4, 46)=3.6, p<0.05] at 10 mg/kg and on day 21
[F(4, 44)=13.3, p<0.001] at 1, 3 and 10 mg/kg (Fig. 1 a).
D9-THC also decreased peripheral distance travelled
in the OF test on day 1 [one-way ANOVA : F(4, 49)=
3.1, p<0.05] at 10 mg/kg and on day 21 [F(4, 44)=12.8,
p<0.001] at 1, 3 and 10 mg/kg (Fig. 1 b). D9-THC also
decreased the total distance travelled in the LD test
[one-way ANOVA : F(4, 46)=9.6, p<0.001] at 10 mg/kg
(Fig. 1 c) and the total number of arm entries in the
EPM [one-way ANOVA : F(4, 42)=4.0, p<0.01] at 3
and 10 mg/kg (Fig. 1 d), conﬁrming its locomotor
suppressant eﬀects.
In contrast, CBD had no eﬀect on any locomotor
activity measure in the OF test (one-way ANOVA :
p>0.05 ; Fig. 1 e, f). CBD (10 mg/kg) signiﬁcantly
decreased the total distance travelled in the LD test
[one-way ANOVA : F(4, 44)=2.6, p<0.05] (Fig. 1 g).
There was a trend towards an eﬀect of CBD on the
total number of EPM arm entries (one-way ANOVA :
p=0.06 ; Fig. 1 h).
Dex-induced locomotor activity
Chronic
There were main eﬀects of chronic D9-THC (repeatedmeasures ANOVA : F(4, 38)=4.6, p<0.01) and time
(5-min block) [F(2.6, 97.8)=196.2, p<0.001] on the
distance travelled in the OF test on day 21, and a
moderate trend towards an interaction of D9-THC with
time (p=0.09) (Fig. 2 a). An interaction contrast between the 15-min baseline (BL) and 30-min post-Dex
periods showed that Dex increased the distance travelled in all D9-THC-treated groups [BLrpost-Dex :
F(1, 38)=284.7, p<0.001]. The magnitude of this increase was dependent on D9-THC dose [BLrpostDexrD9-THC interaction : F(4, 38)=2.8, p<0.05].
Doses and time-points at which D9-THC attenuated
the Dex-induced increase in locomotor activity were
determined by special interaction contrasts (BLr
speciﬁc post-Dex time-pointrD9-THC) (Fig. 2a).
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Table 2. Body temperature, catalepsy and nociception
Parameter

Day

Vehicle

D9-THC 0.3

D9-THC 1

D9-THC 3

Thermic response :
diﬀerence in body
temperature measured
5 min before and 30 min
after injection (D xC)

1
3
5
7
12
14

1.4¡0.3
1.4¡0.3
1.2¡0.3
0.9¡0.4
1.6¡0.2
1.8¡0.4

2.3¡0.3
1.3¡0.3
1.1¡0.5
1.6¡0.3
1.0¡0.3
1.1¡0.2

2.3¡0.4
1.6¡0.1
1.2¡0.2
1.0¡0.2
0.8¡0.4
1.4¡0.4

1.2¡0.4
1.5¡0.2
1.4¡0.3
1.7¡0.2
1.4¡0.3
1.9¡0.4

Catalepsy : latency to
remove both forepaws
from bar and place on
bench, 20 min after
injection (ms)

1
3
5
7
12
14

58.7¡5.2
48.3¡6.5
44.9¡3.1
49.7¡8.0
39.4¡1.2
36.6¡1.0

71.4¡6.8
44.7¡5.3
43.7¡4.3
45.8¡12.7
69.0¡34.1
43.2¡5.4

68.9¡6.8
70.3¡14.3
85.4¡32.4
49.5¡5.9
56.7¡12.2
56.3¡13.2

93.9¡11.4
48.3¡6.2
53.7¡4.9
53.9¡10.1
51.3¡5.6
62.0¡6.8

Nociception : mean latency
to ﬂick tail immersed in
52 xC water, 45 min after
injection (s), measured
over three consecutive
trials

1
14
20

2.4¡0.1
2.6¡0.3
2.5¡0.3

2.6¡0.2
3.1¡0.4
2.4¡0.3

2.6¡0.2
3.0¡0.2
2.5¡0.3

2.9¡0.3
2.9¡0.2
2.5¡0.3

D9-THC 10
x1.8¡1.0*
0.8¡0.4
1.5¡0.2
1.6¡0.3
1.3¡0.2
1.3¡0.1

CBD 1

CBD 5

CBD 10

CBD 50

1.5¡0.7
1.7¡0.3
1.8¡0.3
2.0¡0.2**
0.8¡0.2
1.6¡0.3

1.4¡0.3
1.0¡0.2
1.2¡0.3
1.0¡0.3
1.3¡0.2
1.2¡0.4

2.2¡0.5
1.2¡0.3
1.2¡0.3
1.8¡0.3*
1.6¡0.4
1.2¡0.2

2.2¡0.5
1.4¡0.1
1.5¡0.2
1.1¡0.2
1.1¡0.2
1.4¡0.2

390.5¡137.9*
66.1¡8.2
57.2¡5.1
45.1¡4.8
63.9¡10.6
56.1¡6.4

50.4¡4.5
46.9¡5.9
37.4¡1.9
41.7¡4.5
42.1¡7.0
38.9¡4.7

114.8¡40.3
76.6¡17.3
41.2¡2.9
40.4¡4.6
54.3¡4.2
49.3¡6.7

64.0¡11.3
39.6¡2.1
38.9¡3.6
38.4¡2.2
38.3¡2.4
38.8¡2.8

55.4¡11.3
59.5¡7.8
47.9¡5.6
42.7¡5.7
79.0¡22.2
49.5¡7.1

3.5¡0.4
3.8¡0.2***
3.1¡0.3

2.3¡0.1
3.0¡0.3
2.5¡0.2

2.0¡0.2
2.5¡0.2
2.3¡0.3

2.4¡0.2
2.5¡0.3
2.3¡0.3

2.2¡0.1
2.4¡0.2
1.8¡0.1

D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol.
Body temperature, catalepsy and nociception after injection with D9-THC (0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various days of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA and planned contrasts).
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Fig. 1. Measures of locomotor activity after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol
(CBD) (1, 5, 10 or 50 mg/kg). (a, e). Total distance travelled (open-ﬁeld test, 10 min) on days 1, 15 and 21 of treatment. (b, f)
Distance travelled in the peripheral area (open-ﬁeld test). (c, g) Distance travelled (light-dark test, 10 min) on day 17. (d, h)
Frequency of entries into open and closed arms (elevated plus maze, 5 min) on day 17. Data represent mean¡S.E.M. (n=10).
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle (one-way ANOVA and planned contrasts).

There was a main eﬀect of time (5-min block), but
not CBD, on distance travelled in the OF on day 21
[repeated-measures ANOVA : F(2.2, 92.9)=225.8, p<
0.001] (Fig. 2 b). There was no CBDrtime interaction
(p>0.05). An interaction contrast showed that Dex increased the distance travelled in all CBD-treated groups
[BLrpost-Dex : F(1, 42)=330.1, p<0.001]. The magnitude of this increase was independent of CBD dose
(BLrpost-DexrCBD interaction contrast : p>0.05).

Special interaction contrasts (BLrspeciﬁc post-Dex
time-pointrCBD) showed that CBD (50 mg/kg)
attenuated the Dex-induced increase in locomotor
activity at 35–40 min and 40–45 min (Fig. 2 b).
Acute CBD
In the follow-up experiment investigating the eﬀect of
acute CBD on Dex-induced locomotor activity there
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Fig. 2. Total distance travelled over time (open-ﬁeld test, 45 min) after injection of (a) D9-tetrahydrocannabinol (THC) (0.3, 1,
3 or 10 mg/kg) or (b) cannabidiol (CBD) (1, 5, 10 or 50 mg/kg) during baseline (BL) and after injection of 5 mg/kg Dex
(post-Dex) on day 21 of treatment. Data represent mean¡S.E.M. (n=7–10). # p<0.05 (D9-THC 0.3 vs. vehicle) ; + p<0.05
(D9-THC 1 vs. vehicle) ; # p<0.05, ## p<0.01 (D 9-THC 3 vs. vehicle) ; * p<0.05, ** p<0.01, *** p<0.001 (D9-THC 10 or CBD 50
vs. vehicle) (repeated-measures ANOVA and planned contrasts).

Exploratory activity
Vertical activity in the OF test was decreased by
D9-THC (1, 3 and 10 mg/kg) on day 1 [one-way
ANOVA : F(4, 49)=8.2, p<0.001] and day 15
[F(4, 46)=7.9, p<0.001] and by D9-THC (3 and
10 mg/kg) on day 21 [F(4, 44)=8.4, p<0.001]
(Table 3). This was conﬁrmed by signiﬁcant inhibition
by D9-THC (10 mg/kg) of rearing in the LD test [oneway ANOVA : F(4, 46)=3.5, p<0.05 ; data not shown]
and rearing [one-way ANOVA : F(4, 42)=4.7, p<0.01]
and head dipping [one-way ANOVA : F(4, 42)=3.1,
p<0.05] in the EPM (Table 3).
CBD did not aﬀect vertical activity/rearing in the
OF, LD or EPM tests (one-way ANOVA : p>0.05).
There was a trend towards an eﬀect of CBD on head
dipping in the EPM (one-way ANOVA : p=0.06)
(Table 3).

5000
Vehicle
CBD 1

4000

Distance (cm)

was a main eﬀect of time (5-min block), but not CBD, on
distance travelled in the OF test [repeated-measures
ANOVA : F(2.7, 71.1)=112.0, p<0.001] (Fig. 3). There
was no CBDrtime interaction (p>0.05). Withinsubjects contrasts showed that Dex increased the
distance travelled in all CBD-treated groups [BL vs.
post-Dex : F(1, 26)=211.6, p<0.001]. The magnitude
of this increase was independent of CBD dose (BL vs.
post-DexrCBD interaction contrast : p>0.05). Special
interaction contrasts (BL vs. speciﬁc post-Dex timepointrCBD vs. vehicle) showed that CBD did not
aﬀect the Dex-induced increase in locomotor activity
at any time-point (p>0.05).

CBD 50

3000

Dex (5 mg/kg)
2000
1000
0
0

5

10

15

20

25

30

35

40

45

Time (min)
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Fig. 3. Total distance travelled over time (open-ﬁeld test,
45 min) after a single injection of cannabidiol (CBD) (1 or
50 mg/kg) during baseline (BL) and after injection of
5 mg/kg Dex (post-Dex). Data represent mean¡S.E.M.
(n=9–10).

Anxiety measures
Chronic
D9-THC (10 mg/kg) signiﬁcantly decreased the time
spent in the central zone of the OF test on day 15 [oneway ANOVA : F(4, 46)=2.8, p<0.05] and day 21
[F(4, 44)=3.4, p<0.05] (Fig. 4 a) and decreased the
distance ratio on day 1 [F(4, 49)=3.9, p<0.01], day 15
[F(4, 46)=3.1, p<0.05] and day 21 [F(4, 44)=8.6,
p<0.001] (Fig. 4 b). Similarly, D9-THC (10 mg/kg) decreased the time spent in the light compartment [oneway ANOVA : F(4, 46)=3.5, p<0.05] and the distance

Rearing (EPM) (n)
Head dipping (EPM) (n)

D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol ; OF, open-ﬁeld ; EPM, elevated plus maze.
Frequency of vertical activity (OF test, 10 min) and rearing and head dipping (EPM, 5 min) after injection of D9-THC (0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various
days of treatment.
Data represent mean (¡S.E.M.), n=7–10.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA and planned contrasts).

93.2¡7.3
82.3¡10.6
69.9¡10.7
15.5¡1.2
17.6¡2.0
88.0¡10.5
53.3¡6.3
63.0¡6.2
13.4¡1.4
12.0¡1.3
111.9¡11.5
75.9¡8.8
63.8¡7.9
12.3¡1.8
10.5¡0.9
104.7¡17.0
67.9¡9.6
79.6¡9.3
12.3¡2.2
12.4¡2.8
32.4¡16.9***
19.1¡4.3***
4.3¡1.7***
2.8¡1.1**
4.3¡1.5**
29.9¡13.2***
38.5¡5.1**
35.3¡6.7**
7.4¡2.4
9.7¡2.7
1
15
21
17
17
Vertical activity (OF) (n)

107.9¡6.0
62.9¡7.6
68.3¡7.6
11.2¡2.0
13.1¡1.5

75.8¡7.4
53.9¡5.8
61.6¡7.0
12.0¡1.7
12.2¡1.5

67.8¡9.9*
45.4¡5.9*
55.3¡15.5
12.1¡2.1
9.9¡1.9

CBD 1
D9-THC 10
Day
Parameter

Table 3. Exploratory activity

Vehicle

D9-THC 0.3

D9-THC 1

D9-THC 3

CBD 5

CBD 10

CBD 50
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ratio [one-way ANOVA : F(4, 46)=2.8, p<0.05] in the
LD test (Fig. 4 c, d). There was a trend towards an eﬀect
of D9-THC on time spent in the inner open arm in the
EPM (one-way ANOVA : p=0.08), but no eﬀect on the
open-arm entry ratio (data not shown).
In contrast, CBD (50 mg/kg) increased the time
spent in the central zone of the OF test on day 15 [oneway ANOVA : F(4, 48)=3.5, P<0.05] (Fig. 4 e). There
was a trend towards a signiﬁcant eﬀect of CBD on the
distance ratio on day 15 (one-way ANOVA : p=0.07)
(Fig. 4 f). In the LD test, CBD (1 mg/kg) signiﬁcantly
increased the time spent in the light compartment
[one-way ANOVA : F(4, 44)=3.0, p<0.05] and the distance ratio [F(4, 44)=2.8, p<0.05] (Fig. 4 g, h). There
was a moderate trend towards an eﬀect of CBD on
time spent in the inner open arm in the EPM (one-way
ANOVA : p=0.09), but no eﬀect on the open-arm entry
ratio or percentage of time spent on open arms (data
not shown).
Acute CBD
In the follow-up experiment investigating the eﬀect of
CBD in the EPM there was no eﬀect of CBD on total
number of EPM arm entries, percentage time in the
open arms, ratio of open-arm entries to total arm
entries, time in the centre zone, head dipping, or
rearing (one-way ANOVA : p>0.05 ; data not shown).
Startle response and PPI
All mice displayed identical startle response and PPI
at baseline testing 1 d prior to the ﬁrst injection (data
not shown). There was a main eﬀect of prepulse intensity on PPI (p<0.001) and a signiﬁcant linear contrast between levels of prepulse intensity (p<0.001) on
all test days, indicating that PPI increased with increasing prepulse intensity.
D9-THC (10 mg/kg) decreased the startle response
on day 1 [one-way ANOVA : F(4, 48)=3.1, p<0.05]
and day 18 [F(4, 44)=3.1, p<0.05] (Table 4). There was
no eﬀect of D9-THC on the startle response when mice
were treated with MK-801 (data not shown).
There was no eﬀect of CBD on startle response
on any day (one-way ANOVA : p>0.05). There was
no main eﬀect of D9-THC on PPI on days 1, 7 or 18
(repeated-measures ANOVA : p>0.05, data not shown
for day 7) (Fig. 5a, b). There was a signiﬁcant interaction between D9-THC and prepulse intensity on day 1
[F(6.5, 71.4)=5.0, p<0.001] and day 18 [F(7.0, 70.2)=
5.6, p<0.001]. Planned contrasts showed that acute
D9-THC (0.3, 3 and 10 mg/kg) signiﬁcantly increased
PPI (Fig. 5 a).
There was a main eﬀect of CBD on PPI on day 1
[repeated-measures ANOVA : F(4, 44)=4.9, p<0.01]
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THC 1
THC 3
THC 10

100
50
*
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0
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40
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(b)

Ratio (%)
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CBD 1
CBD 5
CBD 10
CBD 50
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***

0

0
1
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1
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Duration (s)
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**

50
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Duration (s)

(c)

0

200

*

150
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CBD 1
CBD 5
CBD 10
CBD 50

100
50
0

(d)

(h)

40

20

0

60
Vehicle
THC 0.3
THC 1
THC 3
THC 10
**

Ratio (%)

60

Ratio (%)

21

40

Vehicle
CBD 1
CBD 5
CBD 10
CBD 50
**

20

0

Fig. 4. Anxiety-related measures after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol (CBD)
(1, 5, 10 or 50 mg/kg). (a, e) Time spent in the central area (open-ﬁeld test, 10 min) on days 1, 5 and 21 of treatment. (b, f) Distance
ratio (open-ﬁeld test). (c, g) Time spent in the light compartment (light–dark test, 10 min) on day 17. (d, h) Distance ratio
(light–dark test). Data represent mean¡S.E.M. (n=7–10). * p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA
and planned contrasts).

(Fig. 5 c), but not on day 7 (data not shown) or day 18
(p>0.05) (Fig. 5 d). There was no CBDrprepulse
intensity interaction (p>0.05). Planned contrasts
showed that acute (1, 5 and 50 mg/kg) (Fig. 5c) and
chronic (1 mg/kg) (Fig. 5 d) CBD increased PPI.
Social interaction
D9-THC did not alter total SI time (one-way ANOVA :
p>0.05), but decreased the combined frequency of the

social behaviours general sniﬃng, anogenital sniﬃng,
allogrooming, following and climbing over/under
[one-way ANOVA : F(4, 45)=13.2, p<0.001] (Table 5).
D9-THC reduced general sniﬃng frequency [one-way
ANOVA : F(4, 45)=18.6, p<0.001] at 3 and 10 mg/kg
and its duration [one-way ANOVA : F(4, 45)=3.9,
p<0.01] at 10 mg/kg (Table 5). D9-THC (10 mg/kg)
also decreased anogenital sniﬃng frequency [one-way
ANOVA : F(4, 45)=4.5, p<0.01].
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Table 4. Startle response
Day

Vehicle

D9-THC 0.3

D9-THC 1

D9-THC 3

D9-THC 10

CBD 1

CBD 5

CBD 10

CBD 50

1
18

58.1¡4.0
66.8¡4.9

49.8¡3.4
56.0¡9.0

50.4¡6.2
65.3¡7.9

48.8¡4.3
50.1¡6.0

35.7¡4.6**
39.0¡5.2*

44.3¡6.6
54.3¡10.5

57.9¡4.7
71.0¡8.1

52.9¡3.5
64.3¡4.9

52.5¡5.8
65.6¡6.1

D9-THC, D9-tetrahydrocannabinol ; CBD, cannabidiol.
Startle response (arbitrary units) following 120 dB acoustic stimuli [prepulse inhibition (PPI), 30 min] after injection with D9-THC
(0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on various days of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01 vs. vehicle group (one-way ANOVA and planned contrasts).

(c)
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*
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*

***
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*

* *

*

***
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* *

*
0

0
74
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74

Prepulse intensity (dB)

86

(d)

(b)
100

100

Vehicle
THC 0.3
THC 1
THC 3
THC 10

Vehicle
CBD 1
CBD 5
CBD 10
CBD 50

75

% PPI

75

% PPI

82

Prepulse intensity (dB)

50

25

*
*

50

*
25

0

0
74

82

86

Prepulse intensity (dB)

74

82

86

Prepulse intensity (dB)

Fig. 5. % Prepulse inhibition (PPI) after injection of D9-tetrahydrocannabinol (THC) (0.3, 1, 3 or 10 mg/kg) or cannabidiol
(CBD) (1, 5, 10 or 50 mg/kg) on (a, c) day 1 and (b, d) day 18 of treatment. Data represent mean¡S.E.M. (n=8–10).
* p<0.05, *** p<0.001 vs. vehicle group (repeated-measures ANOVA and planned contrasts).

There was no eﬀect of CBD on SI (one-way
ANOVA : p>0.05) (Table 5).
Y-maze
There was no eﬀect of treatment on the percentage
of novel entry triplets, indicating equal spontaneous
alternation. Neither D9-THC nor CBD aﬀected the
number of total arm entries (data not shown).

Passive avoidance
A main eﬀect of trial on the latency to enter the
dark chamber in vehicle- and D9-THC-treated mice
[repeated-measures ANOVA : F(1, 26)=31.0, p<0.001]
indicated that all mice learned to avoid the dark
chamber after training (Fig. 6 a). There was no main
eﬀect of D9-THC (p>0.05) but there was a signiﬁcant
D9-THC treatmentrtrial interaction [F(4, 26)=3.4,

D9-THC, D 9-tetrahydrocannabinol ; CBD, cannabidiol.
Duration and frequency of general sniﬃng, anogenital sniﬃng and total social interaction (SI) (SI test, 10 min) with a standard opponent A/JArc mouse after injection with D9-THC
(0.3, 1, 3 or 10 mg/kg) or CBD (1, 5, 10 or 50 mg/kg) on day 18 of treatment.
Data represent mean (¡S.E.M.), n=8–10.
* p<0.05, ** p<0.01, *** p<0.001 vs. vehicle group (one-way ANOVA and planned contrasts).

30.0¡2.1
52.3¡3.4
11.6¡1.6
48.6¡6.0
80.3¡7.6
29.1¡3.7
51.3¡3.9
15.8¡2.8
48.5¡6.5
80.1¡6.9
30.6¡2.9
55.5¡3.6
16.1¡2.0
50.2¡4.5
84.3¡5.9
General sniﬃng duration (s)
General sniﬃng (n)
Anogenital sniﬃng (n)
Total social interaction duration (s)
Total social interaction (n)

23.5¡1.2
48.1¡2.0
16.3¡2.1
43.7¡2.9
79.3¡5.4

28.2¡2.3
49.6¡4.1
16.6¡2.9
48.3¡3.6
83.4¡6.4

24.7¡1.7
43.1¡2.5*
13.6¡2.1
52.2¡9.5
71.5¡6.0

18.7¡2.7**
21.4¡2.2***
5.7¡1.2*
50.9¡13.1
34.6¡3.2***

24.5¡1.8
47.7¡3.6
16.8¡2.8
42.4¡4.6
77.9¡8.3

CBD 10
CBD 5
CBD 1
D9-THC 10
D9-THC 3
D9-THC 1
D9-THC 0.3
Vehicle
Parameter

Table 5. Social interaction

27.1¡2.5
51.0¡3.2
19.7¡1.4
49.6¡3.8
86.6¡4.7
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p<0.05]. Planned interaction contrasts showed that
D9-THC (10 mg/kg) increased the latency to enter the
dark chamber in the retention trial.
CBD-treated mice also learned to avoid the dark
chamber after training, indicated by a main eﬀect of
trial [repeated-measures ANOVA : F(1, 31)=37.6,
p<0.001] (Fig. 6 b). There was no main eﬀect of CBD or
a CBDrtrial interaction.
Discussion
This study is the ﬁrst to compare acute and
chronic eﬀects of two cannabinoids, the prototypical
psychoactive constituent D9-THC and the nonpsychotomimetic CBD, in a battery of schizophrenia
and anxiety-relevant behavioural tests in male adult
C57BL/6JArc mice. The major ﬁndings were : (i) acute
D9-THC and CBD enhanced PPI ; (ii) chronic CBD, but
not D9-THC, enhanced PPI ; (iii) chronic D9-THC and
CBD, but not acute CBD, attenuated Dex-induced
hyperlocomotion and (iv) chronic, but not acute, CBD
produced moderate anxiolytic-like eﬀects.
D9-THC produced the cannabinoid ‘ tetrad’ of acute
eﬀects (Compton et al. 1993), consistent with its accepted proﬁle as a partial CB1 agonist (Pertwee, 2008).
In contrast, CBD had no eﬀect on tetrad measures of
catalepsy, nociception or locomotion and produced
only modest hyperthermia, suggesting that acute CBD
does not produce the sedative or hypolocomotor
eﬀects of D9-THC in C57BL/6JArc mice (Compton et al.
1992 ; Onaivi et al. 1990 ; Varvel et al. 2006).
Our novel ﬁnding that D9-THC (acute) enhanced
PPI in C57BL/6JArc mice adds to an inconclusive
database on the eﬀects of D9-THC on PPI and
represents the ﬁrst such report of CBD eﬀects. The
results may be species- and strain-dependent since
cannabinoid agonists have previously disrupted PPI
in ddY mice (Nagai et al. 2006) and rats (Schneider &
Koch, 2002), whereas in other animal models, D9-THC
may disrupt (e.g. in socially isolated rats ; Malone &
Taylor, 2006) or enhance PPI (e.g. in neuregulin 1
mutant mice ; Boucher et al. 2007). Importantly, we
observed PPI eﬀects in the absence of changes to the
startle response except with 10 mg/kg D9-THC, which
concomitantly enhanced PPI and decreased the startle
response.
In contrast, few studies exist on the eﬀects of CBD on
PPI, and our ﬁndings that acute (1, 5 and 50 mg/kg)
and chronic (1 mg/kg) CBD enhanced PPI represent
the ﬁrst such report of CBD’s eﬀects. While these
ﬁndings do not in themselves represent antipsychoticlike eﬀects, it is interesting to speculate on whether
such improved baseline sensorimotor gating as that
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(a)

(b)
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THC 0.3
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THC 3
THC 10

*
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100

0

200
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CBD 5
CBD 10
CBD 50
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Fig. 6. Latency to enter dark chamber (passive avoidance test, 5 min) 30 min after injection of (a) D9-tetrahydrocannabinol
(THC) (0.3, 1, 3 or 10 mg/kg) or (b) cannabidiol (CBD) (1, 5, 10 or 50 mg/kg) on days 19 (training) and 20 (retention) of treatment.
Data represent mean¡S.E.M. (n=5–8). * p<0.05 vs. vehicle group (repeated-measures ANOVA and planned contrasts).

observed with acute and chronic CBD here might interact with the eﬀect of genetic or pharmacological
challenges on PPI. Previously, CBD alone had no eﬀect
on PPI in Swiss mice but dose-dependently increased
the startle response and reversed an MK-801-induced
PPI deﬁcit at 5 mg/kg (Long et al. 2006). We aimed
to assess whether repeated treatment with CBD
could reverse the eﬀects of MK-801, which dosedependently disrupts PPI in rodents (Mansbach &
Geyer, 1989 ; Varty et al. 2001 ; Yee et al. 2004) and mimics the glutamatergic hypofunction thought to occur
in schizophrenia. However, MK-801 did not disrupt
PPI in our vehicle group. Since mice experienced two
PPI sessions prior to testing under MK-801, PPI enhancement may have masked its disruptive eﬀect
(Plappert et al. 2006). Future studies will conﬁrm
whether repeated CBD treatment can reverse the
psychotomimetic eﬀect of MK-801 on PPI.
We also investigated the eﬀect of chronic D9-THC or
CBD on the locomotor response to the psychostimulant Dex. Dex produced a typical increase in spontaneous locomotor activity that was attenuated in
mice pre-treated with D9-THC (3 or 10 mg/kg) or CBD
(50 mg/kg). D9-THC-treated mice showed decreased
baseline activity, suggesting a functional antagonism
by D9-THC of Dex-induced hyperlocomotion. In contrast, CBD attenuated Dex-induced hyperlocomotion
without altering baseline locomotor activity. Importantly, acute CBD at low (1 mg/kg) or high (50 mg/kg)
doses did not alter Dex-induced hyperlocomotion.
Although previous studies report that at similar doses
acute CBD reduced Dex- and ketamine-induced
hyperlocomotion (Moreira & Guimaraes, 2005), our
divergent results may be due to genetic diﬀerences
between mouse strains used. Further studies may
elucidate potential cumulative eﬀects of CBD on

brain regions associated with the response to the
psychostimulant. Indeed, changes in hypothalamic
c-fos protein expression and catecholamine release
in the nucleus accumbens core following intracerebroventricular CBD administration in rats
(Murillo-Rodriguez et al. 2006) raise intriguing possibilities for mechanisms that may underlie the eﬀects
we observed. Our study is the ﬁrst to report the eﬀects
of chronic CBD on behaviours related to schizophrenia
and suggests that it might modulate such measures as
PPI and Dex-induced hyperlocomotion.
Another area of therapeutic potential for CBD is in
treating anxiety. We observed that low- and high-dose
chronic CBD produced anxiolytic-like eﬀects, in contrast to the anxiogenic eﬀects observed with acute and
chronic D9-THC. The signiﬁcant eﬀects of D 9-THC and
CBD on distance ratios in the OF and LD tests provide
measures of anxiety-related behaviour that are relatively independent of locomotor activity. Interestingly,
acute doses of CBD (1 and 50 mg/kg) that produced
anxiolytic-like eﬀects in the OF and LD tests after
chronic administration had no eﬀect in the EPM. This
contrasts with previous reports of anxiolytic-like
eﬀects of acute CBD (Campos & Guimaraes, 2008 ;
Guimaraes et al. 1994 ; Moreira et al. 2006 ; Onaivi et al.
1990) and may again be due to species and strain
eﬀects (Belzung, 2001). In the SI test, which measures
anxiety and social withdrawal, D9-THC (10 mg/kg)
reduced general sniﬃng and anogenital sniﬃng frequency, consistent with reports after high dose (van
Ree et al. 1984) or chronic D9-THC treatment (Quinn
et al. 2008). However, sedation might have reduced the
overall activity of our D9-THC (10 mg/kg)-treated
mice. In contrast, CBD did not alter baseline SI, consistent with previous reports in rats (Malone et al.
2009 ; van Ree et al. 1984). Overall, we provide novel

14

L. E. Long et al.

evidence that chronic treatment with CBD produces
anxiolytic-like eﬀects in the LD test in C57BL/6JArc
mice.
Learning and working memory are behavioural
domains of therapeutic interest for schizophrenia,
which is marked by cognitive deﬁcits (Elvevag &
Goldberg, 2000). In the present study D9-THC had no
eﬀect on spontaneous alternation or total arm entries
in the Y-maze. Interestingly, D9-THC did not signiﬁcantly reduce the number of arm entries, perhaps due
to the less aversive nature of the Y-maze compared
with the anxiogenic components of the LD or OF
apparatus. In the PA test, D9-THC dose-dependently
increased the latency to enter the aversive stimuluspaired dark chamber, an unexpected eﬀect since
higher doses of D9-THC generally disrupt short-term
memory (Fadda et al. 2004 ; Quinn et al. 2008 ; Silva de
Melo et al. 2005). Nevertheless, D9-THC no longer induced analgesia at this stage of treatment, excluding
nociceptive interference with the aversive nature of
the electric footshock, and any locomotor eﬀects were
controlled for in the statistical analysis. CBD did not
aﬀect spontaneous alternation in the Y-maze nor
latency to enter the dark chamber in the PA test. These
results, combined with previous observations that
acute CBD had no eﬀect in the radial arm maze
(Lichtman et al. 1995) and that CBD-rich cannabis
extracts had no eﬀect in the Morris water maze
(Fadda et al. 2006), suggest that CBD does not disrupt
memory.
In conclusion, using a comprehensive behavioural
phenotyping strategy in order to capture a number
of features associated with schizophrenia and anxiety
we provide the ﬁrst report that chronic CBD facilitates
sensorimotor gating, exerts anxiolytic-like eﬀects
and attenuates Dex-induced hyperlocomotion in
C57BL/6JArc mice. Meanwhile, acute, but not chronic,
D9-THC facilitates PPI. The chronic onset of the CBD
eﬀects and their complex dose-dependency are novel
ﬁndings that raise intriguing avenues for further
studies of its therapeutic potential. In particular, investigations using speciﬁc behavioural models of
schizophrenia, particularly in genetic mouse models,
will be useful in the future.
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Abstract
Some atypical antipsychotics clinically used to treat schizophrenia induce weight gain by unknown
mechanisms. The dorsal vagal complex (DVC) of the brainstem and the endogenous cannabinoid system
are implicated in the regulation of appetite signalling and food intake. We investigated whether antipsychotic drugs alter cannabinoid receptor-binding density in the DVC. Female Sprague–Dawley rats
were treated with olanzapine, haloperidol, aripiprazole or vehicle for 1 wk (short-term) or 12 wk (chronic).
Quantitative autoradiographic methods were employed to investigate the binding density of cannabinoid
receptors in the DVC using a highly sensitive Beta Imager. Short-term olanzapine induced a signiﬁcant
39 % decrease in cannabinoid receptor binding compared to controls, whilst short-term aripiprazole and
haloperidol had no signiﬁcant eﬀect. Chronic olanzapine treatment induced a signiﬁcant 46 % decrease in
cannabinoid receptor binding compared to controls, aripiprazole slightly decreased cannabinoid receptor
binding (12 %), whilst haloperidol had no eﬀect. Consistent with binding changes, short-term and chronic
olanzapine treatment induced signiﬁcant weight gain, but not aripiprazole or haloperidol. Cannabinoid
receptor binding was negatively correlated to weight gain following chronic olanzapine treatment only
(r=x0.83, p=0.01). In addition, only chronic olanzapine treatment increased food intake. These results
show that olanzapine, an antipsychotic with a high risk of weight gain as a side-eﬀect, signiﬁcantly
decreased cannabinoid receptor binding in the DVC, whilst aripiprazole and haloperidol, antipsychotics
with a low risk of weight gain had little or no eﬀect on binding. These results suggest that a mechanism for
antipsychotic-induced weight gain may be through the modulation of cannabinoid receptors in the DVC.
Received 11 September 2007 ; Reviewed 7 October 2007 ; Revised 19 December 2007 ; Accepted 9 January 2008 ;
First published online 7 February 2008
Key words : Cannabinoid receptor, dorsal vagal complex, olanzapine, weight gain.

Introduction
Antipsychotic drugs such as olanzapine, aripiprazole
and haloperidol play a key role in the therapeutic
treatment of schizophrenia. The clinical eﬃcacies of the
atypical antipsychotics olanzapine and aripiprazole
are considered to be superior to conventional antipsychotics such as haloperidol in treating schizophrenia patients that are unresponsive to conventional
drug therapy, with reduced risk of extrapyramidal
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symptoms (Keefe et al., 2006 ; Naber and Lambert,
2004). However, a signiﬁcant side-eﬀect of olanzapine
is weight gain, which is of social and clinical importance as it may lead to further complications such as
cardiovascular disease, diabetes and non-compliance
to medication (Chagnon et al., 2004). Although the
weight gain side-eﬀect of aripiprazole is controversial,
studies have shown that aripiprazole has less risk than
olanzapine, but poses a higher risk than haloperidol
(Chrzanowski et al., 2006 ; Naber and Lambert,
2004). Many suggestions have been made to explain
the possible mechanisms underlying weight gained
during antipsychotic drug-use (Atmaca et al., 2007 ;
Baptista, 1999 ; Chagnon et al., 2004), however, this
question appears to remain largely unanswered.
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The dorsal vagal complex (DVC) is involved in
gastrointestinal function and responds to hunger and
satiety signals inﬂuencing energy homeostasis and
appetite signalling ; imbalances in this system can
result in metabolic disturbances such as obesity and
metabolic disorders (Blessing, 1997 ; Orr and Davy,
2005). The DVC comprises the dorsal motor nucleus of
the vagus (DMN), nucleus tractus solitarius (NTS) and
the area postrema (AP). The NTS and the hypothalamic arcuate nucleus (Arc) receive information
about energy status via aﬀerent signals from peripheral gut peptides such as ghrelin and leptin (Orr
and Davy, 2005). This signalling results in alterations
of neuronal activity in the brainstem and hypothalamus, which stimulate or suppress appetite and
feeding accordingly (Orr and Davy, 2005).
The appetite-increasing eﬀect of Cannabis sativa
(marijuana) has been observed since AD 300. Administration of the endogenous cannabinoid, anandamide
induces overeating in rats (Williams and Kirkham,
1999) and delta(9)-tetrahydrocannabinol (D9-THC), the
main psychoactive component of marijuana, increases
food consumption in mice (Wiley et al., 2005).
Endogenous cannabinoids exert their eﬀects through
G-protein-coupled receptors, termed cannabinoid
receptors CB1 and CB2. CB1 receptors and mRNA are
widely distributed in the brain, including the DVC of
rats and humans (Derbenev et al., 2004 ; Glass et al.,
1997). A study by Miller et al. (2004) found that injections of CP-55940, a cannabinoid receptor agonist,
into the hindbrain inﬂuenced feeding behaviour by
increasing the intake of palatable food in rats. In
addition, clinical studies have shown that the CB1
receptor antagonist, SR141716A (rimonabant hydrochloride ; Sanoﬁ Aventis, Paris, France), decreases
appetite and body weight (Cota et al., 2003) and CB1
receptor knockout mice consume less food than their
wild-type littermates, even after fasting (Di Marzo
et al., 2001).
Despite the awareness of the inﬂuence of cannabinoid neurotransmission on appetite signalling and
food intake, and the localisation of these receptors in
the region of the brainstem involved in appetite signalling, the physiological eﬀects of antipsychotics on
cannabinoid neurotransmission in the DVC have not
previously been explored. In addition, rimonabant
(Acomplia1) has been approved by the European
Medicines Agency (EMEA) for the treatment of obesity in patients with risk for Type 2 diabetes or heart
disease, and may be a candidate for the treatment
of antipsychotic-induced weight gain. However, it is
unclear whether an interaction exists between antipsychotics and cannabinoid receptors in the brain

centres involved in the regulation of food intake and
body weight. Therefore, in the present study, we
examined the binding of [3H]CP-55940 in the DVC of
rats treated with olanzapine, aripiprazole, haloperidol
or vehicle. We hypothesized that the antipsychotic
known to clinically induce the most weight gain
would induce the most signiﬁcant change in cannabinoid receptor-binding density in the DVC, whilst the
antipsychotic known to induce the lowest weight gain
would cause little or no eﬀect on receptor binding
density.
Methods
Animals, diet and experimental procedures
Female Sprague–Dawley rats (226–250 g) were
obtained from the Animal Resources Centre (Perth,
WA, Australia). They were housed at 22 xC, on a 12-h
light–dark cycle (lights on : 06 : 00 hours), and allowed
ad libitum access to water and standard laboratory
chow diet (3.9 kcal/g ; 10 % fat, 74 % carbohydrate,
16 % protein) throughout the study. Rats were
randomly assigned to one of the following treatments :
0.3 mg/kg.d haloperidol (Sigma Aldrich, St Louis,
MO, USA ; n=26), 1.5 mg/kg.d olanzapine (Eli Lilly,
Indianapolis, IN, USA ; n=25), 2.25 mg/kg.d aripiprazole (Bristol–Myers Squibb, New York, NY, USA ;
n=25), or vehicle (control, n=25). Clinical studies
have shown that haloperidol reaches a therapeutic
level in the treatment of schizophrenia when 65–80 %
of D2 dopamine receptors are occupied in the brain, a
level achieved by a dosage 0.3 mg/kg.d in rats (Kapur
et al., 2000). In this study, dosages of olanzapine
and aripiprazole were determined by comparing their
clinical dose to that of haloperidol. Antipsychotics
were orally administered via premixed drug-chocolate
pellets, three times daily, as previously described by
Deng et al. (2007). Weight gain and food intake were
measured once weekly. After 7 d treatment, 12 rats
from each treatment were sacriﬁced using carbon dioxide asphyxiation, 48 h after the last drug treatment,
to examine short-term treatment eﬀects. Treatment of
the remaining rats (n=13–14 for each treatment) was
continued for a total of 12 wk, after which time they
were sacriﬁced to examine chronic treatment eﬀects.
Therefore, there were eight treatment groups (4 drug
treatmentsr2 time-points). Six to eight rats per treatment group were used to examine [3H]CP-55940
binding in the DVC. All experimental procedures
were approved by the Animal Ethics Committee,
University of Wollongong, and complied with the
Australian Code of Practice for the Care and Use of
Animals for Scientiﬁc Purposes.
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Figure 1. [3H]CP-55940 binding in the dorsal vagal complex (DVC) of rats treated with vehicle [control (a, b), or olanzapine (c, d)]
for 1 wk. (a, c) At the level of Bregma x14.60 mm, (b) at the level of Bregma x13.30 mm, and (d) at the level of Bregma
x13.68 mm (adapted from Paxinos and Watson, 1998).

Histological procedures
Brain tissue was immediately removed after death
and frozen using liquid nitrogen, and then stored at
x80 xC. Coronal sections were cryostatically cut
(14 mm) at x18 xC from the level of Bregma
x11.00 mm to x14.60 mm (Paxinos and Watson,
1998), thaw-mounted onto PolysineTM Microscope
Slides (Menzel GmbH & Co. KG, Braunschweig,
Germany) and stored at x20 xC.
Cannabinoid receptor binding using [3H]CP-55940
Cannabinoid receptor binding was performed as previously described by our group (Newell et al., 2006).
Brieﬂy, slides were air-dried then pre-incubated for
30 min in 50 mM Tris–HCl buﬀer (pH 7.4) containing
5 % bovine serum albumin (BSA) at room temperature.
Sections were incubated for 120 min with 10 nM
[3H]CP-55940 (168 Ci/mmol, PerkinElmer, Boston,
MA, USA) in 50 mM Tris–HCl buﬀer (pH 7.4) containing 5 % BSA to determine total binding, and nonspeciﬁc binding was determined by incubating
subsequent sections in 10 nM [3H]CP-55940 in the
presence of 10 mM CP-55940. Sections were washed in
50 mM Tris–HCl buﬀer (pH 7.4) containing 1 % BSA at
4 xC for 60 min, repeated in fresh buﬀer for a further
180 min. Sections were then washed in 50 mM
Tris–HCl buﬀer for 5 min at 4 xC, dipped in cold
milliQ H2O to remove buﬀer salts and gently dried in a
stream of cool air.
Autoradiography and quantiﬁcation of cannabinoid
receptor binding
Cannabinoid receptor autoradiographic images were
captured using a beta image camera (BioSpace, Paris,

France), as previously described by Newell et al.
(2006). Brieﬂy, the level of radioactivity bound to the
brain sections was counted directly from the amount
of b-particles emitted from the tissue. Exposure time
was 3.5 h at a high-resolution setting. Sections containing known amounts of tritium [3H] ligand were
used to construct a standard curve. Quantitative
analysis of images was performed using b-Image
Plus software (version 4, BioSpace). Cannabinoid
receptor-binding densities in the DVC and cerebellum
were analysed by averaging samples from four
Bregma levels : x13.24 mm, x13.30 mm, x13.68 mm,
x14.60 mm (Figure 1) (Paxinos and Watson, 1998).
Measurements of radioligand binding were converted
to fmol/mg tissue equivalent using the aforementioned standards. Speciﬁc binding was obtained by
subtracting non-speciﬁc binding values from total
binding values. Anatomical positioning of the DVC
was obtained by comparison with a set of corresponding Cresyl Violet-stained slides, assisted by the
use of a standard rat brain atlas (Paxinos and Watson,
1998).
Quantitative data were statistically analysed
using SPSS (version 13, SPSS, Chicago, IL, USA).
Two-way ANOVAs (drugrtreatment duration) were
employed to examine cannabinoid receptor-binding
density in the DVC and cerebellum. Multiple comparisons were performed using post-hoc Tukey tests.
Pearson’s correlations were used to determine the
relationship between cannabinoid receptor binding
and food intake and weight gain in overall groups.
Spearman’s correlations were employed to examine
correlations between speciﬁc treatment groups and
food intake and weight gain due to the smaller
sample size.
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Figure 2. (a, b) [ H]CP-55940 binding density (fmol/mg tissue ; mean¡S.E.M.) in the dorsal vagal complex of rats following 1 wk
(a) or 12 wk (b) treatment with aripiprazole, haloperidol, olanzapine or vehicle (control). (c, d) [3H]CP-55940 binding density
(fmol/mg tissue ; mean¡S.E.M.) in the cerebellum of rats following 1 wk (c) or 12 wk (d) treatment with antipsychotic drugs.
(e, f) Body weight gain (g, mean¡S.E.M.) in rats following 1 wk (e) or 12 wk (f) treatment with antipsychotic drugs.
(g, h) Accumulative food intake (g, mean¡S.E.M.) in rats following 1 wk (g) or 12 wk (h) treatment with antipsychotic drugs.
* 0.01<p<0.05 vs. control ; ** pf0.01 vs. control.

Results
Figure 1 illustrates examples of [3H]CP-55940 binding
in the brainstem. There was a signiﬁcant eﬀect of
treatment (F3,49=64.94, p=0.00) but not duration
(F1,49=2.48, p=0.12) on [3H]CP-55940 binding density
in the DVC. In addition, there was no signiﬁcant

interaction between the two factors (F3,49=2.48,
p=0.07). Compared to controls short-term olanzapine
treatment induced a signiﬁcant x39 % decrease
( p=0.00, Figure 2a) in [3H]CP-55940 binding density in
the DVC, whilst no signiﬁcant change in [3H]CP-55940
binding was observed following short-term aripiprazole (p=0.27, Figure 2a), or haloperidol treatment

Discussion
We investigated the eﬀects of olanzapine, aripiprazole
and haloperidol on the binding of [3H]CP-55940 in the
DVC of rats, food intake and weight gain. A signiﬁcant
decrease in [3H]CP-55940 binding was observed following short-term and chronic olanzapine treatment
compared to controls, whilst only a slight decrease
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(p=0.31, Figure 2a). Chronic olanzapine treatment
induced a signiﬁcant x46 % decrease (p=0.00,
Figure 2b) in [3H]CP-55940 binding density in the DVC
compared to controls, chronic aripiprazole treatment
signiﬁcantly decreased binding but to a lesser
extent than olanzapine (x12 %, p=0.01, Figure 2b),
whilst chronic haloperidol treatment had no eﬀect on
[3H]CP-55940 binding density (p=0.37, Figure 2b).
However, there was no signiﬁcant eﬀect of antipsychotic treatment on [3H]CP-55940 binding in the
cerebellum (F3,48=0.241, p=0.867) after both shortterm and chronic treatment (Figure 2c, d).
A signiﬁcant eﬀect of antipsychotic treatment on
weight gain was observed after 1 wk (F3,44=4.07,
p=0.01). Consistent with changes in [3H]CP-55940
binding density, short-term olanzapine treatment
induced signiﬁcant weight gain (p=0.01, Figure 2e),
but not short-term aripiprazole (p=0.73, Figure 2e) or
haloperidol (p=0.59, Figure 2e) treatment compared
to controls. However, short-term antipsychotic treatment had no signiﬁcant eﬀect on food intake compared to controls (all p>0.05, Figure 2g). There was a
signiﬁcant eﬀect of chronic drug treatment on weight
gain (F3,49=3.172, p=0.03). Chronic olanzapine treatment induced signiﬁcant weight gain (p=0.03, Figure
2f), whereas rats treated with chronic aripiprazole or
haloperidol showed no signiﬁcant weight gain compared to controls (aripiprazole vs. control : p=0.87 ;
haloperidol vs. control : p=0.90 ; Figure 2f). Accordingly, there was a signiﬁcant negative correlation between weight gain and [3H]CP-55940 binding density
in the DVC following chronic olanzapine treatment
only (r=x0.83, p=0.01) (Figure 3a). In addition, there
was a signiﬁcant eﬀect of chronic drug treatment on
food intake (F3,49=8.63, p=0.00). Chronic olanzapine
induced a signiﬁcant increase in food intake in rats
(p=0.04, Figure 2h), however, rats chronically treated
with aripiprazole or haloperidol did not exhibit increased food intake compared to controls (aripiprazole
vs. control : p=0.99 ; haloperidol vs. control : p=0.09 ;
Figure 2h). There was a signiﬁcant negative correlation
between accumulated food intake and [3H]CP-55940
binding density in the DVC (r=x0.41, p=0.03) following chronic antipsychotic treatment (Figure 3b).
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Figure 3. (a) Correlation between [3H]CP-55940 binding
density (fmol/mg tissue) in the dorsal vagal complex (DVC)
and weight gain following chronic (12 wk) treatment with
olanzapine. (b) Correlation between [3H]CP-55940 binding
density (fmol/mg tissue) in the DVC and food intake
following chronic treatment with olanzapine, aripiprazole,
haloperidol or vehicle.

in binding was noted following chronic aripiprazole
treatment, and no signiﬁcant change was apparent
following treatment with haloperidol. In addition,
although there was a high binding density of
[3H]CP-55940 in the cerebellum, binding in this region
was not aﬀected by antipsychotic treatment. This
result suggests that antipsychotic-induced alterations
of cannabinoid receptor binding in the DVC is regionspeciﬁc. In a similar trend, short-term olanzapine
treatment signiﬁcantly increased weight gain, and
chronic olanzapine treatment increased weight gain
and food intake. Whilst acute and chronic aripiprazole
or haloperidol treatment had no eﬀect on weight gain
and food intake compared to controls. These results
coincide with the clinical setting, in which patients
treated with olanzapine exhibit higher weight gain
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than aripiprazole (Naber and Lambert, 2004) and
haloperidol (Zipursky et al., 2005). For example, over
an 8-wk period patients treated with olanzapine had
an increase in body weight of 20 % compared to
aripiprazole (Naber and Lambert, 2004), and a 2-yr
study by Zipursky et al. (2005) reported that olanzapine treatment induced signiﬁcantly higher weight
gain than haloperidol. Zipursky et al. (2005) also
identiﬁed that patients treated with olanzapine had
a ﬁve times greater risk for developing clinically
signiﬁcant weight gain than those treated with haloperidol.
In contrast to the high expression of cannabinoid
CB1 receptors in the DVC (Glass et al., 1997), the distribution of CB2 receptors in the brainstem is controversial. Derbenev et al. (2004) reported that CB2
receptor protein was not present in the rat DVC
following examinations using both reverse transcription–polymerase chain reaction (RT–PCR) and
immunohistochemical methods, however, Van Sickle
et al. (2005) identiﬁed CB2 receptor mRNA expression
and immunoreactivity in the DMN, although at a
much lower level. Since [3H]CP-55940 has a similar
aﬃnity for both CB1 and CB2 receptors (Pertwee, 1999),
CB2 receptors cannot be completely excluded in the
present study. However, due to the low abundance
of CB2 receptors in the DVC, it is probable that
[3H]CP-55940 binding observed in this study was
mostly to the CB1 receptor.
To our knowledge, the present study is the ﬁrst
to observe the eﬀects of antipsychotic drugs on the
binding density of cannabinoid receptors in the
brainstem and its relationship with weight gain.
Previous studies have examined the eﬀects of olanzapine and haloperidol on cannabinoid receptor-binding
density in other regions of the brain ; the outcome dependent on the region studied. For example, olanzapine and haloperidol had no eﬀect on [3H]CP-55940
binding density in the hippocampus, frontal cortex,
striatum and nucleus accumbens (Sundram et al.,
2005), whilst haloperidol increased cannabinoid receptor mRNA levels in the caudate putamen (Mailleux
and Vanderhaeghen, 1993), and [3H]CP-55940 binding
density in the substantia nigra and striatum, but not
the globus pallidus (Andersson et al., 2005). However,
the DVC diﬀers from these regions as it forms a direct
component of the brain–gut axis, receiving signals
from important peripheral satiety hormones such as
ghrelin, leptin, peptide YY (3–36) and cholecystokinin
(Orr and Davy, 2005). The absence of a blood–brain
barrier on the medial and lateral aspects of the
commissural NTS and the AP of the DVC allows
greater access to circulating peptides and expedites

appetite-signalling eﬀects (Gross et al., 1990). In
addition, neurons of the NTS send projections that
converge with neurons derived from the Arc, which is
traditionally thought to be the primary site for the
regulation of food intake (Sainsbury et al., 2002).
As discussed previously, the appetite-enhancing
eﬀects of cannabinoid receptor agonists such as
anandamide and D9-THC are well-documented (Miller
et al., 2004 ; Wiley et al., 2005 ; Williams and Kirkham,
1999). In addition, previous studies show that an
increase in endogenous cannabinoids decreases CB1
receptor mRNA (Rubino et al., 1994) and G-protein
expression (Rubino et al., 1997) in the rat brain. In the
present study, olanzapine treatment signiﬁcantly
induced weight gain and decreased [3H]CP-55940
binding. It is possible that antipsychotic treatment
induces an increase in endogenous cannabinoid release, which leads to a compensatory decrease in cannabinoid receptor-binding density ; the latter of which
may be a result of decreased receptor expression and a
possible functional decrease in G-protein activation.
Although the antipsychotics used in this study may
not possess a proﬁle to act directly on the cannabinoid
system (Naber and Lambert, 2004 ; Richelson and
Souder, 2000), they act on multiple neurotransmitter
systems and may inﬂuence other pathways that
can indirectly aﬀect CB1 receptors. For example cannabinoids can presynaptically inhibit glutamatergic
and GABAergic neurotransmission to anorexigenic
pro-opiomelanocortin (POMC) neurons of the Arc
(Nguyen and Wagner, 2007), which may result in
positive energy balance. In fact, Ho and colleagues
(2007) found a strong correlation between behavioural
feeding changes induced by CB1 agonists (such as
increasing meal frequency, duration and amount of
food consumed) and the inhibition of glutamatergic
neurotransmission presynaptically on anorexigenic
POMC neurons of the Arc. However, studies by
Corchero and colleagues (Corchero et al., 1997, 1999)
found that administration of D9-THC increased POMC
mRNA expression in the Arc of the rat, and that
gonadal steroids could alter the eﬀects of D9-THC on
POMC regulation (Corchero et al., 2001). These studies
suggest that the cannabinoid system can regulate
Arc POMC neuron activation, which inﬂuences food
intake and weight gain, however, further studies are
required to reveal the exact mechanisms.
It is interesting that the NTS is the only nucleus
besides the Arc to express POMC (Schwartz et al.,
2000), however, the role of POMC neurons in the DVC
is unclear. A study by Derbenev and colleagues (2004)
found that cannabinoids act on CB1 receptors located
on presynaptic terminals to inhibit GABAergic and
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glutamatergic synaptic input to DMN neurons.
Therefore, it is reasonable to predict that cannabinoidinduced presynaptic inhibition of POMC neurons
observed in the Arc may also occur in the DVC. Taken
together, these ideas provide a possible pathway for
atypical antipsychotic-induced weight gain whereby a
drug-induced over-expression of endocannabinoids
may lead to the inhibition of anorexigenic POMC
neurons in the DVC causing weight gain. As a compensatory mechanism, cannabinoid receptors located
on the POMC neurons may decrease in an attempt to
restore metabolic homeostasis. In fact, Derbenev et al.
(2004) proposed that the orexigenic eﬀects of cannabinoids may be via the suppression of inhibitory
synapses from the NTS on neurons of the DMN,
induced by the release of endocannabinoids from the
active DMN. Further studies are required to conﬁrm
this mechanism.
The regulation of appetite signalling and energy
homeostasis is highly complex and involves interactions between a variety of neurotransmitter systems.
We previously found that olanzapine treatment decreases the binding density of muscarinic M2 receptors
in the DVC (Deng et al., 2007). Muscarinic M2 and
cannabinoid CB1 receptors are co-localized in the DVC
and it is possible that an interaction may exist between
the muscarinic and endocannabinoid system in the
regulation of energy balance. In the present study,
aripiprazole induced a slight decrease in [3H]CP-55940
binding but had no signiﬁcant eﬀect on weight gain
or food intake, despite results indicating a slight
elevation compared to controls. Although there was a
signiﬁcant change in [3H]CP-55940 binding in the
DVC, it may not have been suﬃcient to induce a
physiological alteration in body weight and food intake. Contrary to olanzapine, aripiprazole does not act
on muscarinic receptors (Naber and Lambert, 2004)
and it is possible that an interaction between cannabinoid and muscarinic M2 receptors is necessary to
facilitate weight gain. In addition, olanzapine treatment decreases serotonin receptor mRNA in the rat
hypothalamus (Huang et al., 2006) and chronic administration of the CB1 receptor antagonist SR141716A
results in increased central serotonin release (Darmani
et al., 2003). Moreover, serotonin receptors are localized in the DVC (Browning and Travagli, 2001). Thus,
another possible mechanism by which olanzapine
may induce weight gain is through the combined
modulation of cannabinoid and serotonergic neurotransmission systems, whereby these antipsychotics
may decrease cannabinoid receptor-binding density in
the DVC, resulting in a decrease in serotonin and an
increase in food intake.
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In conclusion, these results indicate that olanzapine,
an antipsychotic with a high risk of weight gain as
a side-eﬀect decreased cannabinoid receptors in the
DVC, whilst aripiprazole and haloperidol, i.e. drugs
with less risk of weight gain had little or no eﬀect on
cannabinoid receptors in the DVC. This study supports a role for brainstem cannabinoid receptors in the
mechanisms of antipsychotic-induced weight gain.
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It is well known that the peripheral peptide YY (PYY)-central
neuropeptide Y (NPY) Y2 receptor axis plays an important
role in promoting negative energy balance regulation. Both
the hypothalamus and medulla oblongata express a high level
of Y2 receptors; however, the functional role of this receptor
in chronic high-fat diet-induced obesity has not been fully
examined. Using quantitative autoradiography, this study
measured binding densities of total [125I]PYY and Y2 receptors
in the hypothalamus and medulla of chronic high-fat dietinduced obese (DIO), obese-resistant, and low-fat-fed mice.
Plasma PYY was also measured using RIA after 22 wk of dietary intervention. The results revealed that body weight gain
was significantly higher in the obese mice, compared with the
lean mice. Furthermore, PYY and NPY Y2 receptor binding

densities in the medulla of the obese mice were significantly
higher, compared with the lean mice, whereas the level of
plasma PYY was significantly lower in the DIO mice than the
low-fat-fed mice. In conclusion, this study showed that the
DIO mice had low plasma PYY, which may have caused a
compensatory up-regulation of PYY and Y2 receptor densities
in the medulla. A low-level response of PYY-medullary regulation to positive energy balance may have contributed to the
development of high-fat diet-induced obesity in DIO mice;
conversely, a normal response of this regulatory axis in the
obese-resistant mice may have contributed to the maintenance of body weight while on a high-fat diet. (Endocrinology
148: 4704 – 4710, 2007)

P

and medulla oblongata. It is hypothesized that differential
regulation exists in the peripheral PYY and its hypothalamic
and medullar binding densities between the mice prone or
resistant to diet-induced obesity.

EPTIDE YY (PYY) is a member of the pancreatic
polypeptide family, which is structurally and functionally related to the neuropeptide Y (NPY) family (1, 2). PYY
is mainly secreted from the endocrine L cells of the small and
large intestine and released into the circulation in response
to ingestion of food, especially in the presence of a fatty meal
(3, 4). At present, it is known that the peripheral administration of PYY acutely inhibits food intake (5, 6). PYY has a
high affinity to NPY Y2 receptors that is subsequently followed by NPY Y1 and Y5 receptors (7). Furthermore, it has
been suggested that PYY works via the NPY Y2 receptor to
suppress the amount of food intake (8).
In the hypothalamus, many studies have found that PYY
acts on NPY Y2 receptors in the arcuate nucleus to decrease
food intake (9 –12). Additionally, it is known that the medulla
has a high level of binding to PYY (13, 14). However, currently no information is available in regard to hypothalamic
and medullary PYY and Y2 receptor regulation in diet-induced obesity. Using a chronic high-energy diet-induced
obese (DIO) and diet-resistant (DR) mouse model, this study
aimed to examine the levels of plasma PYY together with
PYY and Y2 receptor binding density in the hypothalamus

First Published Online July 5, 2007
Abbreviations: DIO, Diet-induced obese; DR, diet-resistant; DVC,
dorsal vagal complex; IRt, intermediate reticular zone; KHT, Krebs
Henseleit Tris; LF, low-fat diet control; NPY, neuropeptide Y; PYY,
peptide YY; VLM, ventrolateral medulla.
Endocrinology is published monthly by The Endocrine Society (http://
www.endo-society.org), the foremost professional society serving the
endocrine community.

Materials and Methods
Animal model and diets
Forty-eight C57BL/6 mice aged 9 wk were obtained from the Animal
Resource Centre (Perth, Western Australia) and kept in a temperaturecontrolled room at 22 C with a 12-h light, 12-h dark cycle. For the first
week, all mice were given lab chow ad libitum to acclimatize them to their
new surroundings. The mice were then placed in separate cages. Thirtysix mice were randomly chosen and fed a high-fat diet (Table 1) ad libitum
and retrospectively assigned into one of three groups: DIO (n ⫽ 12), DR
(n ⫽ 12), and intermediate, based on their body weight after 22 wk on
this diet (15, 16). The other 12 mice were used as the control group (LF)
and were given ad libitum low-fat diet (Table 1) for 22 wk. During the
experiment, 24-h food intake and body weight were measured weekly.
All experimental procedures were approved by the Animal Ethics Committee, University of Wollongong, Australia, and complied with the
Australian Code of Practice for the Care and Use of Animal for Scientific
Purposes.

Tissue preparation and body composition analysis
After 22 wk of feeding on the high- or low-fat diets, mice were given
an overdose injection of sodium pentobarbitone (120 mg/kg, ip). All
mice were killed between 0700 and 0900 h to minimize circadian variation. Blood samples were collected from the right ventricle of the heart.
Brains were immediately removed after death and frozen in liquid
nitrogen. Coronal brain sections (14 m) were cut at ⫺17 C using a
cryostat and thaw-mounted onto polysine microscope slides (Menzel
GmbH & Co. KG, Braunschweig, Germany).
Total body fat mass was measured via lipid extraction technique (17).
Briefly, the mouse carcass was dried using a freeze drier (FD3 Freeze
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Statistical analysis

TABLE 1. The food composition of the diet used in the
experiment

Cornstarch, kcal, %
Sucrose, kcal, %
Copha, kcal, %
Beef tallow, kcal, %
Sunflower oil, kcal, %
Gelatine, kcal, %
Casein, kcal, %
Fiber, g/kg
Minerals, g/kg
Vitamins, g/kg

LF diet

HF diet

67.73
6.51

38.83
5.39
15.75
15.75
8.07
4.6
11.6
51
67
13

9.75
5.56
10.45
51
67
13

HF, High fat; LF, low fat.

drier; Dynavac Engineering, Sydney, Australia) and weighed before and
after the drying process. After that the body was cut into smaller portions then placed into cellulose thimbles. They were placed in a Soxhlet
apparatus containing petroleum ether, which resulted in complete extraction of all neutral lipids. The total body fat mass was calculated by
measuring the difference in body weight before and after the extraction.

Data were presented as means ⫾ sd. We used the SPSS statistical
package 13.0 (SPSS Inc., Chicago, IL) for our statistical analyses. A
two-way repeated ANOVA (treatment ⫻ weeks as repeated measures)
was used to analyze data of the weekly body weight and energy intake.
Data of PYY binding density, Y2 receptor binding density, and plasma
PYY measurements were assessed by one-way ANOVA, followed by a
post hoc Tukey-Kramer honestly significant difference test for multiple
comparisons among the groups. To analyze correlations between variables measured, a Pearson test was performed.

Results
Body weight, fat mass, and energy intake

A two-way repeated ANOVA revealed significant main
effects of both treatment (F2,33 ⫽ 70.19, P ⬍ 0.001) and the
repeated measurement weeks (F11,363 ⫽ 387.82, P ⬍ 0.001) on
weight gains. There was also a significant interaction between the two factors (F22,363 ⫽ 47.13, P ⬍ 0.001). Although

A Weekly average body weight
50

Y2 receptor binding autoradiography
To measure the Y2 receptor binding density, [Leu31, Pro34]NPY (porcine; Sigma Aldrich) was included in the incubating solution to mask the
NPY Y1 and Y5 receptors (19). Briefly, sections were preincubated for 30
min in KHT buffer. Slides were then incubated for 120 min in KHT buffer
containing 0.1% BSA, 0.05% bacitracin, 100 nm [Leu31, Pro34]NPY, and
25 pm [125I]PYY (Sigma Aldrich). Porcine NPY (1 m) was used to
determine nonspecific binding as mentioned above. The remaining
methods were the same as for [125I]PYY binding autoradiography.
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0
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Weeks after diet

B Weekly average food intake
Average energy Intake
(kJ/mouse/24h)

PYY binding densities were visualized using [125I]PYY as previously
described (18). Sections were preincubated for 30 min in Krebs Henseleit
Tris (KHT) buffer [118 mm NaCl, 4.8 mm KCl, 1.3 mm MgSO4, 1.2 mm
CaCl2, 50 mm glucose, 15 mm NaHCO3, 1.2 mm KH2PO4, 10 mm Tris (pH
7.3)]. Slides were then incubated for 120 min in KHT buffer containing
0.1% BSA, 0.05% bacitracin, and 25 pm [125I]PYY (Sigma Aldrich, St.
Louis, MO). Nonspecific binding was determined by incubating in the
same incubation buffer plus 1 m porcine NPY (Sigma Aldrich). Slides
were then washed (3 ⫻ 5 min) in ice-cold buffer, dipped in ice-cold
distilled water and dried under a gentle stream of cool air. Slides were
stored overnight in desiccators and then apposed to X-OMAT AR film
(Kodak, Rochester, NY) in the presence of standard microscales for 12 d.
Autoradiographs were developed using Kodak D-19 developer and
fixed with Ilford Hypham Rapid Fixer (Ilford Imaging, Clayton, Victoria,
Australia).

Body weight (g)

[125I]PYY binding autoradiography
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Weeks after diet

C Average energy intake
in 22 weeks

Autoradiography images were captured and analyzed using a computer-assisted image analysis system, Multi-Analysis, connected to a
GS-690 imaging densitometer (Bio-Rad Laboratories, Hercules, CA), as
the detailed description was given previously (20). The density of binding was calculated with the aid of the standard curve generated from the
microscales, which then converted to nanocuries per milligram of tissue
equivalent. Individual medullary nuclei were identified with reference
to a standard mouse brain atlas (21).

Average energy Intake
(kJ/mouse/24h)

Quantification

*

#
60
50
40
30
20
10
0
DIO

Plasma PYY
A commercially available PYY (rat, mouse, porcine) RIA kit (Phoenix
Pharmaceuticals, Belmont, CA) was used to measure the plasma level of
PYY. The kit had 100% cross-reactivity with both circulating forms of
PYY, PYY1–36, and PYY3–36 (22, 23).

DR

LF

FIG. 1. Body weight (A), weekly energy intake (B), and average energy intake (C) of chronic DIO, DR, and the control (LF) mice throughout 22 wk of feeding on the high- or low-fat diet. Data are represented
as mean ⫾ SD. Error bars are omitted when smaller than the symbol.
*, P ⬍ 0.05 DIO vs. LF; #, P ⬍ 0.05 DIO vs. DR.
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0.01; DIO vs. LF, P ⫽ 0.007; Fig. 2). No significant difference
was found in the levels of plasma PYY between the DR and
LF groups.

Plasma PYY
(pmol/L)

25

*

20
15
10

PYY binding density and Y2 receptor binding density in the
hypothalamus of DIO, DR, and LF mice

5
0
DIO

DR

LF

FIG. 2. The plasma level of PYY in chronic DIO, DR, and the control
group (LF). Data are represented as mean ⫾ SD. *, P ⬍ 0.01 vs. LF.

there was a consistent increase in the body weight in all
groups, the DIO mice had significantly higher body weight
gain than the DR (P ⫽ 0.007) and LF (P ⫽ 0.001) mice throughout the treatment period (Fig. 1A). The final body weight gain
of the DIO group was 123 and 190% higher (42.7 ⫾ 0.8 g) than
the DR (31.6 ⫾ 0.5 g) and LF mice, respectively (30.0 ⫾ 0.8 g;
F2,33 ⫽ 86.54, P ⬍ 0.001; DIO vs. DR, P ⬍ 0.001; DIO vs. LF,
P ⬍ 0.001). Furthermore, the total fat mass of the DIO group
was 129 and 192% heavier (13.3 ⫾ 0.6 g) than the DR (6.5 ⫾
0.3 g) and LF mice, respectively (5.4 ⫾ 0.4 g; F2,33 ⫽ 94.4, P ⬍
0.001; DIO vs. DR, P ⬍ 0.001; DIO vs. LF, P ⬍ 0.001).
A two-way repeated ANOVA also revealed significant
effects of treatment (F2,33 ⫽ 19.95, P ⬍ 0.001) and the repeated
measurement weeks (F10,330 ⫽ 15.49, P ⬍ 0.001) on food
intake along with a significant interaction between the two
factors (F20,30 ⫽ 7.94, P ⬍ 0.001). Throughout the treatment
period, the DIO mice had a significantly higher energy intake, compared with DR mice (P ⬍ 0.001; Fig. 1B). Although
there was a fluctuation in the energy intake of the LF mice
on the various measurement days, overall, the DIO mice had
a higher energy intake than the LF mice (P ⬍ 0.001; Fig. 1B).
No significant differences were found between the DR and
LF mice. Furthermore, the average energy intake throughout
the 22 wk of feeding was significantly higher in the DIO
group (60.49 ⫾ 0.87 kJ per 24 h), compared with the DR
(53.03 ⫾ 0.91 kJ per 24 h) and LF groups (55.13 ⫾ 0.71 kJ per
24 h; F2,33 ⫽ 21.31, P ⬍ 0.001; DIO vs. DR, P ⬍ 0.001; DIO vs.
LF, P ⬍ 0.001; Fig. 1C).
Plasma PYY

The level of plasma PYY was significantly lower in the DIO
group (32%), compared with the LF group (F2,21 ⫽ 6.26, P ⬍

Although there was a trend that the obese mice had a
higher PYY binding density, compared with the lean mice,
in the dorsomedial and ventromedial hypothalamus, these
differences were not significant (Table 2). There was not any
significant difference in PYY binding density in the arcuate
nucleus and lateral hypothalamus. Furthermore, there were
no significant differences of Y2 receptor binding density in
any hypothalamic nuclei (Table 2) between the groups.
PYY binding density in the medulla of DIO, DR, and
LF mice

A one-way ANOVA revealed that there were significant
differences between the groups for PYY binding density in the
dorsal vagal complex (DVC) containing the nucleus of solitary
tract and dorsal motor nucleus of vagus nerve (F2,10 ⫽ 6.76, P ⫽
0.019), intermediate reticular zone (IRt; F2,10 ⫽ 17.34, P ⫽ 0.001),
and ventrolateral medulla (VLM; F2,10 ⫽ 7.60, P ⫽ 0.014) area
(Figs. 3 and 4). In the DVC, the DIO mice had higher PYY
binding density than that of the DR (68%, P ⫽ 0.015) and LF
mice (37%, P ⫽ 0.079). Similar differences were also observed
in the intermediate reticular zone, in which the DIO had a
significantly higher binding density, compared with the DR
(171%, P ⫽ 0.001) and the LF group (96%; P ⫽ 0.004). In the
VLM, the DIO mice also had a significantly higher binding
density than the DR (122%, P ⫽ 0.022) and the LF group (134%,
P ⫽ 0.015).
Y2 receptor density in the medulla oblongata of DIO, DR,
and LF mice

The DIO mice had significantly higher Y2 receptor binding
density (Figs. 3 and 4), in the DVC, compared with the LF
group (63%; F2,10 ⫽ 4.75, P ⫽ 0.044; DIO vs. LF, P ⫽ 0.041).
In the IRt, the DIO group had 47% higher binding density,
compared with the DR group (F2,10 ⫽ 6.92, P ⫽ 0.02; DIO vs.
DR, P ⫽ 0.023). In the VLM, there were no differences in the
binding density among the DIO, DR, and LF groups.

TABLE 2. The 关125I兴PYY binding and Y2 receptor binding densities in various areas of the hypothalamus of chronic DIO, DR, and the
control (LF) mice
DRa

LFa

F
(2, 10)

P value

284.8 ⫾ 0.7
213.1 ⫾ 27.7
224.6 ⫾ 30.1
248.60 ⫾ 49.3

198.6 ⫾ 66.5
123.7 ⫾ 44.7
131.2 ⫾ 46.1
138.6 ⫾ 41.4

195.7 ⫾ 38.5
172.0 ⫾ 20.9
177.9 ⫾ 42.7
168.3 ⫾ 27.9

3.00
4.39
3.02
5.02

0.160
0.079
0.138
0.064

228.5 ⫾ 17.2
206.2 ⫾ 16.2
222.1 ⫾ 5.3
189.5 ⫾ 30.9

154.3 ⫾ 70.2
125.1 ⫾ 58.9
131.2 ⫾ 51.0
139.9 ⫾ 38.2

170.9 ⫾ 35.5
154.3 ⫾ 37.4
162.6 ⫾ 42.4
143.4 ⫾ 23.7

1.36
1.98
2.83
1.72

0.337
0.232
0.151
0.269

DIOa

Brain area

Total binding with 关 I兴PYY
Arc
DMH
LH
VMH
Y2 receptor binding density
Arc
DMH
LH
VMH
125

Binding densities were quantified at the level of bregma ⫺1.22, ⫺1.70, and ⫺2.18 mm. Arc, Arcuate nucleus; DMH, dorsomedial hypothalamus; LH, lateral hypothalamus.
a
Mean ⫾ SD.
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PYY binding

D

DVC

A
400

Y2 receptor binding

#

400

FIG. 3. The binding densities to
[125I]PYY (A–C) and Y2 receptor (D–F)
in the DVC, IRt, and VLM of chronic
DIO, DR, and the control (LF) mice.
Binding densities were quantified at
the level of bregma ⫺7.32. Data are represented as mean ⫾ SD. *, P ⬍ 0.05, DIO
vs. LF; #, P ⬍ 0.05 DIO vs. DR.
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Discussion

A correlation analysis was carried out among the final
body weight, body fat mass, energy intake of the last week
of the dietary intervention, and the plasma PYY as well as the
medullary PYY binding density and Y2 receptor binding
density of the DIO, DR, and LF mice (Table 3). Final body
weight was highly correlated to the plasma PYY and the PYY
binding densities in all measured areas as well as the Y2
receptor binding densities in the IRt and VLM. Total body fat
was also highly correlated to the plasma PYY, the PYY binding densities in all measured areas, and the Y2 receptor
binding density in the IRt and the VLM. The energy intake
of the last week was significantly correlated to plasma PYY
concentrations and the PYY binding densities and Y2 receptor binding densities in the IRt and the VLM.

The results of this study revealed a significant increase of
medullary PYY and Y2 receptor binding densities in the DIO
mice, compared with the DR and LF mice. This increased
binding density was accompanied by a decrease in plasma
PYY level.
It is known that PYY acts on NPY Y2 receptors in the
hypothalamic arcuate nucleus to decrease food intake (9 –
12). Furthermore, Y2 receptor conditional knockout mice
have been shown to have a significant increase of food
intake (24). Although there is an abundant amount of NPY
receptor in the medulla (25, 26), to our present knowledge,
no information is available in respect to whether the medullary NPY receptors are involved in the regulation of
body weight in high-fat diet-induced obesity.
This study found that the PYY and Y2 receptor binding
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FIG. 4. Photographs depicting the [125I]PYY bindings (B–D) and Y2
receptor bindings (B’ to D’) in the medulla of chronic DIO (B and B’),
DR (C and C’), and the LF (control) group (D and D’). The line box (A)
indicates where the section was taken.

densities in the obese mice were significantly higher than
the lean DR and LF mice in most areas of the medulla
regulating autonomic function (DVC, IRt, and VLM). This
study also found that there was a positive correlation
between PYY binding density in these areas and final body
weight, energy intake, and body fat mass. Furthermore,
although a similar trend was found in some of the hypothalamic nuclei (the dorsomedial and ventromedial hypothalamus), the differences between the obese and lean
mice were not as significant as the findings in the medullary areas. These findings have demonstrated that PYY
possibly acts to regulate energy balance via the medulla to
control food intake rather than working exclusively in the
arcuate hypothalamic nucleus.
The differences in the binding density in the VLM im-

plied that there might be a difference between the obese
and lean mice in their baroreceptor regulation by PYY (27).
This is supported by the finding that the VLM is a site that
plays a crucial role in baroreceptor regulation in hypertensive obese rats (28). In general, there is a tendency for
obese subjects to have higher blood pressure (29 –31).
However, to our present knowledge, there is no literature
available that evaluates the baroreceptor regulation in a
diet-induced obese mouse model.
Studies have shown that an injection of PYY into the
DVC causes similar neuronal inhibition as an injection of
a Y2 agonist (13). This implies that PYY binds to Y2 receptors in the medulla to cause these effects. In the present
study, the obese mice were found to have a significantly
higher Y2 receptor binding density in the DVC and IRt
areas of the medulla, compared with the lean mice. Because the magnitude of the significance in the correlation
between Y2 receptor binding density and body weight,
food intake, and body fat mass was less than that of PYY
binding density, it is possible that the mechanism in which
the PYY regulates the food intake in the medulla might be
not only acting solely on the NPY Y2 receptor binding
density as previously thought but may also by acting
through the NPY Y1 and Y5 receptors.
Plasma PYY in the obese mice in this study was found
to be lower than the high-fat-fed lean and the low-fat-fed
lean mice. Other studies in humans and rodents have also
described a reduced amount of plasma PYY in obese populations (32, 33). This attenuated response of PYY release
in obese populations (34) has been shown to cause an
insufficient inhibitory effect on feeding (35, 36). Findings
from the analysis of PYY null mice also confirm that a
depleted amount of PYY can cause an increase in food
intake (37). This study is the first to analyze the peripheral
plasma PYY as well as its receptor binding density in a
dietary-induced obese animal model. Based on our results,
we suggest that the up-regulation of the medullary PYY
binding density in the DIO mice may be a response to their
low level of plasma PYY. However, it is obvious that in the
diet-induced obese mice, this compensatory regulation of
PYY was not effective enough to reduce the food intake in
this group. This is possibly due to the low amount of PYY
bound as a result of the low plasma PYY the obese mice
had. It is important to note that PYY-immunoreactive neurons have been found in the medulla (38, 39). Therefore,

TABLE 3. The correlation among the body weight, food intake, and plasma level of PYY and binding densities of 关125I兴PYY and Y2
receptor in the medulla nuclei
After 22 wk of high-fat diet
Final body weight

Plasma PYY
Total binding with 关125I兴PYY
DVC
IRt
VLM
Y2 receptor binding density
DVC
IRt
VLM

Total body fat

Energy intake in last week

R value

P value

R value

P value

R value

P value

⫺0.468

0.021

⫺0.475

0.019

⫺0.462

0.023

0.738
0.842
0.803

0.010
0.001
0.003

0.738
0.838
0.817

0.010
0.001
0.002

0.516
0.671
0.777

0.104
0.024
0.005

0.495
0.727
0.618

0.122
0.011
0.043

0.468
0.747
0.634

0.146
0.008
0.036

0.431
0.767
0.841

0.186
0.006
0.001
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a local effect of PYY neurons on PYY binding and Y2
receptor binding cannot be excluded. Further studies are
needed to confirm this issue by measuring the levels of
PYY mRNA and protein expression in the medulla of DIO
mice.
Furthermore, the results of this study suggested that the
elevation of the level of plasma PYY might be effective at
decreasing food intake. However, previous studies have
shown that there were different effects of the peripheral
and central administration of PYY on food intake (40, 41).
Peripheral injections of PYY caused significantly lower
food intake in humans and rodents (including in a DIO
mouse model) (2, 6, 11). Nevertheless, an intracerebroventricular injection of PYY induced higher food intake
(42, 43). On the contrary, when PYY was injected directly
into the hypothalamic arcuate nucleus, food intake was
significantly decreased (6), an effect that was similar to
that observed after a peripheral injection of PYY.
As for the difference in the effects of peripheral vs.
central injections of PYY, one possible explanation could
be that when PYY was injected peripherally, it was transported in the blood directly into areas in the brain with a
high binding affinity to PYY, such as the hypothalamic
arcuate nucleus (and possibly also the DVC), via the highly
permeable blood-brain barrier. In these areas, PYY may
have bound to the anorexigenic NPY Y2 receptor causing
a decrease in food intake, which has been evidenced in Y2
knockout mice in which the anorectic effect of peripheral
PYY injection was diminished (6). However, when injected
centrally into the ventricle, it was likely that PYY bound
to the more orexigenic NPY receptors, such as Y1 and Y5,
caused an increase in food intake. This was also supported
by the finding that the orexigenic effect of intracerebroventricular PYY was reduced in Y1 and Y5 receptor knockout mice (43).
In conclusion, it is clear that in diet-induced obese mice,
there is a dysfunctional PYY regulation. Although there was
an up-regulation in PYY and Y2 receptor binding in the
medulla, the reduced amount of plasma PYY in the obese
mice may have contributed to their high energy intake and
subsequent weight gain.
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Critical insights into the etiology of insulin resistance have been gained by the use of animal
models where insulin action has been modulated by strictly controlled dietary interventions not
possible in human studies. Overall, the literature has moved from a focus on macronutrient
proportions to understanding the unique effects of individual subtypes of fats, carbohydrates and
proteins. Substantial evidence has now accumulated for a major role of dietary fat subtypes in
insulin action. Intake of saturated fats is strongly linked to development of obesity and insulin
resistance, while that of polyunsaturated fats (PUFAs) is not. This is consistent with observations
that saturated fats are poorly oxidized for energy and thus readily stored, are poorly mobilized by
lipolytic stimuli, impair membrane function, and increase the expression of genes associated with
adipocyte profileration (making their own home). PUFAs have contrasting effects in each
instance. It is therefore not surprising that increased PUFA intake in animal models is associated
with improved insulin action and reduced adiposity. Less information is available for carbohydrate
subtypes. Early work clearly demonstrated that diets high in simple sugars (in particular fructose)
led to insulin resistance. However, again attention has rightly shifted to the very interesting issue
of subtypes of complex carbohydrates. While no differences in insulin action have yet been
shown, differences in substrate flux suggest there could be long-term beneficial effects on the fat
balance of diets enhanced in slowly digested/resistant starches. A new area of major interest is in
protein subtypes. Recent results have shown that rats fed high-fat diets where the protein
component was from casein or soy were insulin-resistant, but when the protein source was from
cod they were not. These are exciting times in our growing understanding of dietary factors and
insulin action. While it has been clear for some time that ‘oils ain’t oils’, the same is now proving
true for carbohydrates and proteins.
Dietary macronutrients: Energy balance: Insulin resistance

Background
Insulin resistance is a major player in the etiology of the
metabolic syndrome cluster of diseases. Dietary factors
undoubtedly influence insulin action, but it often appears
that agreement stops with these two statements. Ambrose
Bierce, in his wonderful tome The Devil’s Dictionary,
defined a Trinitarian as ‘one who denies the divinity of a
Unitarian’. Of course, a Unitarian was ‘one who denies the
divinity of a Trinitarian’. In many ways the argument
between the high carbohydrate versus fat-modified schools
of dietary advice have fallen into Bierce’s dichotomous trap.
Non-insulin-dependent or type 2 diabetes mellitus is the
most linear disease descendent of insulin resistance. The
prominent symptom, which provides the definition for the
disease, is the inability to handle carbohydrate. The logical
question is, why advocate a high-carbohydrate diet to
individuals whose core problem is that macronutrient?

The answer, at least partially, concerns the macronutrients
available to substitute for carbohydrate. There is limited
ability to realistically manipulate the levels of protein, and
therefore reducing carbohydrate comes at the cost of
increasing fat. Since obesity is also part of the metabolic
syndrome disease cluster, and insulin resistance is closely
linked with adiposity, then the argument that ‘eating fat
makes you fat’ comes into play. Fortunately, there is a way
forward. Experimental animal investigations of insulin
action, following manipulation not only of macronutrient
proportions, but more particularly of macronutrient subtypes, is writing an exciting new story on diet and insulin
action.
‘Oils ain’t oils’
The experimental animal literature on dietary fat subtypes is
now quite large and coherent. There is evidence for both
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direct effects on insulin action and indirect effects via
induction of obesity. The literature on both has recently
been reviewed, and only a summary is needed here with the
focus on mechanistic insights.
‘Eating fat makes you fat’ is catchy but not well supported as a global concept. Overall there is now an enticing
literature which links intake of saturated fats with development of obesity, but contrasts a neutral, or even protective,
effect of polyunsaturated fatty acids (PUFAs) (Pan et al.
1994; Storlien et al. 1998). Compared to saturated fats,
PUFAs are more readily used for energy when initially
ingested (Leyton et al. 1987). This was demonstrated by
observing labelled CO 2 production after oral administration
of identical amounts of differently labelled fatty acids.
Dramatic differences were observed over the subsequent
24 h, with only a small proportion of the saturated fats being
fully used for energy compared to unsaturated fats (Leyton
et al. 1987). The implication is that the saturated fats are
being stored in adipose tissue depots. Once stored there,
saturated fats are also less readily mobilized by lipolytic
stimuli (Mougios et al. 1995; Halliwell et al. 1996; Raclot
et al. 1997). Increasing the degree of unsaturation at a given
carbon chain length increases the relative mobilizability of
stored fats. This has an interesting implication for physically
active individuals, where selective mobilization of unsaturated fats (Mougios et al. 1995), combined with the greater
propensity of these fats for utilization as energy, means that
such individuals are in danger of ‘saturating down’ their
body lipid stores. As we shall see, this has potentially
negative consequences for a number of aspects of metabolism. Lipids are not just an efficiently stored energy reserve,
they form the membranes of all cells and organelles. Here
again, when saturated fats are incorporated into membranes
they have the capacity to reduce metabolic rate and decrease
receptor (e.g. beta adrenoceptor) binding (Matsuo & Suzuki,
1997) with the obvious implications for energy balance.
Conversely, addition of n-6 PUFAs to the diet can increase
beta adrenoceptor affinity (Nicolas et al. 1991).
In addition to their roles as energy and cell-structural
elements, it is now clear that fatty acids act as potent gene
regulators, notably in the current context on enzymes of
endogenous lipid synthesis and adipocyte proliferation
(Clarke et al. 1997). The beautiful pattern persists, with
saturated fats up-regulating, and PUFAs down-regulating,

these enzymes. Saturated fats are then not only adept at
finding their way into the body’s stores and resistant to
being winkled out, but proficient at making their own home
– good friends in times of want but pernicious in the face of
plenty. Finally, a more recent angle on fats and energy
balance has been exposed (see Table 1). In mice fed diets
high in saturated fats, neuronal activation was seen in the
dorsal-lateral hypothalamus, the classic ‘feeding centre’,
while activity in the ventromedial hypothalamic satiety
centre was suppressed (Wang et al. 1999). This is in line
with development of excess adiposity via a tilting of the
autonomic nervous system balance to favour parasympathetic over sympathetic. This pattern was in contrast to
PUFA feeding where only an increase in ventromedial
hypothalamic neuronal activity was observed, and even
less fat accumulated than in low fat-fed control mice
(Wang et al. 1999). It is important to link this new
information with previous work which has demonstrated an
increase in stress responsivity (indexed by blood glucose and
corticosterone response, and hypothalamic noradrenaline
turnover) with high-fat feeding (Pascoe et al. 1991).
The pattern of low sympathetic nervous system activity/
basal metabolic rate and increased stress responsivity is a
feature of many animal models of the metabolic syndrome.
It is perhaps not surprising that the antiglucorticoid RU486
(Kusunoki et al. 1995), and the alpha-2 adrenoceptor
agonist clonidine (Rocchini et al. 1999), have both been
shown to ameliorate the insulin resistance of high-fat
feeding.
To complete this compelling pattern of dietary fat subtype effects, there is now evidence that ‘dietary fatty acid
composition, independent of adipose tissue mass, is an
important determinant of circulating leptin level’, with
PUFA-enriched diets leading to much higher leptin levels
than those enriched in saturated fats (Cha & Jones, 1998).
This suggests the possibility that there may even be an effect
on the intake side of the energy-balance equation to help
explain the anti-obesogenic effects of PUFAs.
As well as the indirect route via obesity, there is strong
evidence that dietary fat subtypes are also able to modulate
insulin action more directly (Storlien et al. 1996). Early
in vitro studies provided evidence that changes in the
composition of fatty acids within membrane phospholipids
influenced insulin action, altering both insulin binding and

Table 1. Effects of 1 week of feeding diets high in carbohydrate, saturated fat or
polyunsaturated fats on neuronal (c-fos) activation (high-carbohydrate diet set at 100 %)
Lateral hypothalamus*

Ventromedial hypothalamus†

Energy balance

Feeding

Satiety

ANS association

Parasympathetic

Sympathetic

Neuronal activity (%)
high carbohydrate diet
high saturated fat diet
High PUFA diet

100
367
108

100
33
167

* The lateral hypothalamus has traditionally been viewed as a feeding centre and aligned with the
parasympathetic arm of the autonomic nervous system (ANS). Activation of the lateral hypothalamus
is thus associated with positive energy balance.
† The ventromedial hypothalamus is considered a sympathetic nervous system-linked satiety centre,
activation of which will induce negative energy balance.
Adapted from Wang et al. 1999.
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action. In general, the more saturated the fatty acids in
membrane phospholipid, the more deleterious the effect
(Grunfeld et al. 1981; Field et al. 1988). Further, there
was some evidence that the highly unsaturated n-3 fatty
acids were perhaps particularly beneficial (Sohal et al. 1992;
Clandinin et al. 1993). These studies were followed by
in vivo work combining the hyperinsulinaemic, euglycaemic
clamp technique with bolus injection of labelled glucose
and deoxyglucose to index insulin action in individual
tissues after various feeding regimens (Storlien et al.
1991). Skeletal muscle was targeted as the single most
important tissue of insulin-stimulated glucose uptake.
These studies showed that feeding rats for short (3–4week) periods on isocaloric diets, differing only in their
fatty acid profile, was sufficient to provoke major insulin
resistance in some, but not all, high fat-fed groups. Rats fed
diets high in n-3 PUFAs, and with a low n-6 : n-3 PUFA
ratio, maintained normal insulin action. Diets high in
saturated and monounsaturated fats led to profound insulin
resistance in numerous tissues, as did diets with a higher
level of PUFAs where those PUFAs were of the n-6 class
(Storlien et al. 1991).
A variable linked early with whether or not a diet group
developed skeletal muscle insulin resistance was the fatty
acid composition of membrane structural lipids in skeletal
muscle (Storlien et al. 1991). This work has been replicated
a number of times in rodent models and in a number of
human populations (Storlien et al. 1996). In addition,
pharmaceutical insulin sensitizers such as bezafibrate
(Matsui et al. 1997) and benfluorex (L. H. Storlien, unpublished results) also unsaturate lipids, which may be an
important part of their mode of action. However, the
mechanistic basis of altered membrane lipid composition
directly influencing insulin action is not entirely established.
There are a number of possibilities, including effects on
translocation and intrinsic activity of the insulin-regulatable
glucose transporter GLUT4 (Zierath et al. 1997; Hansen et
al. 1998). These workers have shown substantial impairment of insulin-stimulated muscle glucose transport, along
with reduced GLUT4 translocation to the membrane, following high-fat feeding in rats. However, no information is
yet available regarding these metabolic elements and dietary
fatty acid profiles which do not lead to insulin resistance.
Specific diacylgycerol–protein kinase C interactions may
be important. Activation of protein kinase C epsilon is
associated with skeletal muscle insulin resistance in high
fat-fed rats (Schmitz-Peiffer et al. 1997), and it is possible
that interaction with specific fatty acid subtypes in diacylglycerols modulates this activation. Also, there are possible
mechanisms via influences on nitric oxide production,
eicosanoid balance and ion flux. However, no specific
work has yet borne fruit in these directions.
One final aspect of fatty acid profile which must be
considered is the potential effects at the level of the
pancreas. It is now clear that insulin secretion is powerfully,
and differentially, influenced by individual fatty acids (Stein
et al. 1997), with saturated fats in particular leading to
hypersecretion of insulin. Hyperinsulinaemia per se may
lead to insulin resistance.
A second variable identified in early studies as important
for insulin action was muscle storage triglyceride (TG)
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levels, impaired insulin action being closely associated
with high muscle TG levels (Storlien et al. 1991). This
observation has now been replicated in human studies
(Phillips et al. 1996; Pan et al. 1997). Some concern had
been expressed about the location of the TG, but in vivo
NMR studies have been used to show that the relevant
TG was intracellular (Krssak et al. 1999). Using a more
direct approach, we have recently measured insulinstimulated glucose uptake in incubated soleus muscle
using the 2-deoxyglucose method, and then measured TG
in muscle fibres alone after stripping away all interstitial fat
and connective tissue. Again, a highly significant inverse
relationship was found between intramyocyte TG and insulinstimulated glucose metabolism (T. C. Thomas & L. H.
Storlien, unpublished results).
The possibility has been suggested that the concentration
of long-chain fatty acyl-CoA is a marker for skeletal muscle
TG hydrolysis, and accounts for the inhibitory effect of
muscle TG levels on insulin action (Oakes et al. 1997). The
observation that addition of cholate to a high-fat diet
improves insulin is interesting (Ikemoto et al. 1997), in
particular given the data showing that, at least in the liver,
changes in TG accumulation paralleled the cholate-induced
decline in acyl-CoA synthetase mRNA.
This brings into focus our lack of knowledge about what
actually controls the accumulation and distribution of TG in
skeletal muscle. It is clear that it is not just the total
intramyocyte TG that modulates insulin action, but its
distribution is also critical. Muscle TG is substantially
elevated in trained, compared to sedentary, individuals,
but insulin action is improved. Female rats, given access to
running wheels, will build up to an average of over 10 km/d.
We have exploited this chronic exercise model to investigate, using electron microscopy, the effect of ‘training’
on both amount and distribution of intramyocyte TG.
While the work is in its early stages, we can confirm that
intramyocyte TG is greatly elevated, with lipid droplets
very tightly coupled to mitochondria (P.L. Else et al.,
unpublished results). What controls this increase in
TG and its affinity for mitochondria and, in turn, why it
is not deleterious to insulin action are questions of importance in our understanding of skeletal muscle insulin
resistance.
Carbohydrate subtypes
Just as there are simple and complex carbohydrates, there
are simple and complex arguments about the level and form
of carbohydrate intake to optimize insulin action. From
experimental animal work simple sugars, compared to
complex carbohydrates, were found to have a negative
influence on insulin action. These studies were conducted
in rats and, as with the dietary fat subtype work described
above, consisted of a series of pleasingly simple interventions of 3–4 weeks with caloric intake matched and only
the carbohydrate type varied in the diet. Hyperinsulinaemic,
euglycaemic clamps were performed with tracer administration to assess insulin action at the level of the liver
and in individual skeletal muscles, and effects were found
in both. Diets where starch was largely substituted by
either sucrose or fructose were deleterious for insulin
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action (Storlien et al. 1988; Thorburn et al. 1989). The
hypertriglyceridaemic repercussion of elevated fructose
intake was seen as a likely intervening variable. Certainly,
changing the fat source to emphasize n-3 fatty acids ameliorates both the insulin resistance and hypertriglyceridaemia
of high sucrose feeding (Lombardo et al. 1996). Interestingly, glucose itself had no deleterious effect on insulin
action compared to starch. This suggests that the rate of
carbohydrate absorption does not, in the short term, alter
insulin action.
What is even less explored, and potentially of much
greater importance to the broader picture, are the effects
of various forms of complex carbohydrates. However, there
is considerable controversy even in relation to an acceptable
classification framework (Cummings et al. 1997) when we
start impinging on the grey area of resistant starches, soluble
fibre and large-bowel digestion (fatty acids again, of the
short-chain type).
The glycaemic index is a concept which has been around
for many years but still is shrouded in confusion and capable
of inciting some acrimony (Coulston & Reaven 1997;
Wolever 1997). There is still no evidence for direct beneficial effects of low glycaemic-index diets on insulin action
either in animal or human studies. However, there are a
number of very logical bases for suggesting that there may
well be a beneficial effect of slowly digested carbohydrates
in the long run.
Long-term feeding of diets high in carbohydrate, differing only in type of starch, has shown a differential influence
on the insulin response necessary to maintain essentially
normal glucose tolerance. Rats fed on a diet with amylopectin as the starch are markedly hyperinsulinaemic during
an intravenous glucose tolerance test compared to rats fed
a high-starch diet emphasizing amylose (Byrnes et al.
1995; Higgins et al. 1996). This relative hyperinsulinaemic
response becomes more pronounced the longer the feeding
period. Amylose is a straight-chain polysaccharide which,
by virtue of that configuration, is slowly digested. The
branched-chain configuration of amylopectin allows multiple access points for alpha-glucosidase attack and rapid
absorption.
At the molecular level, high-amylose starches have been
shown to increase GLUT4, and decrease fatty acid synthase
gene expression in rat epididymal tissue (Kabir et al. 1998b).
In addition, maximal insulin-stimulated 14C-glucose oxidation
was increased, whereas 14C-glucose incorporation into
lipids was decreased (Kabir et al. 1998a), and glycogen
synthesis in muscle was increased (Denyer et al. 1998), in
amylose-fed compared to amylopectin-fed rats. Taken
together, these results and those noted above are suggestive
of potential effects of amylose-enriched starches on insulin
secretion and/or on substrate repartitioning.
Finally, there are major developments in our understanding of the physiochemistry of starch and the increasingly
blurred boundaries between resistant starches and fibre.
There are few real data here in relation to insulin resistance,
an important emerging field of research.
Protein subtypes
Compared to fat and carbohydrate subtypes, proteins have

been under-studied. Some years ago we noted that rats fed a
synthetic diet were much more insulin-sensitive than
those fed on laboratory chow (Storlien & Jenkins, 1996).
This was puzzling as the synthetic diet had been prepared so
as to closely match the chow macronutrient distribution and
fatty acid profile. Since then, exciting new work has
demonstrated that changing the protein source in synthetic
diets can markedly dictate development, or not, of insulin
resistance in medium- to high-fat-fed rats (Iritani et al.
1997). Follow-up work has shown that high-fat diets prepared with cod protein, as compared to soy or casein protein,
do not lead to insulin resistance (Lavigne et al. 1999).
Further mechanistic investigations showed that the cod
protein improves GLUT4 translocation to skeletal muscle
T-tubules, but not to the plasma membrane (Tremblay et al.
1999). The T-tubule GLUT4 protein correlates with insulinstimulated glucose transport, and is most interesting in
terms of the possibility that a specific protein might be
critical in skeletal muscle insulin-stimulated glucose transport. The effect might be due to a specific protein which has
a gene-specific effect at the intestinal level, a protein which
escapes full digestion, a molecule which is co-extracted with
protein, or indeed a particular amino acid pattern unique to
cod. In this regard the observation that L-glutamine supplementation of a high-fat diet has beneficial effects on
glycaemia and insulinaemia in mice may be relevant
(Opara et al. 1996). The exploration of these possibilities
offers interesting new lines of research.
Summary
Animal models have proven useful in studies of the influence of dietary variables and insulin action. This manuscript
has focused on the macronutrients, and the overriding
message is that we must look beyond the broad categories
of fats, carbohydrates and proteins. A great deal of work has
been done on fatty acid subtypes, and a harmonious pattern
linking saturated fat intake, both indirectly and directly, to
insulin resistance is evident. In contrast, PUFAs are, if
anything, protective. Less is known about carbohydrate
subtypes. While clear data have been obtained regarding
the insulin resistance-inducing effects of sucrose, and in
particular its fructose moiety, little other direct evidence is
available on carbohydrate subtype–insulin action interactions. Finally, new work on protein sources and the profound differences in insulin action they induce is providing
interesting new avenues to explore. What is now clear, and
points in a particularly exciting direction, is that the macronutrients are all potent gene regulators – and subtype
mix will undoubtedly be found important in the precise
patterning of that gene regulation.
Research on experimental animals is important, for the
most part, only in its capacity to inform directions for
human work. This has happened in the field of diet and
insulin action, and there is potential for new and exciting
contributions. Our work has focused on macronutrient
subtypes, inter alia from the recognition that persuading
‘free range’ individuals to introduce and sustain changes
in the macronutrient proportions of their diet has proved
remarkably difficult, at least in our hands. However, changing
individual macronutrient subtype profiles is substantially

Diet and insulin in animal models

easier with the resultant increased capacity for a significant
impact on the prevention and therapy of insulin resistance.
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